Guillermo Garcia-Manero

List of Publications by Citations

1,486 papers	48,237 citations	108 h-index	190 g-index
1,567 ext. papers	56,400 ext. citations	3.8 avg, IF	7.11 L-index

#	Paper	IF	Citations
1486	Guidelines for the use and interpretation of assays for monitoring autophagy. *Autophagy*, **2012**, 8, 445-544	10.2	2783
1485	Revised international prognostic scoring system for myelodysplastic syndromes. *Blood*, **2012**, 120, 2454-65	2.2	1799
1484	Clinical effect of point mutations in myelodysplastic syndromes. *New England Journal of Medicine*, **2011**, 364, 2496-506	59.2	1169
1483	Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. *Blood*, **2004**, 103, 1635-40	2.2	694
1482	Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. *Blood*, **2007**, 109, 52-7	2.2	577
1481	Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. *Blood*, **2009**, 114, 144-7	2.2	576
1480	Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. *Cancer Cell*, **2012**, 22, 153-66	24.3	515
1479	Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. *Cancer*, **2006**, 106, 1090-8	6.4	478
1478	New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. *Journal of Clinical Oncology*, **2012**, 30, 820-9	2.2	466
1477	Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. *Blood*, **2004**, 103, 4396-407	2.2	458
1476	CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. *Genome Research*, **2013**, 23, 1446-61	9.7	442
1475	Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. *Cancer*, **2006**, 106, 1569-80	6.4	441
1474	Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. *Blood*, **2006**, 108, 3271-9	2.2	441
1473	TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. *Blood*, **2014**, 124, 2705-12	2.2	411
1472	Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. *Blood*, **2008**, 111, 1060-6	2.2	397
1471	Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. *Cancer*, **2008**, 113, 1351-61	6.4	386
1470	Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. *Journal of Clinical Oncology*, **2012**, 30, 3376-82	2.2	352

1469	Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. *Blood*, **2007**, 110, 2302-8	2.2	347
1468	High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. *Blood*, **2004**, 103, 2873-8	2.2	344
1467	Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. *Cancer*, **2010**, 116, 5420-31	6.4	334
1466	Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. *Blood*, **2006**, 107, 3469-73	2.2	317
1465	Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. *Journal of Clinical Oncology*, **2009**, 27, 504-10	2.2	306
1464	Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. *Journal of Clinical Oncology*, **2010**, 28, 3880-9	2.2	299
1463	Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. *Journal of Clinical Oncology*, **2010**, 28, 1856-62	2.2	298
1462	Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. *Blood*, **2013**, 121, 4655-62	2.2	296
1461	Loss of the tumor suppressor BAP1 causes myeloid transformation. *Science*, **2012**, 337, 1541-6	33.3	290
1460	A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. *Clinical Cancer Research* , **2006**, 12, 4628-35	12.9	288
1459	A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. *Nature Genetics*, **2009**, 41, 455-9	36.3	287
1458	Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. *Blood*, **2003**, 102, 2379-86	2.2	281
1457	Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. *Blood*, **2010**, 116, 4422-9	2.2	280
1456	Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. *Blood*, **2003**, 101, 473-5	2.2	273
1455	Point-of-care biosensor systems for cancer diagnostics/prognostics. *Biosensors and Bioelectronics*, **2006**, 21, 1932-42	11.8	272
1454	Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. *Blood*, **2007**, 109, 4679-85	2.2	264
1453	Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point. *Cell Reports*, **2015**, 13, 1033-45	10.6	260
1452	Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. *Journal of Clinical Oncology*, **2005**, 23, 3948-56	2.2	259

1451	Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. *Journal of Clinical Oncology*, **2009**, 27, 3842-8	2.2	256
1450	First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. *Blood*, **2010**, 116, 2070-7	2.2	255
1449	Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. *Blood*, **2002**, 99, 3547-53	2.2	251
1448	Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. *Blood*, **2012**, 119, 1981-7	2.2	249
1447	A prognostic score for patients with lower risk myelodysplastic syndrome. *Leukemia*, **2008**, 22, 538-43	10.7	244
1446	Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. *Clinical Cancer Research*, **2005**, 11, 3425-32	12.9	237
1445	DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. *Cancer Research*, **2006**, 66, 5495-503	10.1	231
1444	Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. *American Journal of Hematology*, **2018**, 93, 401-407	7.1	229
1443	Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. *Cancer Discovery*, **2019**, 9, 370-383	24.4	228
1442	Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. *Blood*, **2008**, 112, 981-9	2.2	222
1441	Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. *Blood*, **2003**, 101, 3413-5	2.2	220
1440	Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. *Journal of Clinical Oncology*, **2013**, 31, 2662-70	2.2	203
1439	K-ras(G12V) transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis. *Cell Research*, **2012**, 22, 399-412	24.7	201
1438	Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. *Cancer*, **2003**, 98, 522-8	6.4	200
1437	Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. *Journal of Clinical Oncology*, **2011**, 29, 2521-7	2.2	198
1436	The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. *Blood*, **2018**, 131, 2661-2669	2.2	196
1435	Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. *Cancer*, **2010**, 116, 3830-4	6.4	195
1434	Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. *Blood*, **2003**, 101, 1692-7	2.2	193

1433	Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. *Blood*, **2005**, 105, 940-7	2.2	193
1432	Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2017**, 15, 60-87	7.3	192
1431	Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. *Blood*, **2017**, 129, 572-581	2.2	191
1430	Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. *Lancet Oncology, The*, **2017**, 18, 100-111	21.7	189
1429	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. *Lancet Oncology, The*, **2015**, 16, 1547-1555	21.7	188
1428	Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. *Blood*, **2010**, 115, 1131-6	2.2	185
1427	Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. *Blood*, **2003**, 101, 3794-800	2.2	183
1426	A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. *Blood*, **2008**, 112, 1638-45	2.2	179
1425	Phase I study of bortezomib in refractory or relapsed acute leukemias. *Clinical Cancer Research*, **2004**, 10, 3371-6	12.9	179
1424	Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. *American Journal of Hematology*, **2015**, 90, 732-6	7.1	178
1423	Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. *Blood*, **2012**, 120, 4840-5	2.2	169
1422	Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. *Cancer*, **2009**, 115, 1899-905	6.4	166
1421	SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. *Blood*, **2012**, 119, 569-72	2.2	164
1420	Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. *Blood*, **2003**, 102, 83-6	2.2	164
1419	Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. *New England Journal of Medicine*, **2020**, 382, 140-151	59.2	160
1418	Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. *Cancer*, **2007**, 109, 1133-7	6.4	158
1417	Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. *Blood*, **2007**, 109, 3214-8	2.2	151
1416	Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. *Blood*, **2009**, 113, 6330-7	2.2	149

1415	Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid. *Leukemia Research*, **2005**, 29, 739-48	2.7	148
1414	PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy. *Cell Stem Cell*, **2018**, 23, 700-713.e6	18	147
1413	Oncogenic functions of the transcription factor Nrf2. *Free Radical Biology and Medicine*, **2013**, 65, 750-764	7.8	146
1412	Long-term outcome of acute promyelocytic leukemia treated with all--retinoic acid, arsenic trioxide, and gemtuzumab. *Blood*, **2017**, 129, 1275-1283	2.2	144
1411	Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. *Cancer*, **2008**, 112, 2341-51	6.4	143
1410	NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2011**, 9, 30-56	7.3	140
1409	Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. *Lancet Oncology, The*, **2018**, 19, 240-248	21.7	137
1408	DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. *Clinical Cancer Research*, **2002**, 8, 2217-24	12.9	137
1407	Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. *Clinical Cancer Research*, **2008**, 14, 3906-15	12.9	136
1406	Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. *Haematologica*, **2015**, 100, 653-61	6.6	135
1405	Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. *Blood*, **2009**, 113, 2154-60	2.2	135
1404	Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. *Journal of Clinical Oncology*, **2009**, 27, 4760-6	2.2	133
1403	Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. *Clinical Cancer Research*, **2008**, 14, 6296-301	12.9	133
1402	Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. *Journal of Clinical Oncology*, **2012**, 30, 2204-10	2.2	132
1401	The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. *Cancer*, **2019**, 125, 1470-1481	6.4	132
1400	TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. *Cancer*, **2016**, 122, 3484-3491	6.4	131
1399	Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. *Cancer*, **2015**, 121, 4158-64	6.4	129
1398	Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. *Blood*, **2003**, 101, 97-100	2.2	128

1397	Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. *Blood*, **2016**, 128, 504-7	2.2	125
1396	Changes in DNA methylation of tandem DNA repeats are different from interspersed repeats in cancer. *International Journal of Cancer*, **2009**, 125, 723-9	7.5	124
1395	Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. *Journal of Clinical Oncology*, **2008**, 26, 196-203	2.2	124
1394	Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. *Journal of Clinical Oncology*, **2004**, 22, 1287-92	2.2	124
1393	Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. *Journal of Clinical Oncology*, **2011**, 29, 1963-70	2.2	121
1392	Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. *Journal of Hematology and Oncology*, **2019**, 12, 1	22.4	119
1391	An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. *Blood*, **2015**, 125, 1857-65	2.2	118
1390	Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. *Blood*, **2010**, 116, 3163-70	2.2	118
1389	Hypomethylating agents and other novel strategies in myelodysplastic syndromes. *Journal of Clinical Oncology*, **2011**, 29, 516-23	2.2	116
1388	The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. *Blood*, **2011**, 118, 4541-6; quiz 4759	2.2	115
1387	Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. *American Journal of Hematology*, **2015**, 90, 276-81	7.1	114
1386	Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. *Cancer*, **2003**, 98, 1905-11	6.4	114
1385	Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. *Blood*, **2003**, 101, 4131-6	2.2	113
1384	Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. *Lancet Oncology, The*, **2016**, 17, 496-508	21.7	112
1383	Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. *Leukemia*, **2018**, 32, 1094-1105	10.7	111
1382	Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. *Journal of Clinical Oncology*, **2018**, 36, 1788-1797	2.2	111
1381	Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. *Journal of Clinical Oncology*, **2011**, 29, 2240-6	2.2	110
1380	Cause of death in patients with lower-risk myelodysplastic syndrome. *Cancer*, **2010**, 116, 2174-9	6.4	109

1379	Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. *Cancer*, **2007**, 109, 248-55	6.4	108
1378	Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management. *American Journal of Hematology*, **2018**, 93, 129-147	7.1	108
1377	Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. *Lancet Oncology, The*, **2017**, 18, 1317-1326	21.7	106
1376	Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. *Cancer*, **2016**, 122, 3650-3656	6.4	105
1375	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. *Lancet Haematology,the*, **2018**, 5, e618-e627	14.6	105
1374	Outcome of adults with acute lymphocytic leukemia after second salvage therapy. *Cancer*, **2008**, 113, 3186-91	6.4	103
1373	Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. *Blood*, **2017**, 130, 1514-1522	2.2	102
1372	Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2017**, 17, 897-901	2	101
1371	Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia. *Journal of Clinical Oncology*, **2008**, 26, 5684-8	2.2	100
1370	Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. *Cancer*, **2015**, 121, 556-61	6.4	99
1369	Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. *Clinical Cancer Research*, **2004**, 10, 88-95	12.9	98
1368	Effect of cytarabine and decitabine in combination in human leukemic cell lines. *Clinical Cancer Research*, **2007**, 13, 4225-32	12.9	97
1367	Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management. *American Journal of Hematology*, **2014**, 89, 97-108	7.1	96
1366	Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. *Cancer*, **2003**, 97, 2760-6	6.4	96
1365	Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. *Cancer*, **2007**, 109, 265-73	6.4	94
1364	Time-dependent changes in mortality and transformation risk in MDS. *Blood*, **2016**, 128, 902-10	2.2	93
1363	Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial. *JAMA Oncology*, **2018**, 4, 230-234	13.4	92
1362	Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact. *Epigenetics*, **2010**, 5, 499-508	5.7	92

1361	PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. *Cancer*, **2007**, 110, 2012-8	6.4	92
1360	Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. *Blood*, **2005**, 105, 2281-6	2.2	92
1359	Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?. *Cancer*, **2008**, 112, 837-45	6.4	91
1358	10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. *Lancet Haematology,the*, **2020**, 7, e724-e736	14.6	91
1357	Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound Ephenylethyl isothiocyanate. *Blood*, **2010**, 116, 2732-41	2.2	89
1356	The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results. *Blood*, **2019**, 134, 569-569	2.2	89
1355	Eprenetapopt (APR-246) and Azacitidine in -Mutant Myelodysplastic Syndromes. *Journal of Clinical Oncology*, **2021**, 39, 1584-1594	2.2	89
1354	Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. *Cancer*, **2014**, 120, 2142-9	6.4	88
1353	Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. *Leukemia Research*, **2015**, 39, 348-54	2.7	88
1352	Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. *Cancer*, **2010**, 116, 5568-74	6.4	88
1351	TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. *Leukemia*, **2019**, 33, 1747-1758	10.7	88
1350	Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases. *Cancer*, **2003**, 97, 1920-8	6.4	87
1349	Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. *Cancer*, **2016**, 122, 1871-9	6.4	86
1348	The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. *Cancer*, **2016**, 122, 2186-96	6.4	85
1347	Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. *Leukemia Research* , **2010**, 34, 752-6	2.7	85
1346	Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. *Clinical Cancer Research*, **2002**, 8, 2177-87	12.9	84
1345	Demethylating agents in myeloid malignancies. *Current Opinion in Oncology*, **2008**, 20, 705-10	4.2	83
1344	Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. *Blood*, **2010**, 116, 5818-23; quiz 6153	2.2	81

1343	Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents. *Cancer Investigation*, **2005**, 23, 635-42	2.1	81
1342	Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management. *American Journal of Hematology*, **2015**, 90, 831-41	7.1	80
1341	Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor. *Expert Opinion on Investigational Drugs*, **2011**, 20, 823-9	5.9	80
1340	An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. *Haematologica*, **2015**, 100, 1117-30	6.6	79
1339	Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. *British Journal of Haematology*, **2016**, 172, 392-400	4.5	79
1338	TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. *Journal of Hematology and Oncology*, **2015**, 8, 45	22.4	79
1337	Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes. *Journal of Clinical Oncology*, **2013**, 31, 2548-53	2.2	78
1336	Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. *Leukemia Research*, **2003**, 27, 1077-83	2.7	78
1335	Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. *Blood*, **2006**, 108, 1174-82	2.2	77
1334	Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancers. *Cancer Research*, **2004**, 64, 2411-7	10.1	77
1333	Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. *Cancer*, **2003**, 98, 2636-42	6.4	77
1332	Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium. *Cancer*, **2015**, 121, 876-82	6.4	76
1331	Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. *Lancet Haematology,the*, **2018**, 5, e63-e72	14.6	76
1330	Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. *Cancer*, **2017**, 123, 4391-4402	6.4	76
1329	Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-M□ster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. *American Journal of Hematology*, **2016**, 91, 819-23	7.1	76
1328	Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. *Clinical Cancer Research*, **2005**, 11, 6615-24	12.9	75
1327	Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. *Nature Communications*, **2020**, 11, 5327	17.4	75
1326	Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. *Cancer*, **2008**, 113, 1933-52	6.4	74

1325	Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. *Cancer*, **2006**, 106, 120-7	6.4	73
1324	Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. *Journal of Clinical Oncology*, **2003**, 21, 1722-7	2.2	73
1323	Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee. *Blood*, **2015**, 126, 907-907	2.2	73
1322	SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. *Blood*, **2020**, 136, 157-170	2.2	72
1321	Myelodysplastic syndromes: clinical practice guidelines in oncology. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2013**, 11, 838-74	7.3	72
1320	Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. *Clinical Cancer Research*, **2002**, 8, 2167-76	12.9	72
1319	Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. *British Journal of Haematology*, **2004**, 125, 187-95	4.5	70
1318	Augmented Berlin-Frankfurt-M□ster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). *Cancer*, **2014**, 120, 3660-8	6.4	69
1317	Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. *Journal of Clinical Oncology*, **2002**, 20, 656-64	2.2	69
1316	Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes. *Cancer*, **2017**, 123, 994-1002	6.4	68
1315	Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome. *Cancer Cell*, **2015**, 27, 644-57	24.3	68
1314	Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. *Blood*, **2011**, 118, 4690-3	2.2	68
1313	Aberrant DNA methylation and epigenetic inactivation of Eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia. *Blood*, **2010**, 115, 2412-9	2.2	68
1312	Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. *Cancer Chemotherapy and Pharmacology*, **2003**, 51, 87-90	3.5	68
1311	Therapy with azanucleosides for myelodysplastic syndromes. *Nature Reviews Clinical Oncology*, **2010**, 7, 433-44	19.4	67
1310	Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. *Journal of Clinical Oncology*, **2009**, 27, 1637-43	2.2	67
1309	Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms. *Journal of Clinical Oncology* , **2012**, 30, 2340-7	2.2	67
1308	Epigenetics of acute lymphocytic leukemia. *Seminars in Hematology*, **2009**, 46, 24-32	4	67

1307	Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. *Blood*, **2020**, 136, 674-683	2.2	67
1306	c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer. *Clinical Cancer Research* , **2017**, 23, 2542-2555	12.9	65
1305	A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. *Leukemia and Lymphoma*, **2013**, 54, 321-8	1.9	65
1304	Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. *Leukemia Research*, **2003**, 27, 893-7	2.7	65
1303	Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases. *American Journal of Hematology*, **1999**, 60, 130-5	7.1	65
1302	The emerging role of immune checkpoint based approaches in AML and MDS. *Leukemia and Lymphoma*, **2018**, 59, 790-802	1.9	64
1301	Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. *Journal of Clinical Oncology*, **2010**, 28, 285-91	2.2	64
1300	Acute myeloid leukemia: current progress and future directions. *Blood Cancer Journal*, **2021**, 11, 41	7	64
1299	Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?. *Journal of Clinical Oncology*, **2011**, 29, 4260-5	2.2	63
1298	Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. *Blood*, **2006**, 107, 880-4	2.2	63
1297	Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes. *Cancer*, **2016**, 122, 2857-66	6.4	63
1296	FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. *American Journal of Hematology*, **2013**, 88, 56-9	7.1	62
1295	Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management. *American Journal of Hematology*, **2012**, 87, 692-701	7.1	62
1294	Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. *Lancet Haematology,the*, **2019**, 6, e29-e37	14.6	62
1293	Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. *Cancer*, **2018**, 124, 4044-4055	6.4	62
1292	Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. *Cancer*, **2017**, 123, 294-302	6.4	61
1291	RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis. *Cancer Research*, **2007**, 67, 1997-2005	10.1	61
1290	Chronic myelogenous leukemia: a review and update of therapeutic strategies. *Cancer*, **2003**, 98, 437-57	6.4	61

1289	Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia. *Nature Immunology*, **2017**, 18, 236-245	19.1	60
1288	An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. *Lancet Haematology,the*, **2019**, 6, e194-e203	14.6	59
1287	Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution. *American Journal of Hematology*, **2014**, 89, 813-8	7.1	59
1286	A pilot pharmacokinetic study of oral azacitidine. *Leukemia*, **2008**, 22, 1680-4	10.7	59
1285	Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. *Cancer*, **2008**, 113, 3181-5	6.4	59
1284	Aberrant DNA methylation in pediatric patients with acute lymphocytic leukemia. *Cancer*, **2003**, 97, 695-702	6.4	59
1283	Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. *Oncotarget*, **2016**, 7, 14172-87	3.3	59
1282	Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. *Cancer*, **2002**, 94, 2024-32	6.4	58
1281	Outcome of patients with acute myelogenous leukemia after second salvage therapy. *Cancer*, **2005**, 104, 547-54	6.4	57
1280	Salvage therapy for refractory or relapsed acute lymphocytic leukemia. *Hematology/Oncology Clinics of North America*, **2001**, 15, 163-205	3.1	57
1279	The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. *Clinical Cancer Research*, **2010**, 16, 3923-32	12.9	56
1278	Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. *Lancet Haematology,the*, **2019**, 6, e480-e488	14.6	55
1277	Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. *American Journal of Hematology*, **2013**, 88, 1024-9	7.1	55
1276	Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. *Blood Advances*, **2017**, 1, 1312-1323	7.8	55
1275	Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies. *Haematologica*, **2013**, 98, 217-21	6.6	55
1274	DNA methylation patterns at relapse in adult acute lymphocytic leukemia. *Clinical Cancer Research*, **2002**, 8, 1897-903	12.9	55
1273	Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. *Lancet Haematology,the* , **2019**, 6, e317-e327	14.6	54
1272	Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. *American Journal of Hematology*, **2018**, 93, 1136-1141	7.1	54

1271	Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53. *Cancer*, **2012**, 118, 2879-88	6.4	54
1270	Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. *Blood*, **2011**, 117, 1822-7	2.2	54
1269	Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation. *Journal of Clinical Oncology*, **2011**, 29, 2507-13	2.2	54
1268	Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. *Lancet Oncology, The*, **2012**, 13, 1096-104	21.7	53
1267	Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. *Cancer*, **2012**, 118, 4471-7	6.4	53
1266	Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. *Blood*, **2006**, 107, 480-2	2.2	53
1265	Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. *Cancer*, **2004**, 100, 2592-7	6.4	53
1264	Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. *American Journal of Hematology*, **2018**, 93, 371-374	7.1	53
1263	Decitabine in the treatment of myelodysplastic syndromes. *Expert Review of Anticancer Therapy*, **2010**, 10, 9-22	3.5	50
1262	Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents. *Leukemia and Lymphoma*, **2014**, 55, 1925-9	1.9	49
1261	EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. *Blood*, **2012**, 119, 4524-6	2.2	49
1260	Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls. *Clinical Cancer Research*, **2004**, 10, 68-75	12.9	49
1259	Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. *Blood Advances*, **2019**, 3, 851-861	7.8	49
1258	Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. *American Journal of Hematology*, **2018**, 93, 91-99	7.1	48
1257	Overexpression of the toll-like receptor (TLR) signaling adaptor MYD88, but lack of genetic mutation, in myelodysplastic syndromes. *PLoS ONE*, **2013**, 8, e71120	3.7	48
1256	Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. *Journal of Clinical Oncology*, **2010**, 28, 2755-60	2.2	48
1255	Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML). *Blood*, **2019**, 134, 676-676	2.2	48
1254	A Phase II Study Evaluating the Combination of Nivolumab (Nivo) or Ipilimumab (Ipi) with Azacitidine in Pts with Previously Treated or Untreated Myelodysplastic Syndromes (MDS). *Blood*, **2016**, 128, 344-344	2.2	48

1253	Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. *Nature Communications*, **2018**, 9, 2670	17.4	47
1252	A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias. *Cancer*, **2012**, 118, 3556-64	6.4	47
1251	Biphenotypic acute leukaemia: a case series. *British Journal of Haematology*, **2007**, 138, 213-6	4.5	47
1250	Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. *British Journal of Haematology*, **2015**, 168, 646-53	4.5	46
1249	The hyper-CVAD regimen in adult acute lymphocytic leukemia. *Hematology/Oncology Clinics of North America*, **2000**, 14, 1381-96, x-xi	3.1	46
1248	Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. *Cancer*, **2017**, 123, 426-435	6.4	45
1247	Adaptive response to inflammation contributes to sustained myelopoiesis and confers a competitive advantage in myelodysplastic syndrome HSCs. *Nature Immunology*, **2020**, 21, 535-545	19.1	45
1246	Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. *Journal of Clinical Oncology*, **2011**, 29, 3173-8	2.2	44
1245	Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. *Journal of Clinical Oncology*, **2005**, 23, 2805-12	2.2	44
1244	Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). *Blood*, **2019**, 134, 570-570	2.2	44
1243	Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. *Lancet Haematology,the*, **2018**, 5, e411-e421	14.6	43
1242	Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. *Blood Advances*, **2019**, 3, 508-518	7.8	43
1241	Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. *Leukemia Research*, **2006**, 30, 813-22	2.7	43
1240	A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia. *Clinical Cancer Research*, **2004**, 10, 2908-17	12.9	43
1239	Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML). *Blood*, **2019**, 134, 673-673	2.2	43
1238	Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. *Blood*, **2013**, 122, 2807-11; quiz 2920	2.2	42
1237	Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience. *American Journal of Hematology*, **2004**, 77, 209-14	7.1	42
1236	Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. *Oncotarget*, **2018**, 9, 9714-9727	3.3	42

1235	A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. *Blood Advances*, **2020**, 4, 5580-5588	7.8	42
1234	A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2014**, 14, 401-10	2	41
1233	A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes. *Clinical Cancer Research*, **2015**, 21, 985-94	12.9	41
1232	Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. *American Journal of Hematology*, **2014**, 89, 282-7	7.1	41
1231	Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor. *Cancer*, **2011**, 117, 572-80	6.4	41
1230	Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation. *Haematologica*, **2017**, 102, 1661-1670	6.6	40
1229	Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease. *Cytotherapy*, **2014**, 16, 90-100	4.8	40
1228	Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management. *American Journal of Hematology*, **2011**, 86, 490-8	7.1	40
1227	Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia. *Cancer*, **2009**, 115, 5490-8	6.4	40
1226	Colocalization of tissue transglutaminase and stress fibers in human vascular smooth muscle cells and human umbilical vein endothelial cells. *Experimental Cell Research*, **1997**, 231, 38-49	4.2	40
1225	A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. *Leukemia and Lymphoma*, **2007**, 48, 283-9	1.9	40
1224	Protein expression of a triad of frequently methylated genes, p73, p57Kip2, and p15, has prognostic value in adult acute lymphocytic leukemia independently of its methylation status. *Journal of Clinical Oncology*, **2005**, 23, 3932-9	2.2	40
1223	A Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Adults with Relapsed or Refractory Leukemia: Safety, Clinical Activity, Exposure and Target Inhibition. *Blood*, **2015**, 126, 2547-2547	2.2	40
1222	Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 47-53	4.7	39
1221	Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. *Cancer*, **2017**, 123, 3050-3060	6.4	39
1220	Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. *Cancer Chemotherapy and Pharmacology*, **2014**, 73, 495-501	3.5	39
1219	Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. *American Journal of Hematology*, **2014**, 89, 964-8	7.1	39
1218	Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≥60 years with newly diagnosed acute myeloid leukemia. *American Journal of Hematology*, **2013**, 88, 961-6	7.1	39

1217	Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. *Cancer*, **2017**, 123, 459-467	6.4	39
1216	Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy. *American Journal of Hematology*, **2014**, 89, 395-8	7.1	39
1215	Epigenetic therapy of leukemia: An update. *International Journal of Biochemistry and Cell Biology*, **2009**, 41, 72-80	5.6	39
1214	mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. *Blood Advances*, **2019**, 3, 922-933	7.8	39
1213	Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. *Blood*, **2002**, 100, 1590-5	2.2	39
1212	Epigenetic inactivation of Notch-Hes pathway in human B-cell acute lymphoblastic leukemia. *PLoS ONE*, **2013**, 8, e61807	3.7	38
1211	Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure. *Cancer*, **2007**, 110, 2000-6	6.4	38
1210	Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine. *Blood*, **2019**, 134, 846-846	2.2	38
1209	Phase IB/II Study of Nivolumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML). *Blood*, **2016**, 128, 763-763	2.2	38
1208	Characteristics of Sweet Syndrome in patients with acute myeloid leukemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2015**, 15, 358-363	2	37
1207	Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia. *Leukemia and Lymphoma*, **2015**, 56, 1392-7	1.9	37
1206	Notch pathway activation induces neuroblastoma tumor cell growth arrest. *Pediatric Blood and Cancer*, **2012**, 58, 682-9	3	37
1205	Acute myeloid leukemia outcome: role of nucleotide excision repair polymorphisms in intermediate risk patients. *Leukemia and Lymphoma*, **2010**, 51, 598-605	1.9	37
1204	Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. *Cancer* , **2004**, 100, 581-9	6.4	37
1203	Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies. *PLoS ONE*, **2015**, 10, e0135520	3.7	37
1202	Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial. *Annals of Internal Medicine*, **2020**, 172, 513-522	8	37
1201	Treating Leukemia in the Time of COVID-19. *Acta Haematologica*, **2021**, 144, 132-145	2.7	37
1200	Is acute myeloid leukemia a liquid tumor?. *International Journal of Cancer*, **2013**, 133, 534-43	7.5	36

1199	Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. *Cancer*, **2012**, 118, 2665-73	6.4	36
1198	Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis. *Cancer*, **2009**, 115, 4737-44	6.4	36
1197	The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?. *Cancer*, **2009**, 115, 5202-9	6.4	36
1196	Phase 1b/2 Combination Study of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). *Blood*, **2018**, 132, 3091-3091	2.2	36
1195	Pembrolizumab, a PD-1 Inhibitor, in Patients with Myelodysplastic Syndrome (MDS) after Failure of Hypomethylating Agent Treatment. *Blood*, **2016**, 128, 345-345	2.2	36
1194	HDAC inhibitors repress BARD1 isoform expression in acute myeloid leukemia cells via activation of miR-19a and/or b. *PLoS ONE*, **2013**, 8, e83018	3.7	36
1193	Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. *Blood Advances*, **2020**, 4, 482-495	7.8	36
1192	Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. *Journal of Clinical Oncology*, **2021**, 39, 2768-2778	2.2	36
1191	Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. *Cancer*, **2019**, 125, 2579-2586	6.4	35
1190	Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. *Cancer*, **2015**, 121, 2375-82	6.4	35
1189	Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. *Leukemia Research*, **2015**, 39, 1367-74	2.7	35
1188	Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. *American Journal of Hematology*, **2013**, 88, 831-7	7.1	35
1187	Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry. *Leukemia Research*, **2014**, 38, 149-54	2.7	35
1186	Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system. *Cancer*, **2012**, 118, 4462-70	6.4	35
1185	A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. *British Journal of Haematology*, **2010**, 150, 72-82	4.5	35
1184	HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. *Modern Pathology*, **2007**, 20, 54-62	9.8	35
1183	A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. *American Journal of Hematology*, **2018**, 93, 277-285	7.1	35
1182	Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up. *Leukemia Research*, **2015**, 39, 520-4	2.7	34

1181	Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. *American Journal of Hematology*, **2017**, 92, 7-11	7.1	34
1180	Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. *British Journal of Haematology*, **2010**, 150, 303-12	4.5	34
1179	A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS). *Blood*, **2018**, 132, 465-465	2.2	34
1178	Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. *Cancer*, **2020**, 126, 765-774	6.4	34
1177	DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease. *American Journal of Hematology*, **2019**, 94, 757-766	7.1	33
1176	MYC protein expression is an important prognostic factor in acute myeloid leukemia. *Leukemia and Lymphoma*, **2019**, 60, 37-48	1.9	33
1175	Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment. *Blood*, **2017**, 130, 2084-2091	2.2	33
1174	Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. *American Journal of Hematology*, **2015**, 90, 193-6	7.1	33
1173	Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia. *Journal of Hematopathology*, **2009**, 2, 2-8	0.4	33
1172	EphB2 activity plays a pivotal role in pediatric medulloblastoma cell adhesion and invasion. *Neuro-Oncology*, **2012**, 14, 1125-35	1	33
1171	Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. *Journal of Clinical Oncology*, **2003**, 21, 1050-6	2.2	33
1170	The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients with MLL-Rearranged Leukemia. *Blood*, **2014**, 124, 387-387	2.2	33
1169	SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML). *Blood*, **2016**, 128, 901-901	2.2	33
1168	Overexpression of miR-125a in myelodysplastic syndrome CD34+ cells modulates NF-Β activation and enhances erythroid differentiation arrest. *PLoS ONE*, **2014**, 9, e93404	3.7	33
1167	Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years. *Leukemia Research*, **2017**, 56, 88-95	2.7	32
1166	Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. *American Journal of Hematology*, **2017**, 92, 599-606	7.1	32
1165	Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. *Cancer*, **2017**, 123, 4851-4859	6.4	32
1164	Myelodysplastic syndromes, version 2.2015. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2015**, 13, 261-72	7.3	32

1163	The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial. *Blood*, **2017**, 130, 723-723	2.2	32
1162	Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS. *Oncotarget*, **2016**, 7, 14251-8	3.3	32
1161	Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management. *American Journal of Hematology*, **2020**, 95, 1399-1420	7.1	32
1160	More than 1 abnormality is a dominant characteristic of pure erythroid leukemia. *Blood*, **2017**, 129, 2584-2587	2.2	31
1159	De novo acute myeloid leukemia risk factors: a Texas case-control study. *Cancer*, **2012**, 118, 4589-96	6.4	31
1158	Acute myeloid leukemia with t(9;11)(p21-22;q23): common properties of dysregulated ras pathway signaling and genomic progression characterize de novo and therapy-related cases. *American Journal of Clinical Pathology*, **2010**, 133, 686-93	1.9	31
1157	Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. *American Journal of Hematology*, **2017**, 92, 238-243	7.1	30
1156	The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure. *Haematologica*, **2016**, 101, e224-7	6.6	30
1155	Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia. *British Journal of Haematology*, **2014**, 167, 356-65	4.5	30
1154	A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. *Cancer*, **2017**, 123, 4430-4439	6.4	30
1153	A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. *Cancer*, **2011**, 117, 1236-44	6.4	30
1152	A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome. *Blood*, **2019**, 134, 565-565	2.2	30
1151	Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia. *Future Oncology*, **2016**, 12, 293-302	3.6	30
1150	Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes. *Cancer*, **2019**, 125, 1091-1100	6.4	30
1149	TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis. *British Journal of Haematology*, **2015**, 171, 91-9	4.5	29
1148	Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. *Blood Advances*, **2020**, 4, 5681-5689	7.8	29
1147	Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels. *Cancer*, **2018**, 124, 2704-2713	6.4	29
1146	Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. *British Journal of Haematology*, **2012**, 157, 312-20	4.5	29

1145	Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. *Cancer Chemotherapy and Pharmacology*, **2003**, 52, 449-52	3.5	29
1144	The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions. *Blood*, **2018**, 132, 1-1	2.2	29
1143	Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). *American Journal of Hematology*, **2016**, 91, 227-32	7.1	29
1142	Myeloid/lymphoid neoplasms with FGFR1 rearrangement. *Leukemia and Lymphoma*, **2018**, 59, 1672-1676	1.9	29
1141	Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experience. *American Journal of Hematology*, **2015**, 90, 27-30	7.1	28
1140	Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial. *Lancet Haematology,the*, **2018**, 5, e136-e146	14.6	28
1139	Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes. *Cancer*, **2014**, 120, 1670-6	6.4	28
1138	BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS. *American Journal of Hematology*, **2014**, 89, 499-504	7.1	28
1137	Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy. *Cancer*, **2012**, 118, 3116-22	6.4	28
1136	Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS. *Cancer*, **2012**, 118, 5550-9	6.4	28
1135	Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. *Cancer*, **2011**, 117, 110-5	6.4	28
1134	Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia. *Clinical Cancer Research*, **2005**, 11, 7817-24	12.9	28
1133	Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. *American Journal of Hematology*, **2017**, 92, 845-850	7.1	27
1132	Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies. *Leukemia Research*, **2013**, 37, 1461-7	2.7	27
1131	Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. *Leukemia and Lymphoma*, **2014**, 55, 1337-44	1.9	27
1130	Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies. *Leukemia Research*, **2004**, 28, 991-4	2.7	27
1129	Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response. *European Journal of Haematology*, **2015**, 95, 168-76	3.8	26
1128	Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes. *Modern Pathology*, **2015**, 28, 373-82	9.8	26

1127	Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2012**, 12, 244-51	2	26
1126	The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. *Autophagy*, **2010**, 6, 976-8	10.2	26
1125	A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome. *Blood*, **2019**, 134, 568-568	2.2	26
1124	Metabolic alterations and drug sensitivity of tyrosine kinase inhibitor resistant leukemia cells with a FLT3/ITD mutation. *Cancer Letters*, **2016**, 377, 149-57	9.9	26
1123	Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable. *Blood*, **2018**, 132, 2100-2103	2.2	26
1122	Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia. *Oncologist*, **2015**, 20, 1404-12	5.7	25
1121	Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. *Blood*, **2018**, 131, 1820-1832	2.2	25
1120	Multi-color CD34+ progenitor-focused flow cytometric assay in evaluation of myelodysplastic syndromes in patients with post cancer therapy cytopenia. *Leukemia Research*, **2012**, 36, 974-81	2.7	25
1119	A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. *Cancer*, **2012**, 118, 722-8	6.4	25
1118	Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience. *Leukemia and Lymphoma*, **2014**, 55, 2879-86	1.9	25
1117	Preclinical antileukemia activity of JNJ-26481585, a potent second-generation histone deacetylase inhibitor. *Leukemia Research*, **2010**, 34, 221-8	2.7	25
1116	Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia. *Leukemia Research*, **2008**, 32, 1505-9	2.7	25
1115	DNA methylation in haematological malignancies: the role of decitabine. *Expert Opinion on Investigational Drugs*, **2003**, 12, 1985-93	5.9	25
1114	Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. *American Journal of Hematology*, **2017**, 92, 279-285	7.1	24
1113	A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. *Leukemia*, **2020**, 34, 2489-2492	10.7	24
1112	Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations. *American Journal of Surgical Pathology*, **2018**, 42, 799-806	6.7	24
1111	Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. *Cancer*, **2019**, 125, 3755-3766	6.4	24
1110	Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. *American Journal of Hematology*, **2012**, 87, 127-9	7.1	24

1109	RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype. *British Journal of Haematology*, **2015**, 169, 344-51	4.5	24
1108	Relapse and death during first remission in acute myeloid leukemia. *Haematologica*, **2008**, 93, 633-4	6.6	24
1107	The role of decitabine in the treatment of myelodysplastic syndromes. *Expert Opinion on Pharmacotherapy*, **2007**, 8, 65-73	4	24
1106	Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. *Lancet Haematology,the*, **2020**, 7, e523-e533	14.6	24
1105	Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and thrombocytopenia. *BMC Hematology*, **2016**, 16, 12	2.5	24
1104	Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. *Haematologica*, **2021**, 106, 894-898	6.6	24
1103	Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. *American Journal of Hematology*, **2021**, 96, 282-291	7.1	24
1102	Focal Adhesion Kinase as a Potential Target in AML and MDS. *Molecular Cancer Therapeutics*, **2017**, 16, 1133-1144	6.1	23
1101	Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. *American Journal of Hematology*, **2018**, 93, 84-90	7.1	23
1100	Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. *American Journal of Hematology*, **2019**, 94, 984-991	7.1	22
1099	Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. *Cancer*, **2017**, 123, 629-637	6.4	22
1098	Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes. *American Journal of Hematology*, **2014**, 89, 509-16	7.1	22
1097	Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. *American Journal of Hematology*, **2013**, 88, 365-9	7.1	22
1096	Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias. *Genes Chromosomes and Cancer*, **2010**, 49, 182-91	5	22
1095	Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents. *Leukemia Research*, **2016**, 41, 43-7	2.7	21
1094	Copy number alterations detected as clonal hematopoiesis of indeterminate potential. *Blood Advances*, **2017**, 1, 1031-1036	7.8	21
1093	Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?. *American Journal of Hematology*, **2015**, 90, 1036-40	7.1	21
1092	Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status. *Leukemia Research*, **2009**, 33, 837-9	2.7	21

1091	Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia. *Blood*, **2009**, 113, 1892-8	2.2	21
1090	Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. *Blood*, **2009**, 113, 5058-63	2.2	21
1089	Potential cure of acute myeloid leukemia : analysis of 1069 consecutive patients in first complete remission. *Cancer*, **2007**, 110, 2756-60	6.4	21
1088	Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse. *British Journal of Haematology*, **2006**, 134, 58-60	4.5	21
1087	Lack of p21(CIP1) DNA methylation in acute lymphocytic leukemia. *Blood*, **2002**, 100, 3432-3; author reply 3433-4	2.2	21
1086	Safety and Efficacy, Including Event-Free Survival, of Deferasirox Versus Placebo in Iron-Overloaded Patients with Low- and Int-1-Risk Myelodysplastic Syndromes (MDS): Outcomes from the Randomized, Double-Blind Telesto Study. *Blood*, **2018**, 132, 234-234	2.2	21
1085	Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study. *Blood*, **2019**, 134, 830-830	2.2	21
1084	MYBL2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancy. *ELife*, **2013**, 2, e00825	8.9	21
1083	The role of TGF in hematopoiesis and myeloid disorders. *Leukemia*, **2019**, 33, 1076-1089	10.7	21
1082	Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. *Blood Advances*, **2018**, 2, 1807-1816	7.8	21
1081	A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome. *Clinical Lymphoma, Myeloma and Leukemia*, **2018**, 18, 658-663.e2	2	21
1080	Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. *American Journal of Hematology*, **2017**, 92, E114-E117	7.1	20
1079	Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. *American Journal of Hematology*, **2020**, 95, 612-622	7.1	20
1078	Integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution. *British Journal of Haematology*, **2014**, 166, 646-59	4.5	20
1077	Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome. *American Journal of Hematology*, **2015**, 90, 769-73	7.1	20
1076	Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. *Lancet Haematology,the*, **2015**, 2, e12-20	14.6	20
1075	Prediction model for mortality after intracranial hemorrhage in patients with leukemia. *American Journal of Hematology*, **2011**, 86, 546-9	7.1	20
1074	Characteristics of pericardial effusions in patients with leukemia. *Cancer*, **2010**, 116, 2366-71	6.4	20

1073	Future directions for the use of hypomethylating agents. *Seminars in Hematology*, **2005**, 42, S50-9	4	20
1072	Maintenance with 5-Azacytidine for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients. *Blood*, **2018**, 132, 971-971	2.2	20
1071	First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML). *Blood*, **2013**, 122, 497-497	2.2	20
1070	Defining the Immune Checkpoint Landscape in Patients (pts) with Acute Myeloid Leukemia (AML). *Blood*, **2016**, 128, 2900-2900	2.2	20
1069	KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice. *Blood Advances*, **2018**, 2, 2491-2504	7.8	20
1068	Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia. *Clinical Cancer Research*, **2002**, 8, 2134-41	12.9	20
1067	Chronic myelomonocytic leukemia: Forefront of the field in 2015. *Critical Reviews in Oncology/Hematology*, **2015**, 95, 222-42	7	19
1066	Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases. *Leukemia*, **2018**, 32, 2512-2518	10.7	19
1065	Significance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission. *Biology of Blood and Marrow Transplantation*, **2013**, 19, 214-20	4.7	19
1064	Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD. *British Journal of Haematology*, **2013**, 161, 659-66	4.5	19
1063	Pharmacokinetic evaluation of decitabine for the treatment of leukemia. *Expert Opinion on Drug Metabolism and Toxicology*, **2011**, 7, 661-72	5.5	19
1062	Prognosis of myelodysplastic syndromes. *Hematology American Society of Hematology Education Program*, **2010**, 2010, 330-7	3.1	19
1061	C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome. *Leukemia Research*, **2004**, 28, 373-8	2.7	19
1060	Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986. *Cancer*, **2005**, 103, 2551-7	6.4	19
1059	Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS). *Blood*, **2018**, 132, 905-905	2.2	19
1058	Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS). *Blood*, **2019**, 134, 678-678	2.2	19
1057	Final Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML). *Blood*, **2015**, 126, 453-453	2.2	19
1056	KIR gene haplotype: an independent predictor of clinical outcome in MDS patients. *Blood*, **2016**, 128, 2819-2823	2.2	19

1055	Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. *Lancet Haematology,the*, **2021**, 8, e552-e561	14.6	19
1054	Therapeutic choices after hypomethylating agent resistance for myelodysplastic syndromes. *Current Opinion in Hematology*, **2018**, 25, 146-153	3.3	18
1053	Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R. *American Journal of Hematology*, **2018**, 93, 1245-1253	7.1	18
1052	The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes. *Annals of Hematology*, **2013**, 92, 1335-43	3	18
1051	Analysis of class I and II histone deacetylase gene expression in human leukemia. *Leukemia and Lymphoma*, **2015**, 56, 3426-33	1.9	18
1050	Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells. *Journal of Cellular and Molecular Medicine*, **2010**, 14, 1777-92	5.6	18
1049	Modifying the epigenome as a therapeutic strategy in myelodysplasia. *Hematology American Society of Hematology Education Program*, **2007**, 2007, 405-11	3.1	18
1048	A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes. *Blood*, **2018**, 132, 793-793	2.2	18
1047	An Open-Label, Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in Patients with Low or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic Leukemia (CMML) and Anemia Requiring Transfusion. *Blood*, **2014**, 124, 3251-3251	2.2	18
1046	Frontline Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Acute Lymphoblastic Leukemia (ALL). *Blood*, **2015**, 126, 83-83	2.2	18
1045	An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes. *American Journal of Hematology*, **2017**, 92, 674-682	7.1	17
1044	Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. *Cancer*, **2020**, 126, 2193-2205	6.4	17
1043	Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. *Cancer*, **2018**, 124, 2534-2540	6.4	17
1042	CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia. *Leukemia Research*, **2018**, 72, 79-85	2.7	17
1041	A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome. *American Journal of Hematology*, **2014**, 89, E156-62	7.1	17
1040	Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia. *Journal of Cutaneous Pathology*, **2017**, 44, 1075-1079	1.7	17
1039	Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies. *Investigational New Drugs*, **2015**, 33, 870-80	4.3	17
1038	Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA. *American Journal of Hematology*, **2011**, 86, 237-8	7.1	17

1037	Safety and efficacy of azacitidine in myelodysplastic syndromes. *Drug Design, Development and Therapy*, **2010**, 4, 221-9	4.4	17
1036	Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. *Leukemia Research*, **2005**, 29, 649-52	2.7	17
1035	Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. *Blood*, **2019**, 134, 283-283	2.2	17
1034	A Phase 2 Study of Pracinostat and Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Not Eligible for Induction Chemotherapy: Response and Long-Term Survival Benefit. *Blood*, **2016**, 128, 100-100	2.2	17
1033	Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes. *Journal of Clinical Oncology*, **2021**, 39, 1426-1436	2.2	17
1032	Immunotherapy in Acute Myeloid Leukemia: Where We Stand. *Frontiers in Oncology*, **2021**, 11, 656218	5.3	17
1031	A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. *Cancer Medicine*, **2018**, 7, 5457-5469	4.8	17
1030	Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy. *Haematologica*, **2002**, 87, 1114-6	6.6	17
1029	Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia. *Leukemia and Lymphoma*, **2018**, 59, 2238-2241	1.9	16
1028	Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. *American Journal of Hematology*, **2015**, 90, 1065-70	7.1	16
1027	Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase. *Cancer*, **2003**, 98, 1430-7	6.4	16
1026	Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome. *Blood*, **2018**, 132, 286-286	2.2	16
1025	Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study. *Blood*, **2021**, 138, 244-244	2.2	16
1024	Melatonin enhances sorafenib-induced cytotoxicity in FLT3-ITD acute myeloid leukemia cells by redox modification. *Theranostics*, **2019**, 9, 3768-3779	12.1	15
1023	Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders. *Haematologica*, **2020**, 105, 1567-1574	6.6	15
1022	Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome. *Modern Pathology*, **2018**, 31, 1141-1154	9.8	15
1021	Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis. *Leukemia Research*, **2016**, 48, 1-5	2.7	15
1020	Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. *Clinical Lymphoma, Myeloma and Leukemia*, **2016**, 16, 163-8.e1-2	2	15

1019	Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission. *Leukemia and Lymphoma*, **2010**, 51, 475-80	1.9	15
1018	Aberrant DNA methylation of a cell cycle regulatory pathway composed of P73, P15 and P57KIP2 is a rare event in children with acute lymphocytic leukemia. *Leukemia Research*, **2005**, 29, 881-5	2.7	15
1017	Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML. *Blood*, **2020**, 136, 18-20	2.2	15
1016	Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. *International Journal of Hematology*, **2019**, 109, 545-552	2.3	14
1015	Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide. *Leukemia and Lymphoma*, **2015**, 56, 1342-5	1.9	14
1014	Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia. *American Journal of Hematology* , **2015**, 90, 120-4	7.1	14
1013	Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. *Cancer*, **2018**, 124, 1160-1168	6.4	14
1012	Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions. *Current Oncology Reports*, **2016**, 18, 4	6.3	14
1011	Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype. *European Journal of Haematology*, **2017**, 99, 536-543	3.8	14
1010	Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC). *Leukemia and Lymphoma*, **2017**, 58, 1325-1331	1.9	14
1009	Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care. *Blood Cancer Journal*, **2017**, 7, 644	7	14
1008	Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications. *Clinical Lymphoma, Myeloma and Leukemia*, **2011**, 11, 237-41	2	14
1007	Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy. *Oncologist*, **2009**, 14, 489-96	5.7	14
1006	Downregulation of JUNB mRNA expression in advanced phase chronic myelogenous leukemia. *Leukemia Research*, **2009**, 33, 1361-6	2.7	14
1005	Cytoprotection in acute myelogenous leukemia (AML) therapy. *Seminars in Oncology*, **2004**, 31, 67-73	5.5	14
1004	Current therapy of chronic myelogenous leukemia. *Internal Medicine*, **2002**, 41, 254-64	1.1	14
1003	Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis. *Blood*, **2019**, 134, 555-555	2.2	14
1002	The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial. *Blood*, **2014**, 124, 388-388	2.2	14

1001	Epigenetic therapy in allogeneic hematopoietic stem cell transplantation. *Revista Brasileira De Hematologia E Hemoterapia*, **2013**, 35, 126-33		14
1000	Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. *Blood Advances*, **2021**, 5, 1876-1883	7.8	14
999	Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. *Leukemia*, **2021**, 35, 3282-3286	10.7	14
998	Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. *Cancer*, **2018**, 124, 4192-4201	6.4	14
997	Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes. *Journal of Clinical Oncology*, **2021**, 39, 3737-3746	2.2	14
996	A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. *Leukemia and Lymphoma*, **2018**, 59, 813-820	1.9	13
995	Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. *American Journal of Hematology*, **2019**, 94, 1388-1395	7.1	13
994	Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. *Haematologica*, **2017**, 102, 1709-1717	6.6	13
993	Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome. *Acta Haematologica*, **2002**, 108, 164-7	2.7	13
992	Sequential Combination of Low-Intensity Chemotherapy (Mini-hyper-CVD) Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Phase 2 Trial. *Blood*, **2018**, 132, 553-553	2.2	13
991	A Phase II Study of the Hyper-CVAD Regimen in Sequential Combination with Blinatumomab As Frontline Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL). *Blood*, **2018**, 132, 32-32	2.2	13
990	LCL161, an Oral Smac Mimetic/IAP Antagonist for Patients with Myelofibrosis (MF): Novel Translational Findings Among Long-Term Responders in a Phase 2 Clinical Trial. *Blood*, **2018**, 132, 687-687	2.2	13
989	A Phase Ib/II Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML. *Blood*, **2019**, 134, 176-176	2.2	13
988	Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute Myeloid Leukemia Than FLAG and Idarubicin (FLAG-Ida). *Blood*, **2019**, 134, 290-290	2.2	13
987	Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial. *Blood*, **2019**, 134, 2637-2637	2.2	13
986	Final Results of a Phase I Study of the Histone Deacetylase Inhibitor Vorinostat (Suberoyanilide Hydroxamic Acid, SAHA), in Patients with Leukemia and Myelodysplastic Syndrome.. *Blood*, **2005**, 106, 2801-2801	2.2	13
985	Phase I/II Study of MGCD0103, an Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, in Combination with 5-Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML).. *Blood*, **2007**, 110, 444-444	2.2	13
984	Randomized Phase II Study of Combined Epigenetic Therapy: Decitabine Vs. Decitabine and Valproic Acid in MDS and AML. *Blood*, **2008**, 112, 228-228	2.2	13

983	A Decision Analysis of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with De-Novo Myelodysplastic Syndrome (MDS): Early Transplantation Offers Survival Benefit in Higher-Risk MDS. *Blood*, **2011**, 118, 115-115	2.2	13
982	Results for Phase II Clinical Trial of LCL161, a SMAC Mimetic, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (post-ET MF). *Blood*, **2016**, 128, 3105-3105	2.2	13
981	Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML. *Blood*, **2021**, 138, 371-371	2.2	13
980	The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. *American Journal of Hematology*, **2020**, 95, 144-150	7.1	13
979	Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. *Nature Communications*, **2021**, 12, 2607	17.4	13
978	Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. *Leukemia*, **2021**, 35, 3542-3550	10.7	13
977	Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. *Blood Cancer Discovery*, **2021**, 2, 125-134	7	13
976	Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS. *Leukemia Research*, **2018**, 73, 51-57	2.7	13
975	Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome. *Cancer*, **2019**, 125, 2233-2241	6.4	12
974	Long-term results of frontline dasatinib in chronic myeloid leukemia. *Cancer*, **2020**, 126, 1502-1511	6.4	12
973	Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib. *Cancer*, **2011**, 117, 5085-93	6.4	12
972	Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). *British Journal of Haematology*, **2010**, 148, 386-93	4.5	12
971	Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens. *Cancer*, **2009**, 115, 101-6	6.4	12
970	Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study. *Blood*, **2018**,	2.2	12
969	Phase 1 Dose Escalation and Expansion Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BET Inhibitor FT-1101 As a Single Agent in Patients with Relapsed or Refractory Hematologic Malignancies. *Blood*, **2019**, 134, 3907-3907	2.2	12
968	Effect of Romiplostim in Patients (pts) with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Azacytidine. *Blood*, **2008**, 112, 224-224	2.2	12
967	Efficacy of Frontline Nilotinib Therapy in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP). *Blood*, **2011**, 118, 454-454	2.2	12
966	Phase I/II Trial of the MEK1/2 Inhibitor Trametinib (GSK1120212) in Relapsed/Refractory Myeloid Malignancies: Evidence of Activity in Patients with RAS Mutation-Positive Disease. *Blood*, **2012**, 120, 677-677	2.2	12

965	Salvage Chemotherapy with Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). *Blood*, **2015**, 126, 3721-3721	2.2	12
964	The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial. *Blood*, **2016**, 128, 1642-1642	2.2	12
963	Survival Outcome of Patients with Acute Myeloid Leukemia Transformed from Myeloproliferative Neoplasms. *Blood*, **2016**, 128, 1940-1940	2.2	12
962	A Clinical Study of OPN-305, a Toll-like Receptor 2 (TLR-2) Antibody, in Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received Prior Hypomethylating Agent (HMA) Therapy. *Blood*, **2016**, 128, 227-227	2.2	12
961	Efficacy of a Type I FLT3 Inhibitor, Crenolanib, with Idarubicin and High-Dose Ara-C in Multiply Relapsed/Refractory FLT3+ AML. *Blood*, **2016**, 128, 2744-2744	2.2	12
960	Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine. *American Journal of Hematology*, **2021**, 96, 589-598	7.1	12
959	Fatigue, symptom burden, and health-related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria. *Cancer Medicine*, **2019**, 8, 543-553	4.8	12
958	Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. *American Journal of Hematology*, **2017**, 92, 924-928	7.1	11
957	Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia. *Cancer*, **2019**, 125, 3219-3224	6.4	11
956	Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia. *British Journal of Haematology*, **2015**, 170, 590-3	4.5	11
955	Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor. *Leukemia and Lymphoma*, **2015**, 56, 1012-9	1.9	11
954	Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study. *Leukemia Research*, **2020**, 94, 106369	2.7	11
953	Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. *Annals of Hematology*, **2018**, 97, 1183-1191	3	11
952	A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. *Cancer*, **2016**, 122, 3336-3343	6.4	11
951	Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States. *Cancer Medicine*, **2019**, 8, 6559-6565	4.8	11
950	Can we improve outcomes in patients with acute myelogenous leukemia? Incorporating HDAC inhibitors into front-line therapy. *Best Practice and Research in Clinical Haematology*, **2012**, 25, 427-35	4.2	11
949	Clinical and cytogenetic characteristics of myelodysplastic syndrome in patients with HIV infection. *Leukemia Research*, **2012**, 36, 1376-9	2.7	11
948	Myelodysplastic syndromes with deletions of chromosome 11q lack cryptic MLL rearrangement and exhibit characteristic clinicopathologic features. *Leukemia Research*, **2011**, 35, 351-7	2.7	11

947	Rare case of septic arthritis caused by Candida krusei: case report and literature review. *Journal of Rheumatology*, **2012**, 39, 1308-9	4.1	11
946	Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study. *Blood*, **2018**, 132, 906-906	2.2	11
945	Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL). *Blood*, **2019**, 134, 3807-3807	2.2	11
944	Phase I/II Study of Ruxolitinib (RUX) with Decitabine (DAC) in Patients with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Phase I Results. *Blood*, **2016**, 128, 4262-4262	2.2	11
943	Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial. *Blood*, **2016**, 128, 588-588	2.2	11
942	Quantitative proteomic analysis of histone modifications in decitabine sensitive and resistant leukemia cell lines. *Clinical Proteomics*, **2016**, 13, 14	5	11
941	Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. *Cancer*, **2016**, 122, 3812-3820	6.4	11
940	Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study. *American Journal of Hematology*, **2013**, 88, 198-200	7.1	10
939	Low frequency of H3.3 mutations and upregulated DAXX expression in MDS. *Blood*, **2013**, 121, 4009-11	2.2	10
938	Treatment of higher-risk myelodysplastic syndrome. *Seminars in Oncology*, **2011**, 38, 673-81	5.5	10
937	A Clinical Study of Tomaralimab (OPN-305), a Toll-like Receptor 2 (TLR-2) Antibody, in Heavily Pre-Treated Transfusion Dependent Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received and Failed on Prior Hypomethylating Agent (HMA) Therapy. *Blood*, **2018**, 132, 798-798	2.2	10
936	Hematologic Improvement-Neutrophil and -Platelet in the MEDALIST Trial: Multilineage Data from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions. *Blood*, **2019**, 134, 4243-4243	2.2	10
935	Results of a Phase I/II Study of the Combination of 5-aza-2?-Deoxycytidine (DAC) and Valproic Acid (VPA) in Patients (pts) with Leukemia.. *Blood*, **2004**, 104, 263-263	2.2	10
934	Dynamics of BCR-ABL Kinase Domain Mutations in Patients with Chronic Myeloid Leukemia (CML) after Treatment with One, Two or Three Tyrosine Kinase Inhibitors (TKI).. *Blood*, **2006**, 108, 750-750	2.2	10
933	Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) and Decitabine in Patients with Relapsed, Refractory or Poor Prognosis Leukemia.. *Blood*, **2007**, 110, 897-897	2.2	10
932	SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML. *Blood*, **2012**, 120, 3625-3625	2.2	10
931	Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) after Failure of Hypomethylating Agents (HMAs). *Blood*, **2014**, 124, 163-163	2.2	10
930	Successful Emulation of IV Decitabine Pharmacokinetics with an Oral Fixed-Dose Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine, in Subjects with Myelodysplastic Syndromes (MDS): Final Data of Phase 1 Study. *Blood*, **2016**, 128, 114-114	2.2	10

929	Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. *American Journal of Hematology*, **2020**, 95, 1288-1295	7.1	10
928	A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. *Haematologica*, **2021**, 106, 2121-2130	6.6	10
927	Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. *BMC Cancer*, **2016**, 16, 652	4.8	10
926	The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. *Leukemia*, **2021**, 35, 691-700	10.7	10
925	Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy. *Clinical Advances in Hematology and Oncology*, **2008**, 6, 1-15	0.6	10
924	TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. *Cancer*, **2017**, 123, 3717-3724	6.4	9
923	LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents. *Leukemia and Lymphoma*, **2020**, 61, 1493-1499	1.9	9
922	Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. *Leukemia and Lymphoma*, **2018**, 59, 1312-1322	1.9	9
921	Down-regulation of EZH2 expression in myelodysplastic syndromes. *Leukemia Research*, **2016**, 44, 1-7	2.7	9
920	Response kinetics and factors predicting survival in core-binding factor leukemia. *Leukemia*, **2018**, 32, 2698-2701	10.7	9
919	Clinical outcomes in adult patients with aplastic anemia: A single institution experience. *American Journal of Hematology*, **2017**, 92, 1295-1302	7.1	9
918	The search for better prognostic models in myelodysplastic syndromes. *Current Hematologic Malignancy Reports*, **2011**, 6, 13-21	4.4	9
917	Current and future management options for myelodysplastic syndromes. *Drugs*, **2010**, 70, 1381-94	12.1	9
916	Clinical impact of the clone size in MDS cases with monosomy 7 or 7q deletion, trisomy 8, 20q deletion and loss of Y chromosome. *Leukemia Research*, **2011**, 35, 834-6	2.7	9
915	Treatment strategies in myelodysplastic syndromes. *Cancer Investigation*, **2008**, 26, 208-16	2.1	9
914	Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature. *Leukemia Research*, **2004**, 28, 657-60	2.7	9
913	Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside. *Cancer*, **2003**, 97, 3010-6	6.4	9
912	Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia. *Leukemia Research*, **2003**, 27, 301-4	2.7	9

911	Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia. *Investigational New Drugs*, **2001**, 19, 13-20	4.3	9
910	Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS). *Blood*, **2018**, 132, 232-232	2.2	9
909	Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS). *Blood*, **2018**, 132, 1831-1831	2.2	9
908	Inotuzumab Ozogamicin (Ino) May Overcome the Impact of Philadelphia Chromosome (Ph)-like Phenotype in Adult Patients (pts) with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). *Blood*, **2019**, 134, 1641-1641	2.2	9
907	Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome. *Blood*, **2019**, 134, 4240-4240	2.2	9
906	Clinical Relevance of CRp in Untreated AML.. *Blood*, **2005**, 106, 541-541	2.2	9
905	Phase II Study Of The Hyper-CVAD Regimen In Combination With Ofatumumab As Frontline Therapy For Adults With CD-20 Positive Acute Lymphoblastic Leukemia (ALL). *Blood*, **2013**, 122, 2664-2664	2.2	9
904	Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS). *Blood*, **2015**, 126, 461-461	2.2	9
903	A Randomized, Placebo-Controlled, Phase II Study of Pracinostat in Combination with Azacitidine (AZA) in Patients with Previously Untreated Myelodysplastic Syndrome (MDS). *Blood*, **2015**, 126, 911-911	2.2	9
902	Combination of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: Early results from a phase II study.. *Journal of Clinical Oncology*, **2021**, 39, 7001-7001	2.2	9
901	Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy. *Cancer*, **2021**, 127, 3541-3551	6.4	9
900	Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis. *Clinical Lymphoma, Myeloma and Leukemia*, **2018**, 18, 528-532	2	9
899	Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents. *American Journal of Hematology*, **2017**, 92, 351-358	7.1	8
898	Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. *Blood Advances*, **2020**, 4, 1670-1677	7.8	8
897	Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia. *American Journal of Hematology*, **2012**, 87, 317-8	7.1	8
896	Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study. *Cancer*, **2010**, 116, 5272-8	6.4	8
895	Safety and Efficacy of Blinatumomab in Patients with Central Nervous System (CNS) Disease: A Single Institution Experience. *Blood*, **2018**, 132, 2702-2702	2.2	8
894	Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). *Blood*, **2019**, 134, 2647-2647	2.2	8

893	Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. *Blood*, **2019**, 134, 823-823	2.2	8
892	Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse. *Blood*, **2019**, 134, 3806-3806	2.2	8
891	Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML). *Blood*, **2020**, 136, 37-38	2.2	8
890	Phase II Study of CEP701, an Orally Available JAK2 Inhibitor, in Patients with Primary Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis.. *Blood*, **2007**, 110, 3543-3543	2.2	8
889	A Phase 1 Study to Assess the Absolute Bioavailability and Safety of An Oral Solution of Decitabine In Subjects with Myelodysplastic Syndromes (MDS),. *Blood*, **2011**, 118, 3801-3801	2.2	8
888	Results From the Dose Escalation Phase of a Randomized Phase 1⁄2 First-in-Human (FIH) Study of SGI-110, a Novel Low Volume Stable Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA) in Patients with Relapsed/Refractory MDS and AML. *Blood*, **2012**, 120, 414-414	2.2	8
887	Phase II Study of the Frontline Hyper-CVAD in Combination with Ofatumumab for Adult Patients (pts) with CD-20 Positive Acute Lymphoblastic Leukemia (ALL). *Blood*, **2015**, 126, 1295-1295	2.2	8
886	Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia. *Blood*, **2017**, 130, 815-815	2.2	8
885	Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. *Blood Advances*, **2021**, 5, 2173-2183	7.8	8
884	Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. *Cancer*, **2021**, 127, 2648-2656	6.4	8
883	A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. *Cancer*, **2021**, 127, 3761-3771	6.4	8
882	Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy. *American Journal of Hematology*, **2016**, 91, 1221-1226	7.1	8
881	Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia. *Cancer*, **2019**, 125, 1855-1866	6.4	8
880	Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation. *American Journal of Hematology*, **2020**, 95, 227-229	7.1	8
879	Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome. *British Journal of Haematology*, **2021**, 195, 378-387	4.5	8
878	Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response. *Leukemia and Lymphoma*, **2016**, 57, 812-9	1.9	7
877	Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival. *Clinical Lymphoma, Myeloma and Leukemia*, **2015**, 15, 556-62	2	7
876	Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1. *Modern Pathology*, **2020**, 33, 1678-1689	9.8	7

875	Genetic rescue of lineage-balanced blood cell production reveals a crucial role for STAT3 antiinflammatory activity in hematopoiesis. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E2311-E2319	11.5	7
874	Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations. *International Journal of Hematology*, **2018**, 107, 689-695	2.3	7
873	Dietary intake of vegetables, fruits, and meats/beans as potential risk factors of acute myeloid leukemia: a Texas case-control study. *Nutrition and Cancer*, **2013**, 65, 1132-40	2.8	7
872	Histone methylation in myelodysplastic syndromes. *Epigenomics*, **2011**, 3, 193-205	4.4	7
871	Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients. *Blood*, **2018**, 132, 230-230	2.2	7
870	Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (Pts) with Revised International Prognostic Scoring System (IPSS-R) Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC)	2.2	7
869	Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia. *Blood*, **2019**, 134, 645-645	2.2	7
868	Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study. *Blood*, **2020**, 136, 9-11	2.2	7
867	PEG-Intron for Myeloproliferative Diseases: An Update of Ongoing Phase II Study.. *Blood*, **2004**, 104, 1517-1517	2.2	7
866	Phase I/II Study of the Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor MGCD0103 in Combination with Azacitidine in Patients (pts) with High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML).. *Blood*, **2006**, 108, 1954-1954	2.2	7
865	Efficacy of Nilotinib (formerly AMN107) in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP). *Blood*, **2008**, 112, 446-446	2.2	7
864	Phase I Study of the Oral Histone Deacetylase Inhibitor SB939 In Patients with Advanced Hematologic Malignancies. *Blood*, **2010**, 116, 3292-3292	2.2	7
863	Phase I Study to Assess the Safety and Tolerability of AZD1152 In Combination with Low Dose Cytosine Arabinoside In Patients with Acute Myeloid Leukemia (AML). *Blood*, **2010**, 116, 656-656	2.2	7
862	Final Report of a Phase I Trial of Decitabine with or without hyperCVAD In Relapsed Acute Lymphocytic Leukemia (ALL). *Blood*, **2010**, 116, 867-867	2.2	7
861	Very High Rates of Clinical and Cytogenetic Response with the Combination of the Histone Deacetylase Inhibitor Pracinostat (SB939) and 5-Azacitidine in High-Risk Myelodysplastic Syndrome. *Blood*, **2012**, 120, 3821-3821	2.2	7
860	Phase 1 Dose-Escalation/Expansion Study Of ARRY-614 In Patients With IPSS Low/Int-1 Risk Myelodysplastic Syndromes. *Blood*, **2013**, 122, 387-387	2.2	7
859	Panobinostat Plus Azacitidine in Adult Patients with MDS, CMML, or AML: Results of a Phase 2b Study. *Blood*, **2015**, 126, 2861-2861	2.2	7
858	CC-486 (Oral Azacitidine) Monotherapy in Patients with Acute Myeloid Leukemia (AML). *Blood*, **2015**, 126, 452-452	2.2	7

857	Comparison of Efficacy and Safety Results in 103 Treatment-Naïve Acute Myeloid Leukemia (TN-AML) Patients Not Candidates for Intensive Chemotherapy Using 5-Day and 10-Day Regimens of Guadecitabine (SGI-110), a Novel Hypomethylating Agent (HMA). *Blood*, **2015**, 126, 458-458	2.2	7
856	Validation of International Working Group (IWG) Response Criteria in Higher-Risk Myelodysplastic Syndromes (MDS): A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC). *Blood*, **2015**, 126, 909-909	2.2	7
855	Low-Dose Hypomethylating Agents (HMAs) Are Effective in Patients (Pts) with Low- or Intermediate-1-Risk Myelodysplastic Syndrome (MDS): A Report on Behalf of the MDS Clinical Research Consortium. *Blood*, **2015**, 126, 94-94	2.2	7
854	Ruxolitinib (RUX) in Combination with 5-Azacytidine (AZA) As Therapy for Patients (pts) with Myelofibrosis (MF). *Blood*, **2016**, 128, 1127-1127	2.2	7
853	Cladribine Combined with Idarubicin and Ara-C (CLIA) As a Frontline and Salvage Treatment for Young Patients (≤55 yrs) with Acute Myeloid Leukemia. *Blood*, **2016**, 128, 1639-1639	2.2	7
852	CPX-351 for the Treatment of High-Risk Patients with Acute Myeloid Leukemia. *Blood*, **2016**, 128, 4047-4047	2.2	7
851	Preclinical activity of FF-10501-01, a novel inosine-5'-monophosphate dehydrogenase inhibitor, in acute myeloid leukemia. *Leukemia Research*, **2017**, 59, 85-92	2.7	7
850	Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. *Cancer*, **2021**, 127, 2025-2038	6.4	7
849	Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. *Blood Cancer Journal*, **2021**, 11, 98	7	7
848	Persistence of immunophenotypically aberrant CD34+ myeloid progenitors is frequent in bone marrow of patients with myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms treated with hypomethylating agents. *Journal of Clinical Pathology*, **2016**,	3.9	7
847	A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure. *Leukemia and Lymphoma*, **2019**, 60, 2207-2213	1.9	7
846	Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide: A case report. *Medicine (United States)*, **2019**, 98, e14011	1.8	7
845	Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome. *Hematological Oncology*, **2019**, 37, 96-102	1.3	7
844	Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti-PD-1-based therapy. *Blood Advances*, **2021**, 5, 4569-4574	7.8	7
843	A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes. *Haematologica*, **2002**, 87, 804-7	6.6	7
842	Current management of patients with chronic myelomonocytic leukemia. *Current Opinion in Oncology*, **2017**, 29, 79-87	4.2	6
841	Very high levels of lactate dehydrogenase at diagnosis predict central nervous system relapse in acute promyelocytic leukaemia. *British Journal of Haematology*, **2015**, 169, 595-7	4.5	6
840	The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes. *Leukemia and Lymphoma*, **2015**, 56, 390-4	1.9	6

839	Association of anemia and cognitive dysfunction in patients with acute myelogenous leukemia and myelodysplastic syndrome. *American Journal of Hematology*, **2011**, 86, 950-2	7.1	6
838	Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AML. *Leukemia Research*, **2003**, 27, 475-9	2.7	6
837	Phase I-II Study of Crenolanib Combined with Standard Salvage Chemotherapy and Crenolanib Combined with 5-Azacitidine in Acute Myeloid Leukemia Patients with FLT3 Activating Mutations. *Blood*, **2018**, 132, 2715-2715	2.2	6
836	Outcomes with Subsequent FLT3-Inhibitor (FLT3i) Based Therapies in FLT3-Mutated (mu) Patients (pts) Refractory/Relapsed (R/R) to One or More Prior FLT3 Inhibitor Based Therapies: A Single Center Experience. *Blood*, **2018**, 132, 663-663	2.2	6
835	Interim Analysis of a Phase II Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with Azacitidine in Advanced Myelodysplastic Syndrome (MDS). *Blood*, **2019**, 134, 567-567	2.2	6
834	Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS). *Blood*, **2019**, 134, 566-566	2.2	6
833	A Phase I Study of the Histone Deacetylase Inhibitor MGCD0103 (MG-0103) Given as a Three-Times Weekly Oral Dose in Patients with Leukemia or Myelodysplastic Syndromes (MDS).. *Blood*, **2005**, 106, 4639-4639	2.2	6
832	MK-0457, a Novel Multikinase Inhibitor, Has Activity in Refractory AML, Including Transformed JAK2 Positive Myeloproliferative Disease (MPD), and in Philadelphia-Positive ALL.. *Blood*, **2006**, 108, 1967-1967	2.2	6
831	Outcome with the Hyper-CVAD and Imatinib Mesylate Regimen as Frontline Therapy for Adult Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).. *Blood*, **2006**, 108, 284-284	2.2	6
830	Outcome of Allogeneic Stem Cell Transplantation after Hypomethylating Therapy with 2?-Deoxy-5 Azacytidine for Patients with Myelodysplastic Syndrome.. *Blood*, **2007**, 110, 1468-1468	2.2	6
829	Oral (po) and Intravenous (iv) Clofarabine for Patients (pts) with Myelodysplastic Syndrome (MDS). *Blood*, **2008**, 112, 222-222	2.2	6
828	Phase II Study of Vorinostat in Combination with Idarubicin (Ida) and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS).. *Blood*, **2009**, 114, 1055-1055	2.2	6
827	A Phase II Randomized Bayesian Study of Very Low Dose Subcutaneous Decitabine Administered Daily or Weekly Times Three in Patients with Lower Risk Myelodysplastic Syndrome (MDS).. *Blood*, **2009**, 114, 119-119	2.2	6
826	Efficacy and Safety of Romiplostim in Patients with Low or Intermediate-Risk Myelodysplastic Syndrome (MDS) Receiving Decitabine.. *Blood*, **2009**, 114, 1769-1769	2.2	6
825	FLT3 Inhibitor Treatment in FLT3-Mutated AML Is Associated with Development of Secondary FLT3-TKD Mutations. *Blood*, **2011**, 118, 1493-1493	2.2	6
824	Extended Dosing of Oral Azacitidine (CC-486) for 14 and 21 Days Provides More Effective Methylation Reversal Than a 7-Day Schedule. *Blood*, **2012**, 120, 1337-1337	2.2	6
823	TP53 Mutation Status Divides MDS Patients with Complex Karyotypes into Distinct Prognostic Risk Groups: Analysis of Combined Datasets from the International Working Group for MDS-Molecular Prognosis Committee. *Blood*, **2014**, 124, 532-532	2.2	6
822	A Patient-Reported Outcome Measure for Symptoms and Symptom Burden of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). *Blood*, **2015**, 126, 2094-2094	2.2	6

821	Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Large Single-Center Experience: Analysis of Clinical and Molecular Characteristics and Patient Outcomes. *Blood*, **2015**, 126, 3746-3746	2.2	6
820	CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies. *Blood*, **2016**, 128, 905-905	2.2	6
819	Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML). *Blood*, **2021**, 138, 246-246	2.2	6
818	Phase I and Expansion Study of Eprenetapopt (APR-246) in Combination with Venetoclax (VEN) and Azacitidine (AZA) in TP53-Mutant Acute Myeloid Leukemia (AML). *Blood*, **2021**, 138, 3409-3409	2.2	6
817	Updated Results of a Phase II Study of Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. *Blood*, **2021**, 138, 2298-2298	2.2	6
816	Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes. *Leukemia*, **2020**, 34, 872-881	10.7	6
815	Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. *Journal of Hematology and Oncology*, **2020**, 13, 132	22.4	6
814	Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials. *Leukemia*, **2019**, 33, 554-558	10.7	6
813	Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies. *Leukemia*, **2019**, 33, 371-378	10.7	6
812	A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy. *British Journal of Haematology*, **2020**, 188, 404-412	4.5	6
811	The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes. *American Journal of Hematology*, **2021**, 96, 241-250	7.1	6
810	Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions. *Cancer*, **2018**, 124, 4601-4609	6.4	6
809	Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. *Blood Cancer Journal*, **2021**, 11, 162	7	6
808	Use of hypomethylating agents in myelodysplastic syndromes. *Clinical Advances in Hematology and Oncology*, **2007**, 5, 544-52	0.6	6
807	Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. *American Journal of Hematology*, **2020**, 95, 734-739	7.1	5
806	CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast count. *Leukemia and Lymphoma*, **2016**, 57, 1965-8	1.9	5
805	Progress in Myelodysplastic Syndromes: Clinicopathologic Correlations and Immune Checkpoints. *Clinical Lymphoma, Myeloma and Leukemia*, **2017**, 17S, S16-S25	2	5
804	Improving survival in myelodysplastic syndromes. *Lancet Oncology, The*, **2009**, 10, 200-1	21.7	5

803	Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome. *British Journal of Haematology*, **2007**, 138, 555-7	4.5	5
802	Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study. *Blood*, **2018**, 132, 84-84	2.2	5
801	Phase I Study of Palbociclib Alone and in Combination in Patients with Relapsed and Refractory (R/R) Leukemias. *Blood*, **2018**, 132, 4057-4057	2.2	5
800	Final Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agent Therapy. *Blood*, **2020**, 136, 23-24	2.2	5
799	A Phase I Study of Tipifarnib in Combination with Imatinib Mesylate (IM) for Patients (Pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Who Failed IM Therapy.. *Blood*, **2004**, 104, 1011-1011	2.2	5
798	Use of All-Transretinoic Acid (ATRA) + Arsenic Trioxide (ATO) To Eliminate or Minimize Use of Chemotherapy (CT) in Untreated Acute Promyelocytic Leukemia (APL).. *Blood*, **2004**, 104, 393-393	2.2	5
797	Clofarabine Plus Cytarabine (ARA-C) Combination Is Active in Newly Diagnosed Patients (PTS) Age 50 with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).. *Blood*, **2004**, 104, 875-875	2.2	5
796	High-Dose (HD) Imatinib Provides Better Responses in Patients with Untreated Early Chronic Phase (CP) CML.. *Blood*, **2006**, 108, 2143-2143	2.2	5
795	Delayed Achievement of Molecular Responses Is Associated with Increased Risk of Progression among Patients (pts) with Chronic Myelogenous Leukemia (CML) In Chronic Phase (CP) Treated with Imatinib (IM).. *Blood*, **2006**, 108, 432-432	2.2	5
794	Better Molecular Response to Imatinib for Patients (pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Carrying the b3a2 Transcript Compared to b2a2.. *Blood*, **2007**, 110, 1939-1939	2.2	5
793	A 3,239 -Patient Combined Eastern Cooperative Oncology Group (ECOG), M.D. Anderson Cancer Center (MDA) Analysis of the Effect of CR vs. Responses Blood, **2007**, 110, 298-298	2.2	5
792	Outcome of Patients (pts) with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) Post Decitabine Failure.. *Blood*, **2008**, 112, 1659-1659	2.2	5
791	Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome. *Blood*, **2008**, 112, 2985-2985	2.2	5
790	Acute Erythroleukemia: An Analysis of 108 Patients Treated with Cytarabine-Containing Regimens at the M.D. Anderson Cancer Center.. *Blood*, **2008**, 112, 925-925	2.2	5
789	FLT3 Inhibitor Therapy for Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Impact On Survival According to FLT3 Status.. *Blood*, **2009**, 114, 1026-1026	2.2	5
788	A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Patients with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML).. *Blood*, **2009**, 114, 117-117	2.2	5
787	Clinical Development of MGCD0103, An Isotype-Selective HDAC Inhibitor: Pericarditis/Pericardial Effusion in the Context of Overall Safety and Efficacy.. *Blood*, **2009**, 114, 4756-4756	2.2	5
786	Final Report of a Phase II Study of 5-Azacitidine and Vorinostat in Patients (pts) with Newly Diagnosed Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) Not Eligible for Clinical Trials Because Poor Performance and Presence of Other Comorbidities. *Blood*, **2011**, 118, 608-608	2.2	5

785	Comparing Outcomes of Patients with Secondary AML: Treatment-Related MDS/AML, AML Secondary to Myeloproliferative Neoplasms (t-MPN), and AML with Prior Malignancies. *Blood*, **2012**, 120, 3557-3557	2.2	5
784	Outcome Of Patients (pts) With Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure. *Blood*, **2013**, 122, 388-388	2.2	5
783	Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients (≥60 years) with Acute Lymphoblastic Leukemia (ALL). *Blood*, **2014**, 124, 794-794	2.2	5
782	Presence of 4 or More Driver Mutations Predicts Poor Response to Hypomethylating Agent (HMA) Therapy and Poor Overall Survival in MDS. *Blood*, **2015**, 126, 1663-1663	2.2	5
781	Results of First in Human (FIH) Phase 1 Pharmacokinetic (PK) Guided Dose-Escalation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS). *Blood*, **2015**, 126, 1683-1683	2.2	5
780	Safety, Pharmacokinetics, and Efficacy of BP-100-1.01 (Liposomal Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and	2.2	5
779	An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS). *Blood*, **2015**, 126, 609-609	2.2	5
778	A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS). *Blood*, **2015**, 126, 910-910	2.2	5
777	Phase I/II Study of DFP-10917 in Relapsed/Refractory AML Demonstrates Efficacy and Safety Profile Suitable for Phase III Study. *Blood*, **2016**, 128, 2822-2822	2.2	5
776	Initial Results of a Phase 2 Study of Guadecitabine (SGI-110), a Novel Subcutaneous (sc) Hypomethylating Agent, for Patients with Previously Untreated Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). *Blood*, **2016**, 128, 346-346	2.2	5
775	A Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia: Results from a Phase I/II Study. *Blood*, **2021**, 138, 696-696	2.2	5
774	The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis. *Haematologica*, **2021**, 106, 2853-2858	6.6	5
773	Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. *Nature Communications*, **2021**, 12, 6071	17.4	5
772	Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. *Leukemia and Lymphoma*, **2020**, 61, 3120-3127	1.9	5
771	Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. *Cancer* , **2021**, 127, 2641-2647	6.4	5
770	Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. *Leukemia*, **2021**, 35, 1494-1498	10.7	5
769	Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup. *Cancer Genetics*, **2016**, 209, 205-14	2.3	5
768	Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. *Cancer*, **2021**, 127, 381-390	6.4	5

767	Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia. *Cancer*, **2020**, 126, 1448-1459	6.4	5
766	Deacetylase inhibitors for the treatment of myelodysplastic syndromes. *Leukemia and Lymphoma*, **2015**, 56, 1205-12	1.9	4
765	Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial. *Leukemia and Lymphoma*, **2018**, 59, 2135-2143	1.9	4
764	Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis. *Haematologica*, **2016**, 101, e324-7	6.6	4
763	Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study. *Leukemia and Lymphoma*, **2017**, 58, 866-871	1.9	4
762	Clonal evolution of acute myeloid leukemia relapsed after 19 years of remission. *American Journal of Hematology*, **2015**, 90, E134-5	7.1	4
761	Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure. *Therapeutic Advances in Hematology*, **2014**, 5, 29-34	5.7	4
760	Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. *Leukemia and Lymphoma*, **2010**, 51, 1478-84	1.9	4
759	Spontaneous Remission of Acute Myeloid Leukemia: Report of Three Cases and Review of the Literature. *Clinical Leukemia*, **2008**, 2, 64-67		4
758	Prognostic implications of epigenetic silencing of p15INK4B in acute promyelocytic leukemia. *Leukemia*, **2003**, 17, 839-40	10.7	4
757	NCCN Guidelines Insights: Myelodysplastic Syndromes, Version 3.2022.. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2022**, 20, 106-117	7.3	4
756	Preliminary Results from a Phase II Study of the Combination of Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome. *Blood*, **2018**, 132, 464-464	2.2	4
755	Cell-Type Specific Mechanisms of Hematopoietic Stem Cell (HSC) Expansion Underpin Progressive Disease in Myelodysplastic Syndromes (MDS) and Provide a Rationale for Targeted Therapies. *Blood* , **2018**, 132, 1798-1798	2.2	4
754	Updated Results of Phase 2 Study of Ruxolitinib in Combination with 5-Azacitidine in Patients with Myelofibrosis. *Blood*, **2018**, 132, 352-352	2.2	4
753	The Impact of Treatment Recommendation By Leukemia Artificial Intelligence Program (LEAP) on Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). *Blood*, **2019**, 134, 1642-1642	2.2	4
752	Title: 12 Versus 8 Prophylactic Intrathecal (IT) Chemotherapy Administration Decrease Incidence of Central Nervous System (CNS) Relapse in Patients (pts) with Newly Diagnosed Philadelphia (Ph)-Positive Acute Lymphocytic Leukemia (ALL). *Blood*, **2019**, 134, 3810-3810	2.2	4
751	Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics and Outcomes in the Rapidly Evolving Modern Targeted Therapy Era. *Blood*, **2019**, 134, 2723-2723	2.2	4
750	Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the Medalist Study. *Blood*, **2020**, 136, 10-12	2.2	4

749	Long-Term Incidence and Outcome of BCR-ABL Mutations in Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib Mesylate - P-Loop Mutations Are Not Associated with Worse Outcome.. *Blood*, **2004**, 104, 1007-1007	2.2	4
748	Plausibility of Delaying Induction Therapy in Untreated AML.. *Blood*, **2004**, 104, 879-879	2.2	4
747	Decitabine Low-Dose Schedule (100 mg/m2/Course) in Myelodysplastic Syndrome (MDS). Comparison of 3 Different Dose Schedules.. *Blood*, **2005**, 106, 2522-2522	2.2	4
746	Pleural Effusion in Patients (pts) with Chronic Myelogenous Leukemia (CML) Treated with Dasatinib after Imatinib Failure.. *Blood*, **2006**, 108, 2164-2164	2.2	4
745	Immune Modulation of Minimal Residual Disease (MRD) in Patients (pts) with Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CP): A Randomized Trial of Frontline High-Dose (HS) Imatinib Mesylate (IM) with or without Pegylated-Interferon (PEG-IFN) and GM-CSF.. *Blood*, **2006**, 108, 2207-2207	2.2	4
744	Maintenance Therapy with 5-Azacytidine (5-AC) after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS): A Dose and Schedule Finding Study.. *Blood*, **2006**, 108, 3668-3668	2.2	4
743	Multivariate Evaluation of the Prognostic and Therapeutic Relevance of Cytogenetics in a Merged European-American Cohort of 3860 Patients with MDS.. *Blood*, **2007**, 110, 247-247	2.2	4
742	Multivariate Analysis Suggests That the Prognostic Impact of Poor Cytogenetics Is Potentially Underestimated in the IPSS.. *Blood*, **2007**, 110, 248-248	2.2	4
741	Benefit of Anti-Infectious Prophylaxis in Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Receiving Frontline Targeted Therapy. *Blood*, **2007**, 110, 2858-2858	2.2	4
740	Pegylated Interferon-ALFA-2A (PEG-IFN-α-2A; PEGASYS) Therapy Renders High Clinical and Molecular Response Rates in Patients with Essential Thrombocythemia (ET) and Polycythemia VERA (PV). *Blood*, **2008**, 112, 658-658	2.2	4
739	Long Term Followup and Patterns of Failure in Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Treated On Studies Combining a Hypomethylating Agent and the Histone Deacetylase Inhibitor (HDACi) Valproic Acid.. *Blood*, **2009**, 114, 2074-2074	2.2	4
738	Chemoimmunotherapy with Cyclophosphomide, Fludarabine, Alemtuzumab and Rituximab (CFAR) Is Effective in Relapsed Patients with Chronic Lymphocytic Leukemia (CLL).. *Blood*, **2009**, 114, 3431-3431	2.2	4
737	A Prognostic Model of Therapy-Related Myelodysplastic syndrome .. *Blood*, **2009**, 114, 3796-3796	2.2	4
736	Updated Results of Combination Cytokine Immunotherapy In the Treatment of Aplastic Anemia and Myelodysplastic Syndrome (MDS). *Blood*, **2010**, 116, 2920-2920	2.2	4
735	Frontline Therapy for Older Patients (pts) with Acute Myeloid Leukemia (AML): Clofarabine Plus Low-Dose Cytarabine Induction Followed by Prolonged Consolidation with Clofarabine Plus Low-Dose Cytarabine Alternating with Decitabine. *Blood*, **2010**, 116, 336-336	2.2	4
734	Phase II Study of 5-Azacitidine and Vorinostat In Patients (pts) with Newly Diagnosed Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) Not Eligible for Clinical Trials Because Poor Performance or Presence of Other comorbidities. *Blood*, **2010**, 116, 604-604	2.2	4
733	Phase 1 Dose-Escalation/Expansion Study of the p38/Tie2 Inhibitor ARRY-614 in Patients with IPSS Low/Int-1 Risk Myelodysplastic Syndromes. *Blood*, **2011**, 118, 118-118	2.2	4
732	24-Month Analysis of the Impact of Chelation on Clinical Outcomes in a 600 Patient Registry of Lower-Risk MDS Patients. *Blood*, **2011**, 118, 2800-2800	2.2	4

731	Phase 1/ 2 Study of Sapacitabine and Decitabine Administered Sequentially in Elderly Patients with Newly Diagnosed AML,. *Blood*, **2011**, 118, 3630-3630	2.2	4
730	Validation of a Prognostic Model and the Impact of SF3B1, DNMT3A, and Other Mutations in 289 Genetically Characterized Lower Risk MDS Patient Samples. *Blood*, **2011**, 118, 969-969	2.2	4
729	A Phase I/II Study Of Cytarabine Or Azacitidine In Combination With Tosedostat In Older Patients With AML Or High-Risk MDS. *Blood*, **2013**, 122, 2698-2698	2.2	4
728	Relationship Between Chelation and Clinical Outcomes in Lower-Risk Patients with Myelodysplastic Syndrome (MDS): Registry Analysis at 5 Years. *Blood*, **2014**, 124, 1350-1350	2.2	4
727	A Phase 1b/2a Study of Birinapant in Combination with 5-Azacitadine in Patients with Myelodysplastic Syndrome Who Are Naïve, Refractory to or Have Relapsed on 5-Azacitadine: a Preliminary Analysis. *Blood*, **2014**, 124, 3263-3263	2.2	4
726	Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS). *Blood*, **2014**, 124, 385-385	2.2	4
725	First Clinical Results of a Randomized Phase 2 Dose-Response Study of SGI-110, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate (Int) or High Risk (HR) Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). *Blood*, **2014**, 124, 529-529	2.2	4
724	Phase II Study of Cladribine, Idarubicin, and Cytarabine (araC) in Patients with Acute Myeloid Leukemia (AML). *Blood*, **2015**, 126, 2541-2541	2.2	4
723	Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat. *Blood*, **2016**, 128, 1166-1166	2.2	4
722	Frontline Ofatumumab in Combination with Hyper-CVAD for Adult Patients with CD-20 Positive Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial. *Blood*, **2016**, 128, 2783-2783	2.2	4
721	Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study. *Blood*, **2016**, 128, 3167-3167	2.2	4
720	A New Clinically-Based Subclassification Proposal in CMML with Significant Prognostic Implications to Overcome the MDS/MPN Categorizing Dilemma. *Blood*, **2016**, 128, 4320-4320	2.2	4
719	Clinical Application of Artificial Intelligence in Patients with Chronic Myeloid Leukemia in Chronic Phase. *Blood*, **2016**, 128, 940-940	2.2	4
718	Venetoclax (Ven) added to intensive chemo with cladribine, idarubicin, and AraC (CLIA) achieves high rates of durable complete remission with low rates of measurable residual disease (MRD) in pts with newly diagnosed acute myeloid leukemia (AML).. *Journal of Clinical Oncology*, **2020**, 38, 7539-7539	2.2	4
717	Azacitidine, Venetoclax and Pevonedistat As Frontline Therapy for Patients with Secondary Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy: Results from a Phase I/II Study. *Blood*, **2021**, 138, 2349-2349	2.2	4
716	Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. *Clinical Lymphoma, Myeloma and Leukemia*, **2021**, 21, 338-344	2	4
715	Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion. *British Journal of Haematology*, **2016**, 173, 161-5	4.5	4
714	A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. *American Journal of Hematology*, **2019**, 94, 74-79	7.1	4

713	Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis. *Leukemia and Lymphoma*, **2021**, 62, 224-228	1.9	4
712	Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. *Blood Advances*, **2021**, 5, 3163-3173	7.8	4
711	Validation of the 2016 revisions to the WHO classification in lower-risk myelodysplastic syndrome. *American Journal of Hematology*, **2017**, 92, E168-E171	7.1	3
710	Nivolumab (Nivo) in Combination with Azacytidine (AZA) in Relapsed and Frontline Elderly Acute Myeloid Leukemia (AML). *Clinical Lymphoma, Myeloma and Leukemia*, **2017**, 17, S9	2	3
709	Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia. *Cancer*, **2019**, 125, 1665-1673	6.4	3
708	Clinical value of event-free survival in acute myeloid leukemia. *Blood Advances*, **2020**, 4, 1690-1699	7.8	3
707	Evaluation of epidemiological factors in survival of patients with de novo myelodysplastic syndromes. *Cancer Causes and Control*, **2014**, 25, 425-35	2.8	3
706	Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations. *Leukemia and Lymphoma*, **2014**, 55, 1431-4	1.9	3
705	Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship. *Cancer*, **2017**, 123, 609-616	6.4	3
704	Standard therapy for patients with myelodysplastic syndromes. *Clinical Lymphoma, Myeloma and Leukemia*, **2011**, 11, 303-13	2	3
703	Integrating care for patients with lower risk myelodysplastic syndrome. *Seminars in Oncology*, **2011**, 38, 658-66	5.5	3
702	Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). *Blood*, **2018**, 132, 231-231	2.2	3
701	What Is the Optimal Time to Initiate Hypomethylating Agents (HMA) in Higher Risk Myelodysplastic Syndromes (MDS)?. *Blood*, **2018**, 132, 3098-3098	2.2	3
700	Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis. *Blood*, **2018**, 132, 3131	2.2	3
699	Long Term Follow-up on Phase 2 Study on the Efficacy and Safety of Blinatumomab in Adult Patients with Relapsed Refractory B-Precursor Acute Lymphoblastic Leukemia. *Blood*, **2018**, 132, 4017-4017	2.2	3
698	Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients (Pts) with LR-MDS Enrolled in the MEDALIST Trial. *Blood*, **2019**, 134, 2999-2999	2.2	3
697	Activity of Venetoclax-Based Therapy in Myelodysplastic Syndrome (MDS). *Blood*, **2019**, 134, 1726-1726	2.2	3
696	Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) in Complete Molecular Response (CMR) within 3 Months of Therapy with Tyrosine Kinase Inhibitors (TKIs). *Blood*, **2019**, 134, 1296-1296	2.2	3

695	Loss of EZH2 Protein Expression in Myelodysplastic Syndrome Correlates with EZH2 Mutation and Portends a Worse Outcome. *Blood*, **2019**, 134, 3016-3016	2.2	3
694	Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib + Injectable Azacitidine (AZA) Versus Injectable Azacitidine in Treatment-Naive Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS). *Blood*, **2019**, 134, 4268-4268	2.2	3
693	A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy. *Blood*, **2019**, 134, 2927-2927	2.2	3
692	Hypomethylation Dynamics Following Decitabine Therapy in Chronic Myelogenous Leukemia.. *Blood*, **2004**, 104, 2956-2956	2.2	3
691	Phase II Study of Decitabine in Combination with Imatinib Mesylate in Patients with Accelerated (AP) or Blastic Phase (BP) of Chronic Myeloid Leukemia (CML).. *Blood*, **2005**, 106, 1099-1099	2.2	3
690	Outcome with the Hyper-CVAD and Imatinib Mesylate Regimen in Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).. *Blood*, **2005**, 106, 1830-1830	2.2	3
689	Continuous Infusion/Subcutaneous Alemtuzumab (Campath-1H) Plus Rituximab Is Active for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).. *Blood*, **2005**, 106, 2963-2963	2.2	3
688	MK-0457 Is a Novel Aurora Kinase and Janus Kinase 2 (JAK2) Inhibitor with Activity in Transformed JAK2-Positive Myeloproliferative Disease (MPD).. *Blood*, **2006**, 108, 4893-4893	2.2	3
687	Outcomes of MDS Patients with Chromosome 7 Abnormalities Treated with 5-Azacytidine.. *Blood*, **2007**, 110, 1449-1449	2.2	3
686	Intensively Timed Induction (ITI) Chemotherapy in Adults with Acute Myelogenous Leukemia (AML).. *Blood*, **2007**, 110, 1851-1851	2.2	3
685	Significance of Suboptimal Response to Imatinib, as Defined by the European LeukemiaNet, in Long-Term Outcome for Patients (Pts) with Chronic Phase (CP) Chronic Myeloid Leukemia (CML).. *Blood*, **2007**, 110, 1932-1932	2.2	3
684	Efficacy of Nilotinib (AMN107) in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP).. *Blood*, **2007**, 110, 29-29	2.2	3
683	Phase II Study of Dasatinib (SPRYCEL) in Philadelphia Chromosome-Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis.. *Blood*, **2007**, 110, 3551-3551	2.2	3
682	Phase I Study of the Akt-Inhibitor Triciribine Phosphate Monohydrate in Patients with Advanced Hematologic Malignancy. *Blood*, **2008**, 112, 2987-2987	2.2	3
681	A Randomized Phase IIa Study of Vorinostat in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes: Preliminary Results. *Blood*, **2008**, 112, 5084-5084	2.2	3
680	Combination of Sorafenib, Idarubicin, and Cytarabine Has a High Response Rate in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Younger Than 65 Years. *Blood*, **2008**, 112, 768-768	2.2	3
679	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Deferasirox (Exjade) in Patients with Low/Intermediate-1 Risk MDS and Transfusional Iron Overload.. *Blood*, **2009**, 114, 4854-4854	2.2	3
678	Phase I Trial Results for SL-401, a Novel Cancer Stem Cell (CSC) Targeting Agent, Demonstrate Clinical Efficacy at Tolerable Doses In Patients with Heavily Pre-Treated AML, Poor Risk Elderly AML, and High Risk MDS. *Blood*, **2010**, 116, 3298-3298	2.2	3

677	Evaluation of Oral Azacitidine Using Extended Treatment Schedules: A Phase I Study. *Blood*, **2010**, 116, 603-603	2.2	3
676	Oral Azacitidine (AZA) Activity in Patients with Acute Myelogenous Leukemia (AML). *Blood*, **2011**, 118, 1546-1546	2.2	3
675	Validating the Lower-Risk MD Anderson Prognostic Scoring System (LR-PSS) and the Revised International Prognostic Scoring System (IPSS-R) for Patients with Myelodysplastic Syndromes. *Blood*, **2011**, 118, 1720-1720	2.2	3
674	Determination of a Phase II Dose of Panobinostat in Combination with 5-Azacitidine in Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia. *Blood*, **2011**, 118, 459-459	2.2	3
673	Clinical Significance of Deeper Molecular Responses with Four Modalities of Tyrosine Kinase Inhibitors As Frontline Therapy for Chronic Myeloid Leukemia. *Blood*, **2012**, 120, 164-164	2.2	3
672	Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelodysplastic Syndromes. *Blood*, **2012**, 120, 424-424	2.2	3
671	The Clinical Impact of Time to Response in De Novo Accelerated Phase Chronic Myeloid Leukemia (CML-AP). *Blood*, **2012**, 120, 72-72	2.2	3
670	Outcome Of Patients (pts) With Myelofibrosis (MF) After Ruxolutinib (Rux) Therapy. *Blood*, **2013**, 122, 1584-1584	2.2	3
669	A Randomized Phase II Study Of Sapacitabine In MDS Refractory To Hypomethylating Agents. *Blood* , **2013**, 122, 2752-2752	2.2	3
668	48-Month Update On Survival and AML Transformation In a 600-Patient Registry Of Lower-Risk MDS Patients. *Blood*, **2013**, 122, 2775-2775	2.2	3
667	Phase II Trial Of Cladribine and Low-Dose AraC (LDAC) Alternating With Decitabine In Older Patients With Acute Myeloid Leukemia (AML). *Blood*, **2013**, 122, 5011-5011	2.2	3
666	A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). *Blood*, **2014**, 124, 3252-3252	2.2	3
665	Outcomes of Patients with Myelodysplastic Syndromes (MDS) Who Achieve Stable Disease after Treatment with Hypomethylating Agents (HMA). *Blood*, **2014**, 124, 3273-3273	2.2	3
664	Phase II Study of Cladribine and Low-Dose Cytarabine (AraC) Alternating with Decitabine in Older Patients with Acute Myeloid Leukemia (AML). *Blood*, **2014**, 124, 3671-3671	2.2	3
663	Survival Impact of Patients (Pts) with Chronic Myeloid Leukemia (CML) Due to Failure from the Use of One or More Tyrosine Kinase Inhibitors (TKI). *Blood*, **2015**, 126, 1587-1587	2.2	3
662	Long-Term Outcome of Myelodysplastic Syndromes (MDS) Patients Treated with Erythropoiesis Stimulating Agents (ESAs). *Blood*, **2015**, 126, 1696-1696	2.2	3
661	Single-Center Experience of Immunosuppressive Therapy with or without Eltrombopag in Patients with Aplastic Anemia. *Blood*, **2015**, 126, 4779-4779	2.2	3
660	5-Azacytidine (AZA) in Combination with Ruxolitinib (RUX) As Therapy for Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs). *Blood*, **2015**, 126, 823-823	2.2	3

659	Combination of Sorafenib and 5-Azacytidine in Older Patients with Untreated Acute Myeloid Leukemia with FLT3-ITDmutation. *Blood*, **2016**, 128, 1611-1611	2.2	3
658	Phase 1 Results of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Advanced Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Hypomethylating Agent (HMA) Failures. *Blood*, **2016**, 128, 1640-1640	2.2	3
657	Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). *Blood*, **2016**, 128, 2011-2011	2.2	3
656	A Randomized Phase II Study of Low-Dose Decitabine Versus Azacitidine in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium. *Blood*, **2016**, 128, 226-226	2.2	3
655	Current Diagnosis Patterns for Acute Myeloid Leukemia (AML) in Clinical Practice Compared with World Health Organization (WHO) 2008 Recommendations: Outcomes from the CONNECT Myelodysplastic Syndromes (MDS) and AML Disease Registry. *Blood*, **2016**, 128, 3548-3548	2.2	3
654	Optimal Treatment Order of Lenalidomide and Hypomethylating Agents for Lower-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium. *Blood*, **2016**, 128, 4322-4322	2.2	3
653	Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic Syndrome. *Blood*, **2021**, 138, 537-537	2.2	3
652	Final Results of a Phase 2 Study of Sotatercept (ACE-011) for Anemia of MPN-Associated Myelofibrosis. *Blood*, **2021**, 138, 144-144	2.2	3
651	Decitabine Induces High Response Rates in Patients with Chronic Myelomonocytic Leukemia (CMML).. *Blood*, **2006**, 108, 2655-2655	2.2	3
650	Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. *Leukemia and Lymphoma*, **2020**, 61, 2811-2820	1.9	3
649	Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. *Blood Cancer Journal*, **2021**, 11, 52	7	3
648	PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2016**, 16 Suppl, S67-73	2	3
647	Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. *American Journal of Hematology*, **2021**, 96, E50-E53	7.1	3
646	Germline DNMT3A mutation in familial acute myeloid leukaemia. *Epigenetics*, **2021**, 16, 567-576	5.7	3
645	Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation **2021**, 9,		3
644	Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemia. *Leukemia Research*, **2021**, 101, 106511	2.7	3
643	Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation. *Leukemia Research*, **2018**, 73, 78-85	2.7	3
642	Phase II study of single-agent nivolumab in patients with myelofibrosis. *Annals of Hematology*, **2021** , 100, 2957-2960	3	3

641	Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience. *Blood Advances*, **2021**, 5, 5415-5419	7.8	3
640	Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML.. *Blood Cancer Journal*, **2022**, 12, 77	7	3
639	Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy. *Leukemia and Lymphoma*, **2019**, 60, 3172-3180	1.9	2
638	AML-190: Anti-TIM-3 Antibody MBG453 in Combination with Hypomethylating Agents (HMAs) in Patients with High-Risk Myelodysplastic Syndrome (HR-MDS) and Acute Myeloid Leukemia: A Phase 1 Study. *Clinical Lymphoma, Myeloma and Leukemia*, **2020**, 20, S188-S189	2	2
637	Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. *Leukemia*, **2020**, 34, 2914-2924	10.7	2
636	The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia. *American Journal of Hematology*, **2020**, 95, 1127	7.1	2
635	Time to response and survival in hypomethylating agent-treated acute myeloid leukemia. *Leukemia and Lymphoma*, **2018**, 59, 1012-1015	1.9	2
634	Prognostic significance of hyperdiploidy in adult acute myeloid leukemia. *American Journal of Hematology*, **2018**, 93, E357-E360	7.1	2
633	Progress in myelodysplastic syndromes. *Clinical Lymphoma and Myeloma*, **2009**, 9 Suppl 3, S286-92		2
632	Decitabine in myelodysplastic syndromes: viewpoints. *Drugs*, **2006**, 66, 959-60	12.1	2
631	Leukemia and lymphoma: what is the role for intrathecal prophylactic treatment in adults?. *Expert Review of Neurotherapeutics*, **2004**, 4, S25-31	4.3	2
630	Ultrasensitive Duplex Sequencing of Pretreatment ABL1 Kinase Domain Mutations in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. *Blood*, **2018**, 132, 1548-1548	2.2	2
629	Results of a Phase 1, Dose-Escalation Study of FF-10501-01 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Hypomethylating Agent (HMA)-Resistant Myelodysplastic Syndrome (MDS). *Blood*, **2018**, 132, 1438-1438	2.2	2
628	Pan-Myeloid Leukemia Analysis: Machine Learning-Based Approach to Predict Phenotype and Clinical Outcomes Using Mutation Data. *Blood*, **2018**, 132, 1801-1801	2.2	2
627	Pattern of Immune-Mediated Toxicities in Patients with Myelodysplastic Syndrome (MDS) Treated with Nivolumab and Ipilimumab. *Blood*, **2018**, 132, 4367-4367	2.2	2
626	Characteristics and Role of Lenalidomide Therapy in Patients with Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis. *Blood*, **2018**, 132, 5513-5513	2.2	2
625	Predicting Induction Toxicity with 7+3: Analysis of SWOG Trial S1203. *Blood*, **2018**, 132, 1403-1403	2.2	2
624	Prognostic Significance of Baseline FLT3-ITD Mutant Allele Burden in Acute Myeloid Leukemia Treated with Intensive Chemotherapy with/without Sorafenib. *Blood*, **2018**, 132, 3983-3983	2.2	2

623	KDM6B Overexpression and TET2 Deficiency Cooperatively Drive Development of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia-like Phenotype in Mice. *Blood*, **2019**, 134, 562-562	2.2	2
622	Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Receiving First Salvage Chemotherapy. *Blood*, **2019**, 134, 735-735	2.2	2
621	Value of Minimal Residual Disease (MRD) Monitoring Using Real-Time Quantitative PCR in Patients with Acute Promyelocytic Leukemia (APL) Treated with ATRA, ATO, +/- GO. *Blood*, **2019**, 134, 3851-3851	2.2	2
620	Timing for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myelomonocytic Leukemia (CMML): A Joint Study from the International MDS/MPN Working Group and the Chronic Malignancies Working Party of the EBMT. *Blood*, **2019**, 134, 4581-4581	2.2	2
619	A Phase 3 Randomized Study (PRIMULA) of the Epigenetic Combination of Pracinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, with Azacitidine (AZA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Intensive Chemotherapy (IC). *Blood*, **2019**, 134, 2652-2652	2.2	2
618	Donor Clonal Hematopoiesis Increases Risk of Acute Graft Versus Host Disease after Matched Related Transplantation in AML and MDS Patients. *Blood*, **2019**, 134, 47-47	2.2	2
617	Comprehensive Analysis of Genotype and Prior Exposures in Therapy-Related Myeloid Neoplasms (t-MNs). *Blood*, **2019**, 134, 458-458	2.2	2
616	Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration to Maximize Response and Survival Benefit. Survival Benefit Not Restricted to Patients with Objective Response. *Blood*, **2019**, 134, 3846-3846	2.2	2
615	Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD). *Blood*, **2019**, 134, 1299-1299	2.2	2
614	Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis. *Blood*, **2019**, 134, 1656-1656	2.2	2
613	Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement. *Blood*, **2019**, 134, 2582-2582	2.2	2
612	The Impact of PHF6 Mutations in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia. *Blood*, **2019**, 134, 1436-1436	2.2	2
611	Outcomes of Patients with Acute Myeloid Leukemia (AML) with Myelodysplasia Related Changes (AML-MRC) Are Dependent on Diagnostic Criteria and Therapy. *Blood*, **2019**, 134, 1312-1312	2.2	2
610	A Phase I/II Study of Intravenous LBH589, a Novel Histone Deacetylase (HDAC) Inhibitor, in Patients (pts) with Advanced Hematologic Malignancies.. *Blood*, **2004**, 104, 1802-1802	2.2	2
609	Clinical Significance of Molecular Monitoring in Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with Imatinib Therapy.. *Blood*, **2004**, 104, 272-272	2.2	2
608	Outcome with the Hyper-CVAD and Rituximab Regimen in Burkitt (BL) and Burkitt-Like (BLL) Leukemia/Lymphoma.. *Blood*, **2004**, 104, 3297-3297	2.2	2
607	A Phase II Study of Temsirolimus (CCI-779) in Patients with Advanced Leukemias.. *Blood*, **2004**, 104, 4523-4523	2.2	2
606	Correlation of Different Responses to Imatinib on Survival of Patients (pts) with Chronic Myelogenous Leukemia (CML) in Accelerated (AP) and Blast Phase (BP).. *Blood*, **2005**, 106, 1103-1103	2.2	2

605	Chemo-Immunotherapy with Hyper-CVAD Plus Ritixumab for Adult Burkitt and Burkitt Type Lymphoma (BL) or Acute Lymphoblastic Leukemia (B-ALL).. *Blood*, **2005**, 106, 149-149	2.2	2
604	Final Results of a Phase I/II Study of the Combination of the Hypomethylating Agent 5-aza-2?-Deoxycytidine (DAC) and the Histone Deacetylase Inhibitor Valproic Acid (VPA) in Patients with Leukemia.. *Blood*, **2005**, 106, 408-408	2.2	2
603	Detection of Residual p73 DNA Methylation Predicts for Shorter Disease Free and Overall Survival in Patients (pts) with Philadelphia (Ph) Chromosome Negative Acute Lymphocytic Leukemia (ALL) in Remission.. *Blood*, **2006**, 108, 2333-2333	2.2	2
602	Decitabine Induces Responses in Patients with Myelodysplastic Syndrome (MDS) after Failure of Azacitidine Therapy.. *Blood*, **2006**, 108, 518-518	2.2	2
601	Survival and Efficacy of Decitabine in Myelodysplastic Syndromes (MDS), Analysis of the 5-Day IV Dosing Regimen.. *Blood*, **2007**, 110, 115-115	2.2	2
600	A Phase I Study of the Combination of the Histone Deacetylase Inhibitor Vorinostat with Idarubicin in Advanced Acute Leukemia.. *Blood*, **2007**, 110, 1842-1842	2.2	2
599	Eph Receptor Tyrosine Kinases and Ephrin Ligands Are Epigenetically Inactivated in Acute Lymphoblastic Leukemia and Are Potential New Tumor Suppressor Genes in Human Leukemia.. *Blood*, **2007**, 110, 2128-2128	2.2	2
598	Intensification of Hyper-CVAD with L-Asparaginase, Vincristine, and Dexamethasone ("Augmented Hyper-CVAD") Has Activity in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL).. *Blood*, **2007**, 110, 4324-4324	2.2	2
597	Maintenance Therapy with Low-Dose Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed or Refractory AML or MDS: A Dose and Schedule Finding Study.. *Blood*, **2008**, 112, 1134-1134	2.2	2
596	Identification of Multiple Promoter Associated CpG Islands Commonly Methylated in Both Acute Lymphocytic Leukemia (ALL) and Chronic Lymphocytic Leukemia(CLL) Using Novel Genome-Wide Microarray Technique: Implications for Common Primordial Molecular Pathways in Lymphoid Leukemias.. *Blood*, **2008**, 112, 2263-2263	2.2	2
595	Phase 2 Study of Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome- Outcome in Previously Untreated Patients.. *Blood*, **2009**, 114, 1053-1053	2.2	2
594	Oral Clofarabine in the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome.. *Blood*, **2009**, 114, 118-118	2.2	2
593	A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, in Older Patients with Myelodysplastic Syndrome (MDS) Refractory to Hypomethylating Agents.. *Blood*, **2009**, 114, 1758-1758	2.2	2
592	Count Recovery in AML Patients Achieving a Complete Response.. *Blood*, **2009**, 114, 2062-2062	2.2	2
591	Hypomethylating Therapy for the Treatment of Acute Erythroleukemia Patients.. *Blood*, **2009**, 114, 2069-2069	2.2	2
590	Patterns of Molecular Response to and Relapse After Combination of Sorafenib, Idarubicin, and Cytarabine in Patients with Newly Diagnosed FLT3-Mutant Acute Myeloid Leukemia (AML).. *Blood*, **2009**, 114, 2079-2079	2.2	2
589	Myelodysplastic Syndrome with Fibrosis: Experience of a Single-Institution with 139 Patients.. *Blood* , **2009**, 114, 2775-2775	2.2	2
588	Comorbidities and Myelodysplatic Syndromes.. *Blood*, **2009**, 114, 2789-2789	2.2	2

587	Prognositc Factors and Survival in Patients with Hypocellular Myelodysplastic Syndrome: Development of a Disease Specific Prognostic Score.. *Blood*, **2009**, 114, 3819-3819	2.2	2
586	Lack of IKZF1 Aberrant DNA Methylation in Acute Lymphocytic Leukemia.. *Blood*, **2009**, 114, 982-982	2.2	2
585	Phase II Study of All-Trans Retinoic Acid (ATRA), Arsenic Trioxide (ATO), with or without Gemtuzumab OzogamIcin (GO) for the Frontline Therapy of Patients with Acute Promyelocytic Leukemia (APL).. *Blood*, **2010**, 116, 1080-1080	2.2	2
584	A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, In Older Patients with MDS Refractory to Hypomethylating Agents. *Blood*, **2010**, 116, 1857-1857	2.2	2
583	Discrepancy In Diagnosis of Myelodysplastic Syndrome (MDS) Between Referral and Tertiary Care Centers: Experience at MD Anderson Cancer Center (MDACC). *Blood*, **2010**, 116, 1870-1870	2.2	2
582	The Achievement of An Early Complete Cytogenetic Response (CCyR) Is A Major Determinant for Outcome In Patients (pts) with Early Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs).. *Blood*, **2010**, 116, 3429-3429	2.2	2
581	Phase I Study of the Combination of 5-Azacitidine Sequentially with High-Dose Lenalidomide in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML). *Blood*, **2011**, 118, 2613-2613	2.2	2
580	Hyper-CVAD and Rituximab for De Novo Burkitt Lymphoma/Leukemia. *Blood*, **2011**, 118, 2698-2698	2.2	2
579	A Phase I/II Trial of Combination of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) for the Treatment of Patients with Refractory or Relapsed (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). *Blood*, **2012**, 120, 3587-3587	2.2	2
578	Phase1/2 Single Arm Study of Rigosertib (ON 01910.Na) in Patients (Pts) with Relapsed or Refractory Acute Leukemia or Transformed Myeloproliferative Neoplasms. *Blood*, **2012**, 120, 3606-3606	2.2	2
577	Comparing The Prognostic Value Of Risk Stratifying Models For Patients With Lower-Risk Myelodysplastic Syndromes (MDS): Is One Model Better? A Report on The Behalf of The MDS Clinical Research Consortium. *Blood*, **2013**, 122, 1505-1505	2.2	2
576	Survival Outcomes In Relapsed/Refractory Acute Myeloid Leukemia Patients Who Achieve Less-Than-Complete Response After Salvage Therapy. *Blood*, **2013**, 122, 2654-2654	2.2	2
575	Expression Of Immune Checkpoints PD-L1, PD-L2, PD-1 and CTLA4 Predict For Prognosis and Resistance To Hypomethylating Agents (HMAs) In Myelodysplastic Syndromes (MDS). *Blood*, **2013**, 122, 2767-2767	2.2	2
574	Replacing Gemtuzumab Ozogamicin With Idarubicin In Frontline Fludarabine, Cytarabine and G-CSF Based Regimen Does Not Compromise Outcome In Core Binding Factor Acute Myelogenous Leukemia. *Blood*, **2013**, 122, 3971-3971	2.2	2
573	Comparison of Symptom Burden in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). *Blood*, **2014**, 124, 2652-2652	2.2	2
572	A Bayesian Phase II Randomized Trial of Azacitidine Versus Azacitidine + Vorinostat in Patients with Newly Diagnosed AML or High-Risk MDS with Poor Performance Status, Organ Dysfunction, or Other Comorbidities. *Blood*, **2014**, 124, 3277-3277	2.2	2
571	Phase II Clinical Trial Results of Dasatinib for Frontline Therapy in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP). *Blood*, **2014**, 124, 4565-4565	2.2	2
570	Initial Results of a Randomized Phase II Study of Low Dose Decitabine (DAC) Versus Low Dose Azacitidine (AZA) in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS). *Blood*, **2014**, 124, 4640-4640	2.2	2

569	Clinical Outcome of De Novo Adult Acute Lymphoblastic Leukemia (ALL) with 11q23/Mixed Lineage Leukemia (MLL) Gene Rearrangements. *Blood*, **2014**, 124, 5342-5342	2.2	2
568	Pracinostat in Combination with Azacitidine Produces a High Rate and Rapid Onset of Disease Remission in Patients with Previously Untreated Acute Myeloid Leukemia (AML). *Blood*, **2014**, 124, 947-947	2.2	2
567	Survivorship in APL- Outcomes of Acute Promyelocytic Leukemia (APL) Patients (pts) after Maintaining Complete Remission (CR) for at Least 3 Years. *Blood*, **2014**, 124, 954-954	2.2	2
566	Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Salvage Therapy for Adult Patients with Refractory/Relapse (R/R) Acute Lymphoblastic Leukemia (ALL). *Blood*, **2014**, 124, 964-964	2.2	2
565	Outcome of Patients with Relapsed/Refractory (R/R) Acute Lymphoid Leukemia (ALL) after Failure of Inotuzumab Ozogamicin. *Blood*, **2015**, 126, 1298-1298	2.2	2
564	Additional Chromosomal Abnormalities in Philadelphia Chromosome-Negative Metaphases Appearing during Therapy with Imatinib, Dasatinib, Nilotinib and Ponatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia. *Blood*, **2015**, 126, 1577-1577	2.2	2
563	TP53 Mutated MDS Patients Respond Equally to Hypomethylating Agents but Have Significantly Shorter Response Duration Compared to Patients with Wild Type TP53. *Blood*, **2015**, 126, 1681-1681	2.2	2
562	Efficacy and Safety of Eltrombopag for Treatment of Patients with Myelodysplastic Syndromes after Hypomethylating-Agent Failure: A Phase 2 Clinical Trial. *Blood*, **2015**, 126, 1691-1691	2.2	2
561	Response to Treatment Among SF3B1 Mutated Myelodysplastic Syndromes (MDS): A Case-Control Study from the MDS Clinical Research Consortium (MDS CRC). *Blood*, **2015**, 126, 1697-1697	2.2	2
560	Clinical Impact of First Complete Remission (CR1) Duration on Outcome of Patients with Relapsed Philadelphia Negative Pre-B Acute Lymphoblastic Leukemia (ALL). *Blood*, **2015**, 126, 2504-2504	2.2	2
559	Anti-Leukemia Effect of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Advanced Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Hypomethylating Agent (HMA) Failures. *Blood*, **2015**, 126, 3800-3800	2.2	2
558	High-Risk Subtype of Ph-like Acute Lymphoblastic Leukemia (ALL) in Adults: Dismal Outcomes of CRLF2+ ALL Patients Treated with Intensive Chemotherapy. *Blood*, **2016**, 128, 1082-1082	2.2	2
557	Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS). *Blood*, **2016**, 128, 112-112	2.2	2
556	Phase II Study of the Salvage Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin (INO) for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). *Blood*, **2016**, 128, 1606-1606	2.2	2
555	Randomized Phase II Trial of Two Schedules of Decitabine As Frontline Therapy in Elderly Patients with Acute Myeloid Leukemia Ineligible for Standard Cytotoxic Induction Regimens. *Blood*, **2016**, 128, 1612-1612	2.2	2
554	Complete Remissions (CRs) with Azacitidine Regimens Compared to Crs with 7+3 Induction Chemotherapy and the Effect on Overall Survival. *Blood*, **2016**, 128, 1613-1613	2.2	2
553	Phase IB/II Study of Lirilumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML). *Blood*, **2016**, 128, 1641-1641	2.2	2
552	Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated Adult T-Cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma. *Blood*, **2016**, 128, 177-177	2.2	2

551	Cardiovascular Events Among Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs). *Blood*, **2016**, 128, 1919-1919	2.2	2
550	A Phase II Clinical Trial of Azacitidine and Vorinostat for Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) with Poor Performance Status, Comorbidities, Other Active Malignancies or Organ Dysfunction Not Eligible for Conventional Clinical Trials. *Blood*, **2016**, 128, 1999-1999	2.2	2
549	Elevated Ferritin Predicts for Inferior Survival in Patients with Acute Leukemia and May be an Early Marker of a Underlying Systemic Pathologic Inflammation. *Blood*, **2016**, 128, 2791-2791	2.2	2
548	Decitabine Followed By Clofarabine, Idarubicin, and Cytarabine (DAC-CIA) in Relapsed/Refractory Acute Myeloid Leukemia (AML). *Blood*, **2016**, 128, 2817-2817	2.2	2
547	Overexpression of KDM6B, an Epigenetic and Innate Immune Regulator, Results in Hematopoietic Alterations of Mice Including Changes in Hematopoietic Stem Cells. *Blood*, **2016**, 128, 3149-3149	2.2	2
546	Myelodysplastic Syndromes with NPM1 Mutations May Constitute a Unique Entity Associated with Improved Outcomes When Treated with AML-like Chemotherapy. *Blood*, **2016**, 128, 3171-3171	2.2	2
545	Outcome of Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) By Age Group over 35 Years: A Single Institution Experience. *Blood*, **2016**, 128, 3975-3975	2.2	2
544	The Role of Chip-Related DNA Damage Response Dysfunction in Therapy-Related Myeloid Neoplasms. *Blood*, **2016**, 128, 958-958	2.2	2
543	Correlation between mutation clearance and clinical response in elderly patients with acute myeloid leukemia (AML) treated with azacitidine and pracinostat.. *Journal of Clinical Oncology*, **2017**, 35, 7034-7034	2.2	2
542	Updated Results from a Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. *Blood*, **2021**, 138, 3400-3400	2.2	2
541	Updated Results from a Phase II Study of Hyper-CVAD with Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. *Blood*, **2021**, 138, 1233-1233	2.2	2
540	Hypomethylating Agent (HMA) Therapy and Venetoclax (VEN) with FLT3 Inhibitor "Triplet" Therapy Is Highly Active in Older/Unfit Patients with FLT3 Mutated AML. *Blood*, **2021**, 138, 798-798	2.2	2
539	Molecular Responses Are Observed across Mutational Spectrum in Treatment-Naïve Higher-Risk Myelodysplastic Syndrome Patients Treated with Venetoclax Plus Azacitidine. *Blood*, **2021**, 138, 241-241	2.2	2
538	Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts.. *Leukemia*, **2022**,	10.7	2
537	The cure of leukemia through the optimist's prism. *Cancer*, **2021**, 128, 240	6.4	2
536	Significant Clinical Activity of the Combination of 5-Azacytidine, Valproic Acid and All-Trans Retinoic (ATRA) Acid in Leukemia: Results of a Phase I/II Study.. *Blood*, **2006**, 108, 160-160	2.2	2
535	Use of Post-Treatment Clinical Data To Predict Response to Decitabine.. *Blood*, **2007**, 110, 1448-1448	2.2	2
534	Safety and Tolerability of Lurbinectedin (PM01183) in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. *Blood*, **2018**, 132, 2722-2722	2.2	2

533	Addition of Gemtuzumab Ozogamicin (GO) to Fludarabine, Cytarabine and G-CSF (FLAG) Based Induction Regimen Results in Better Early Molecular Response and Relapse Free Survival Compared to Idarubicin (FLAG-Ida) in Newly Diagnosed Core Binding Factor Leukemia. *Blood*, **2018**, 132, 3993-3993	2.2	2
532	Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome. *Leukemia and Lymphoma*, **2021**, 62, 1187-1194	1.9	2
531	A Phase II Expansion Study Of Vorinostat In Combination With Idarubicin and Cytarabine For Patients With Acute Myelogenous Leukemia (AML) With FLT3 Molecular Alterations. *Blood*, **2013**, 122, 2684-2684	2.2	2
530	Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3). *American Journal of Hematology*, **2020**, 95, E326-E329	7.1	2
529	Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS). *American Journal of Hematology*, **2021**, 96, E246-E249	7.1	2
528	Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. *American Journal of Hematology*, **2021**, 96, 914-924	7.1	2
527	Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. *Cancer*, **2021**, 127, 3381-3389	6.4	2
526	Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience. *Leukemia and Lymphoma*, **2021**, 62, 909-917	1.9	2
525	Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium. *Cancer Medicine*, **2021**, 10, 447-453	4.8	2
524	Myelodysplastic Syndromes: A New Decade. *Clinical Lymphoma, Myeloma and Leukemia*, **2021**,	2	2
523	Evaluating new treatment options for MDS. *Clinical Advances in Hematology and Oncology*, **2007**, 5, 1-9; quiz 10-2	0.6	2
522	Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy.. *Nature Communications*, **2022**, 13, 1970	17.4	2
521	Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study.. *Lancet Haematology,the*, **2022**, 9, e350-e360	14.6	2
520	Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts. *American Journal of Hematology*, **2019**, 94, E188-E190	7.1	1
519	Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, 213-219.e4	2	1
518	Results of a Phase 1/2a dose-escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes. *Leukemia and Lymphoma*, **2020**, 61, 1943-1953	1.9	1
517	Blast-phase chronic myelomonocytic leukemia: more than just semantics. *Leukemia*, **2018**, 32, 2093-2094	10.7	1
516	Myelodysplastic syndromes should been renamed as myelodysplastic neoplasms. *Leukemia Research*, **2013**, 37, 463-4	2.7	1

515	Interaction between myelomonocytic and lymphoid cells in a patient with acute myelomonocytic leukemia and chronic lymphocytic leukemia. *Leukemia and Lymphoma*, **2014**, 55, 1425-7	1.9	1
514	Factors Associated with Early Therapy Initiation in Patients (pts) with Myelodysplastic Syndromes (MDS) in the Connect MDS/AML Disease Registry. *Blood*, **2018**, 132, 4731-4731	2.2	1
513	Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study. *Blood*, **2018**, 132, 2674-2674	2.2	1
512	Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. *Blood*, **2018**, 132, 2667-2667	2.2	1
511	Characteristics and Outcomes of Patients (pts) with Malignancy-Associated Hemophagocytic Lymphohistiocytosis (M-HLH) in Adults: A Single-Center, Prospective Analysis of 36 Pts. *Blood*, **2018**, 132, 3689-3689	2.2	1
510	Phase 2 Study of Lenalidomide Maintenance for Patients with High-Risk Acute Myeloid Leukemia in Remission. *Blood*, **2018**, 132, 2714-2714	2.2	1
509	Predictors of Outcomes in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia at First Relapse in the Era of Tyrosine Kinase Inhibitors. *Blood*, **2018**, 132, 2659-2659	2.2	1
508	Weight Increase during Induction Therapy Predicts Intensive Care Unit (ICU) Transfer in Patients (Pts) with Acute Promyelocytic Leukemia (APL). *Blood*, **2018**, 132, 4003-4003	2.2	1
507	Cladribine Combined with Idarubicin and High-Dose AraC (CLIA2) As a Frontline and Salvage Treatment for Young Patients (≤55 yrs) with Acute Myeloid Leukemia. *Blood*, **2018**, 132, 4039-4039	2.2	1
506	Induced PD-1 Expression on Bone Marrow CD34+ Cells from MDS Patients Treated with 5-Azacitadine in Combination with Nivolumab and/or Ipilimumab. *Blood*, **2018**, 132, 1807-1807	2.2	1
505	Phase II Study of Blinatumomab in Patients with B-Cell Lineage Acute Lymphocytic Leukemia with Positive Minimal/Measurable Residual Disease. *Blood*, **2018**, 132, 5212-5212	2.2	1
504	Safety and Efficacy of Non-Irradiated Granulocyte Transfusions (GTX) in Neutropenic Patients with Severe or Refractory Abdominal Infections: A Single Center Retrospective Analysis of 119 Transfusions in 22 Patients. *Blood*, **2018**, 132, 3815-3815	2.2	1
503	Phase 2 Study of Nilotinib 400 Mg Twice Daily in Newly Diagnosed Patients with Accelerated Phase of Chronic Myeloid Leukemia, Results after 5.7 Years of Follow-up. *Blood*, **2018**, 132, 3011-3011	2.2	1
502	Sequencing of Circulating Cell-Free DNA in Patients with AML Detects Clinically Significant Mutations Not Detected in Bone Marrow: The Role for Complementary Peripheral Blood and Bone Marrow Genomic Analysis. *Blood*, **2019**, 134, 2592-2592	2.2	1
501	Activity of Multiple Targetable Therapies in FLT3-Mutated (mu) Acute Myeloid Leukemia (AML) Patients (pts) with Concurrent Isocitrate Dehydrogenase Mutation (IDHm). *Blood*, **2019**, 134, 1447-1447	2.2	1
500	Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS). *Blood*, **2019**, 134, 2642-2642	2.2	1
499	Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes. *Blood*, **2019**, 134, 1715-1715	2.2	1
498	Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best Achieved with Adequate Treatment Duration. *Blood*, **2019**, 134, 2957-2957	2.2	1

497	Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30). *Blood*, **2019**, 134, 3015-3015	2.2	1
496	A Randomized Trial of High-Dose (HD) Imatinib Mesylate (IM) with or without Peg-Interferon (PEG-IFN) and GM-CSF as Frontline Therapy for Patients with Chronic Myeloid Leukemia (CML) in Early Chronic Phase (CP).. *Blood*, **2005**, 106, 1084-1084	2.2	1
495	Chromosomal Abnormalities in Philadelphia Chromosome (Ph)-Negative Metaphases Appearing during Imatinib Mesylate (IM) Therapy in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase.. *Blood*, **2005**, 106, 1090-1090	2.2	1
494	Outcome of Salvage Therapy in Patients (pts) with Chronic Myeloid Leukemia (CML) Who Failed Imatinib after Developing BCR-ABL Kinase Mutation.. *Blood*, **2005**, 106, 1092-1092	2.2	1
493	Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia (ALL): The MDACC Experience with Intensified L-Asparaginase and Vincristine in Adult ALL Salvage.. *Blood*, **2005**, 106, 1840-1840	2.2	1
492	Clofarabine and Clofarabine Plus Low-Dose Cytarabine (ara-C) as Induction Therapy for Patients (pts) ≥60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML).. *Blood*, **2005**, 106, 2804-2804	2.2	1
491	A Pilot Trial of Imatinib, Low-Dose Cytarabine (ara-C) and Idarubicin (Ida) in Patients (pts) with Chronic Myeloid Leukemia (CML) in Myeloid Blastic Phase (BP).. *Blood*, **2005**, 106, 4840-4840	2.2	1
490	Secondary Leukemia after Imatinib Mesylate (IM) Therapy for Chronic Myelogenous Leukemia (CML).. *Blood*, **2005**, 106, 4862-4862	2.2	1
489	Cytopenias in Patients (pts) with Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP) Treated with Dasatinib (SPRYCEL®): Clinical Features and Management, Including Outcome after Hematopoietic Growth Factor Therapy.. *Blood*, **2006**, 108, 2163-2163	2.2	1
488	A Phase II Study of Azacitidine (Vidaza®) for Patients with Myelofibrosis (MF).. *Blood*, **2006**, 108, 2706-2706	2.2	1
487	Patients with Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Targeted Therapy May Benefit from Prophylactic Measures Against Infections.. *Blood*, **2006**, 108, 4483-4483	2.2	1
486	Prognostic Significance of β2 Microglobulin Levels in Acute Myeloid Leukemia: Analysis of 1293 Patients.. *Blood*, **2006**, 108, 802-802	2.2	1
485	Results of an Exploratory Study of Oral (po) and Intravenous (iv) Clofarabine in Patients with Myelodysplastic Syndrome.. *Blood*, **2007**, 110, 1455-1455	2.2	1
484	Lenalidomide in High-Risk Myelodysplastic Syndrome and Acute Myelogenous Leukemia Associated with Chromosome 5 Abnormalities.. *Blood*, **2007**, 110, 1459-1459	2.2	1
483	Analysis of Class I and II Histone Deacetylase Fails To Identify a Human Leukemia Specific Expression Profile.. *Blood*, **2007**, 110, 2130-2130	2.2	1
482	Phase I Study of 5-aza-2?-Deoxycitidine, Alone or in Combination with Hyper-CVAD, in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL).. *Blood*, **2007**, 110, 2826-2826	2.2	1
481	Randomized Study of Decitabine Versus Observation or Continued Cytotoxic Chemotherapy in Patients with Intermediate and Poor Risk Acute Myeloid Leukemia in First or Subsequent Complete Remission.. *Blood*, **2007**, 110, 2859-2859	2.2	1
480	Survival Outcomes for Patients (Pts) with Chronic Myeloid Leukemia (CML) with Clonal Evolution (CE) Treated with 2nd Generation Tyrosine Kinase Inhibitors (TKI) after Imatinib Failure.. *Blood*, **2007**, 110, 2949-2949	2.2	1

479	Pegylated Interferon-alfa-2a (PEG-IFN-□-2A; PEGASYS□for Essential Thrombocythemia (ET) and Polycythemia Vera (PV): An Update of an Ongoing Phase II Study.. *Blood*, **2007**, 110, 3542-3542	2.2	1
478	Final Update of Phase I-II Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome.. *Blood*, **2007**, 110, 441-441	2.2	1
477	Association of Pleural Effusion and Bleeding in Patients with Chronic Myelogenous Leukemia Receiving Dasatinib.. *Blood*, **2008**, 112, 2112-2112	2.2	1
476	Imatinib Frontline Therapy Is Safe and Effective in Patients with Chronic Myeloid Leukemia (CML) with Liver and/or Renal Dysfunction.. *Blood*, **2008**, 112, 2126-2126	2.2	1
475	Hypomethylating Therapy in Patients with AML and High-Risk MDS and Chromosome 5 and 7 Abnormalities Is Associated with An Improved Outcome Compared to Conventional Chemotherapy. *Blood*, **2008**, 112, 2955-2955	2.2	1
474	Stem Cell Transplantation in Remission Improves Survival in Acute Myelogenous Leukemia Associated with FLT3 Mutations. *Blood*, **2008**, 112, 3302-3302	2.2	1
473	Epigenetic Silencing of the RUNX3 Gene by Promoter Hypermethylation in Patients with Acute Myeloid Leukemia.. *Blood*, **2008**, 112, 3341-3341	2.2	1
472	Combined Therapy with Lenalidomide and Prednisone Renders Durable Clinical, Histopathological, and Molecular Responses in Patients with Myelofibrosis. *Blood*, **2008**, 112, 662-662	2.2	1
471	Baseline Serum Ferritin Predicts Rate of Infection in Patients with Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome.. *Blood*, **2009**, 114, 1611-1611	2.2	1
470	Augmented Hyper-CVAD in Adult ALL Salvage Therapy: The MDACC Experience of Hyper-CVAD Using Dose-Intense Vincristine, Dexamethasone, and Pegaspargase.. *Blood*, **2009**, 114, 2031-2031	2.2	1
469	Chromosomal Abnormalities In Philadelphia Chromosome (Ph)-Negative Metaphases Appearing During Second Generation Tyrosine Kinase Inhibitors (2nd TKI) Therapy In Patients (pts) with Chronic Myeloid Leukemia (CML).. *Blood*, **2010**, 116, 1232-1232	2.2	1
468	Intracranial Hemorrhage (ICH) In Patients (Pts) Presenting with Myeloid Leukemia to a Tertiary Care Center. *Blood*, **2010**, 116, 2170-2170	2.2	1
467	Impact of RAS Mutations In Myelodysplastic Syndrome (MDS). *Blood*, **2010**, 116, 2926-2926	2.2	1
466	Phase Ib Study of Oral Panobinostat In Combination with 5-Azacitidine (5-aza) In Patients with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). *Blood*, **2010**, 116, 4957-4957	2.2	1
465	Comorbidities and Overall Survival In Myelodysplastic Syndromes (MDS): Development of a Prognostic Model Incorporating IPSS and Age with ACE-27 Comorbidity Index. *Blood*, **2010**, 116, 605-605	2.2	1
464	High Expression of Autophagy Related Proteins Negatively Impacts Clinical Outcomes in Acute Myelogenous Leukemia□ime to Target Autophagy to Improve Therapy Outcomes?. *Blood*, **2011**, 118, 2513-2513	2.2	1
463	FLT3 Inhibitors Are Promising Salvage Therapy for Relapsed or Refractory Acute Myeloid Leukemia (AML) in Patients with FLT3-ITD Mutations,. *Blood*, **2011**, 118, 3623-3623	2.2	1
462	Combination of Sorafenib and 5-Azacytidine Has Significant Activity in Patients with Relapsed/Refractory or Untreated Acute Myeloid Leukemia and FLT3-ITD mutation. *Blood*, **2012**, 120, 1519-1519	2.2	1

461	Phase 1 Study of ABT-348, A Dual Aurora/VEGF-Receptor Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies.. *Blood*, **2012**, 120, 2617-2617	2.2	1
460	Outcome of Elderly Patients with Acute Myeloid Leukemia (AML) Post Hypomethylating Agent (HMA) Failure.. *Blood*, **2012**, 120, 2627-2627	2.2	1
459	Detection of Recurrent Mutations by Pooled Targeted Next-Generation Sequencing in MDS Patients Prior to Treatment with Hypomethylating Agents or Stem Cell Transplantation. *Blood*, **2012**, 120, 311-311	2.2	1
458	Outcomes Continue to Be Favorable for De Novo Philadelphia Chromosome Negative B-Lymphoblastic Leukemia (ALL) After Therapy with Hyper-CVAD (with or without Rituximab) Regimen. *Blood*, **2012**, 120, 3572-3572	2.2	1
457	Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis - One Year Update. *Blood*, **2012**, 120, 3588-3588	2.2	1
456	Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome. *Blood*, **2012**, 120, 3619-3619	2.2	1
455	Relationship Between Chelation and Clinical Outcomes in 600 Lower-Risk MDS Patients: Registry Analysis At 36 Months. *Blood*, **2012**, 120, 3800-3800	2.2	1
454	Induction of PD-1 and PD-1 Ligand Expression by Hypomethylating Agents (HMA) in Myelodysplastic Syndromes and Acute Myelogenous Leukemia Suggest a Role for T Cell Function in Clinical Resistance to Hmas. *Blood*, **2012**, 120, 3810-3810	2.2	1
453	Low Dose Azacitidine (AZA) Reduces the Incidence of Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). *Blood*, **2012**, 120, 742-742	2.2	1
452	Natural History and Potential for Cure of Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Therapy with Recombinant Interferon-Alfa: 30-Year Update From M.D. Anderson Cancer Center. *Blood*, **2012**, 120, 918-918	2.2	1
451	Clofarabine Plus Low-Dose Cytarabine For The Treatment Of Patients Withhigher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing After, Or Are Refractory To, Hypomethylator Agent Therapy. *Blood*, **2013**, 122, 1525-1525	2.2	1
450	DNA Demethylation Activity Over Time and Safety Of 3 Different Dose-Escalation Regimens Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In The Treatment Of Relapsed/Refractory Patients With MDS and AML. *Blood*, **2013**, 122, 1548-1548	2.2	1
449	Prior Hypomethylating Agents Or Chemotherapy Does Not Improve The Outcome Of Allogeneic Hematopoietic Transplantation For High Risk MDS. *Blood*, **2013**, 122, 305-305	2.2	1
448	Long Term Follow-Up Of De Novo Or Minimally Treated Burkitt Lymphoma/Leukemia (BL/B-ALL) After Frontline Therapy Per The Hyper-CVAD Regimen With Or Without Rituximab: 20-Year Cumulative Experience. *Blood*, **2013**, 122, 3917-3917	2.2	1
447	Early Results Of a Phase I/II Trial Of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) For Patients (Pts) With Acute Myeloid Leukemia and Myelodysplastic Syndrome. *Blood*, **2013**, 122, 3949-3949	2.2	1
446	Prognostic Factors For Outcome In Patients (pts) With Myelofibrosis (MF) Treated With Ruxolitinib (Rux). *Blood*, **2013**, 122, 4050-4050	2.2	1
445	Persistence of Minimal Residual Disease Assessed By Multi-Parameter Flow Cytometry (MFC) at 30 and 90 Days after Achieving Complete Remission Predicts Outcome in Patients with Acute Myeloid Leukemia. *Blood*, **2014**, 124, 1015-1015	2.2	1
444	Doctor-Patient Communication and Perception of Treatment Discontinuation in Myelodysplastic Syndromes (MDS) Diverge at the Time of Disease Progression. *Blood*, **2014**, 124, 2642-2642	2.2	1

443	Comparison of Continuation of HMA Vs Allogeneic Stem Cell Transplant and Its Timing in Myelodysplastic Syndromes: Can It Wait? Results of a Retrospective Study. *Blood*, **2014**, 124, 4666-4666	2.2	1
442	An International Data Set for the Study of Chronic Myelomonocytic Leukemia (CMML) Validates Modern Prognostic Scoring Systems and Demonstrates a Critical Need for Novel Prognostication Strategies. *Blood*, **2014**, 124, 530-530	2.2	1
441	Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Who Have Relapsed or Are Refractory to Hypomethylating Agent (HMA) Therapy. *Blood*, **2014**, 124, 534-534	2.2	1
440	Outcomes of Patients with Relapsed/Refractory (R/R) B-Cell Acute Lymphocytic Leukemia (ALL) Post Blinatumomab Failure. *Blood*, **2015**, 126, 1335-1335	2.2	1
439	Long Non-Coding RNA Induces De Novo Myelodysplastic Syndrome through Epigenetic Regulation. *Blood*, **2015**, 126, 1640-1640	2.2	1
438	Characterization of Fever, Infection, and Cytokine Release Syndrome (CRS) in Adult Patients with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab. *Blood*, **2015**, 126, 2530-2530	2.2	1
437	Fusion Transcript Reduction in Core Binding Factor Acute Myeloid Leukemia: Maintenance Strategy with Hypomethylating Agents. *Blood*, **2015**, 126, 2604-2604	2.2	1
436	Seven Year Follow up of Chronic Myeloid Leukemia (CML) Patients Treated with Nilotinib 400 Mg Twice Daily - a Single Center Study at MDACC. *Blood*, **2015**, 126, 2796-2796	2.2	1
435	Impact of Cytogenetic Abnormalities and Cytogenetic Response to Hypomethylating Agents (HMAs) in Patients (pts) with Lower Risk Myelodysplastic Syndromes (MDS). *Blood*, **2015**, 126, 2877-2877	2.2	1
434	Prognostic Impact of Rare Single Abnormalities in Myelodysplastic Syndromes. *Blood*, **2015**, 126, 2879-2879	2.2	1
433	Outcome of Adult Patients with Philadelphia Negative B Cell Acute Lymphoblastic Leukemia after Frontline Therapy Failure. *Blood*, **2015**, 126, 3718-3718	2.2	1
432	Qualitative and Quantitative Correlation of PML-Rara Fusion Transcript from Peripheral Blood and Bone Marrow Samples By Quantitative Real-Time PCR in Patients with Acute Promyelocytic Leukemia. *Blood*, **2015**, 126, 3756-3756	2.2	1
431	Results of a Phase I/II Study of DFP-10917, a Nucleoside Analog, Given By Continuous Infusion (CI) in Patients (pts) with Relapsed or Refractory Acute Leukemia. *Blood*, **2015**, 126, 3804-3804	2.2	1
430	Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Survival for Patients with Chronic Myelomonocytic Leukemia. *Blood*, **2015**, 126, 4347-4347	2.2	1
429	Clinical and Molecular Characterization of p53-Mutated Acute Myeloid Leukemia. *Blood*, **2015**, 126, 564-564	2.2	1
428	Long-Term Experience with Hypomethylating Agents in Patients with Chronic Myelomonocytic Leukemia. *Blood*, **2016**, 128, 111-111	2.2	1
427	CML Patients Outcome after TKI Discontinuation: A Single Institution Experience in the US. *Blood*, **2016**, 128, 1923-1923	2.2	1
426	Pure Erythroid Leukemia Is Characterized By TP53mutations, a Complex Karyotype with Chromosome 17 Abnormalities, and Adverse Risk Independent of Therapy Type. *Blood*, **2016**, 128, 2852-2852	2.2	1

425	Achievement of Minimal Residual Disease Negativity By Multiparameter Flow Cytometry Is an Important Therapeutic Endpoint in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Salvage Treatment. *Blood*, **2016**, 128, 2916-2916	2.2	1
424	Clinical Implications of TP53 Mutations in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) Treated with the Hypercvad-Based Regimens. *Blood*, **2016**, 128, 2917-2917	2.2	1
423	Is Serial Monitoring of Myeloid Mutations Clinically Relevant in Myelodysplastic Syndromes (MDS): A Report on Behalf of the MDS Clinical Research Consortium (CRC). *Blood*, **2016**, 128, 297-297	2.2	1
422	Life after Ponatinib Failure: Outcomes of Chronic and Accelerated Phase CML Patients Who Discontinued Ponatinib in the Salvage Setting. *Blood*, **2016**, 128, 3073-3073	2.2	1
421	Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing after, or Are Refractory to, Hypomethylating Agent (HMA) Therapy. *Blood*, **2016**, 128, 3166-3166	2.2	1
420	STAG2 Mutations Are an Independent Prognostic Factor in Patients with Myelodysplastic Syndromes. *Blood*, **2016**, 128, 3182-3182	2.2	1
419	Ruxolitinib (RUX) in Combination with Azacytidine (AZA) in Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs). *Blood*, **2016**, 128, 4246-4246	2.2	1
418	Hematopoietic Architecture of MDS before and after Progression Reveals Two Biologically Distinct Disease Subtypes. *Blood*, **2016**, 128, 4310-4310	2.2	1
417	Phase I Study of Ruxolitinib for Patients (Pts) with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Who Failed at Least One Line of Therapy. *Blood*, **2016**, 128, 4318-4318	2.2	1
416	Phase II Study of the Frontline Hyper-CVAD in Combination with Ponatinib for Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. *Blood*, **2016**, 128, 757-757	2.2	1
415	Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study. *Blood*, **2021**, 138, 66-66	2.2	1
414	Quizartinib (Quiz) with Decitabine (DAC) and Venetoclax (VEN) Is Highly Active in Patients (pts) with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) - RAS/MAPK Mutations Continue to Drive Primary and Secondary Resistance. *Blood*, **2021**, 138, 370-370	2.2	1
413	Impact of Frontline Treatment Approach in Patients with Secondary AML and Prior Hypomethylating Agent Exposure: A Retrospective Analysis of 562 Patients with Treated Secondary AML. *Blood*, **2021**, 138, 794-794	2.2	1
412	A Phase II Study of Mini-Hyper-CVD Plus Venetoclax in Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. *Blood*, **2021**, 138, 1239-1239	2.2	1
411	Phase 1 Results of Novel Combination Therapy: BET Inhibitor PLX51107 with Azacitidine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). *Blood*, **2021**, 138, 3421-3421	2.2	1
410	A Phase II Study of Blinatumomab for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia. *Blood*, **2021**, 138, 4398-4398	2.2	1
409	Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS). *Blood*, **2021**, 138, 2323-2323	2.2	1
408	Allogeneic Hematopoietic Cell Transplantation Outcomes of Patients with R/R AML or Higher-Risk MDS Treated with the TIM-3 Inhibitor MBG453 (Sabatolimab) and Hypomethylating Agents. *Blood*, **2021**, 138, 3677-3677	2.2	1

407	Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia. *Blood*, **2021**, 138, 701-701	2.2	1
406	A Phase I/II Study of Venetoclax in Combination with 5-Azacytidine in Treatment-Naïve and Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML). *Blood*, **2021**, 138, 535-535	2.2	1
405	Phase II Study of Cladribine, Idarubicin, Cytarabine (CLIA) Plus Gilteritinib in Patients with FLT3 Mutated Acute Myeloid Leukemia (AML). *Blood*, **2021**, 138, 2330-2330	2.2	1
404	Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Updated Results of a Phase II Trial. *Blood*, **2021**, 138, 1270-1270	2.2	1
403	Initial Results of Phase I/II Study of Azacitidine in Combination with Quizartinib for Patients with Myelodysplastic Syndrome and Myelodysplastic/Myeloproliferative Neoplasm with FLT3 or CBL Mutations. *Blood*, **2021**, 138, 1536-1536	2.2	1
402	Hematopoiesis under telomere attrition at the single-cell resolution. *Nature Communications*, **2021**, 12, 6850	17.4	1
401	Characteristics and Prognosis of Patients (pts) with Acute Megakaryocytic Leukemia (AMegL) Treated at M.D. Anderson Cancer Center Since 1987.. *Blood*, **2004**, 104, 3003-3003	2.2	1
400	Prolonged Administration of Arsenic Trioxide (Trisenox) for Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) at MD Anderson Cancer Center: A Phase II Study.. *Blood*, **2004**, 104, 4731-4731	2.2	1
399	Blockade of Adaptive Defensive Changes in Cholesterol Uptake and Synthesis in AML by the Addition of Pravastatin to Idarubicin + High Dose Ara-C: A Phase I Study.. *Blood*, **2005**, 106, 405-405	2.2	1
398	Farnesyl Transferase Inhibitor (Tipifarnib, Zarnestra; Z) in Combination with Standard Chemotherapy with Idarubicin (Ida) and Cytarabine (ara-C) for Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).. *Blood*, **2005**, 106, 2796-2796	2.2	1
397	The Cyclin-Dependent Kinase Inhibitor p57KIP2 Functions as a Tumor Suppressor Gene in Human Leukemia.. *Blood*, **2005**, 106, 1604-1604	2.2	1
396	Survival Benefit with Decitabine Compared to Historical Experience with Intensive Chemotherapy in Patients with Higher Risk Myelodysplastic Syndrome (MDS).. *Blood*, **2006**, 108, 2652-2652	2.2	1
395	Clinical Responses to Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Are Associated with Specific Gene Expression Signatures in Patients with Advanced Leukemias: Results of a Phase I Trial.. *Blood*, **2006**, 108, 2320-2320	2.2	1
394	All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (As2O3) Combination Therapy Induces High Rates of Durable Molecular Remission in Newly Diagnosed Acute Promyelocytic Leukemia (APL).. *Blood*, **2007**, 110, 1834-1834	2.2	1
393	Phase I Study of Sapacitabine, an Oral Nucleoside Analogue, in Patients with Advanced Leukemias or Myelodysplastic Syndromes (MDS).. *Blood*, **2007**, 110, 884-884	2.2	1
392	Salvage Therapy Outcomes in a Historical Cohort of Patients with Relapsed or Refractory Acute Myeloid Leukemia. *Blood*, **2018**, 132, 3985-3985	2.2	1
391	Single-Cell RNA Sequencing Reveals Distinct Hematopoietic Stem Cell Hierarchies in MDS. *Blood*, **2019**, 134, 771-771	2.2	1
390	Ultra-Accurate Assessment of Pretreatment ABL1 Kinase Domain (KD) Mutations in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Using Duplex Sequencing (DS). *Blood*, **2019**, 134, 2578-2578	2.2	1

389	t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm?. *Annals of Hematology*, **2020**, 99, 487-500	3	1
388	Effect of Azacytidine on the Hematopoietic Stem and Progenitor Cell Compartments of MDS Mouse Models: Unveiling the Mechanisms of Remission and Relapse. *Blood*, **2015**, 126, 2852-2852	2.2	1
387	Importance of Complete Remission on Predicting Overall Survival in Patients with Lower-Risk Myelodysplastic Syndromes (MDS). *Blood*, **2016**, 128, 4332-4332	2.2	1
386	Acute Myeloid Leukemia in Adolescents and Young Adults (AYA): The MD Anderson Cancer Center (MDACC) Experience. *Blood*, **2008**, 112, 3982-3982	2.2	1
385	Development and Validation of a New Prognostic Model for Myelodysplastic Syndrome (MDS) That Accounts for Events Not Considered by the International Prognostic Scoring System (IPSS). *Blood*, **2008**, 112, 635-635	2.2	1
384	Clinical Significance of Dose Reductions of Second-Generation Tyrosine Kinase Inhibitors (TKI) in Patients (Pts) with Chronic Myeloid Leukemia (CML). *Blood*, **2008**, 112, 3217-3217	2.2	1
383	Genome-Wide Chip-Seq Analysis of Histone Methylation Reveals Modulators of NF-Β Signaling and the Histone Demethylase JMJD3 as Implicated in Disease Progression in Myelodysplastic Syndrome (MDS).. *Blood*, **2009**, 114, 291-291	2.2	1
382	Antifungal Prophylaxis (AFP) for Patients (Pts) with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Undergoing Intensive Chemotherapy: An Experience with 730 Pts.. *Blood*, **2009**, 114, 3102-3102	2.2	1
381	Levels of Nrf2 and Keap1 Are Associated with Poor Prognostic Features In Myelodysplastic Syndromes (MDS). *Blood*, **2010**, 116, 1874-1874	2.2	1
380	A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia. *Blood*, **2011**, 118, 967-967	2.2	1
379	Outcome Of Patients With Myelodysplastic Syndrome (MDS) With Bone Marrow Blasts Between 10-30% Treated With Hypomethylating Agents Versus Intensive Chemotherapy. *Blood*, **2013**, 122, 2788-2788	2.2	1
378	Final Report Of Phase II Study Of Sorafenib and 5-Azacytidine In Patients With Relapsed Or Untreated Acute Myeloid Leukemia and FLT3-ITD mutation. *Blood*, **2013**, 122, 3934-3934	2.2	1
377	Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia. *British Journal of Haematology*, **2020**, 191, e10-e13	4.5	1
376	Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect MDS/AML Disease Registry. *EJHaem*, **2020**, 1, 58-68	0.9	1
375	Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations. *American Journal of Hematology*, **2020**, 95, E313-E315	7.1	1
374	Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. *Cancer*, **2021**, 127, 3113-3124	6.4	1
373	A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival. *Leukemia Research*, **2021**, 104, 106555	2.7	1
372	What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)?. *Leukemia and Lymphoma*, **2021**, 62, 2762-2767	1.9	1

371	Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. *Leukemia*, **2021**,	10.7	1
370	Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. *Cancer*, **2021**, 127, 3552-3565	6.4	1
369	Investigating protein patterns in human leukemia cell line experiments: A Bayesian approach for extremely small sample sizes. *Statistical Methods in Medical Research*, **2020**, 29, 1181-1196	2.3	1
368	Myelodysplastic syndrome with t(6;9)(p22;q34.1)/DEK-NUP214 better classified as acute myeloid leukemia? A multicenter study of 107 cases. *Modern Pathology*, **2021**, 34, 1143-1152	9.8	1
367	Pembrolizumab for myelodysplastic syndromes after failure of hypomethylating agents in the phase 1b KEYNOTE-013 study.. *Leukemia and Lymphoma*, **2022**, 1-9	1.9	1
366	A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia.. *Leukemia and Lymphoma*, **2022**, 1-10	1.9	1
365	MDS/MPN-RS-T justified inclusion as a unique disease entity?. *Best Practice and Research in Clinical Haematology*, **2020**, 33, 101147	4.2	0
364	Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure.. *Journal of Hematology and Oncology*, **2022**, 15, 12	22.4	0
363	Ponatinib and Bosutinib Discontinuation in Chronic Myeloid Leukemia (CML): Single Center Experience. *Blood*, **2018**, 132, 5447-5447	2.2	0
362	The Achievement of a 3-Month Complete Cytogenetic Response (3-mo CCyR) to Second Generation (2nd) Tyrosine Kinase Inhibitors (TKI) Post Imatinib Failure Is the Only Predictive Factor for Event-Free (EFS) and Overall Survival (OS). *Blood*, **2010**, 116, 2289-2289	2.2	0
361	Long-Term Outcome for De Novo Lymphoblastic Lymphoma (LL) After Frontline Therapy with Hyper-CVAD Regimen and Variants.. *Blood*, **2010**, 116, 2831-2831	2.2	0
360	Clinical Relevance of Driver Mutations and Number of Driver Mutations in Patients with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. *Blood*, **2016**, 128, 54-54	2.2	0
359	Tagraxofusp (SL-401) in Patients with Chronic Myelomonocytic Leukemia (CMML): Updated Results of an Ongoing Phase 1/2 Trial. *Blood*, **2021**, 138, 538-538	2.2	0
358	Low-Dose Dasatinib 50 Mg/Day Versus Standard-Dose Dasatinib 100 Mg/Day As Frontline Therapy in Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis. *Blood*, **2021**, 138, 631-631	2.2	0
357	The Prognostic Implication of Adult Comorbidity Evaluation 27 Score in CML Patients on Tyrosine-Kinase Inhibitors. *Blood*, **2021**, 138, 2554-2554	2.2	0
356	Treatment Patterns and Outcomes of Patients with Lower-Risk Myelodysplastic Syndromes in the Connect Myeloid Disease Registry. *Blood*, **2021**, 138, 3686-3686	2.2	0
355	Evolution of Genomic Landscape in Acute Myeloid Leukemia after Decitabine and Venetoclax. *Blood*, **2021**, 138, 1304-1304	2.2	0
354	A Phase II Study of 5-Azacytidine (AZA) and Venetoclax As Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission. *Blood*, **2021**, 138, 2326-2326	2.2	0

353	Outcomes of Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents. *Blood*, **2021**, 138, 2613-2613	2.2	0
352	Analysis of Duration of Response, Exposure-Adjusted Safety and Progression to Acute Myeloid Leukemia (AML) for Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Receiving Luspatercept in the MEDALIST Study. *Blood*, **2021**, 138, 1524-1524	2.2	0
351	A Phase I Study of the Combination of Venetoclax and Azacitidine in Relapse/Refractory Higher Risk Myelodysplastic Syndrome (MDS). *Blood*, **2021**, 138, 3704-3704	2.2	0
350	Mutational Landscape of MDS Patients with HMA Failure Revealed By the Correlative Analysis from Inspire Trial. *Blood*, **2021**, 138, 1517-1517	2.2	0
349	Updated Results of a Phase 1/2 Study of Lower Dose CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia after Failure to Hypomethylating Agents. *Blood*, **2021**, 138, 3674-3674	2.2	0
348	A Phase I/II Study of Venetoclax in Combination with ASTX727 (cedazuridine/decitabine) in Treatment-Naïve High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML). *Blood*, **2021**, 138, 245-245	2.2	0
347	Characteristics and Outcomes of Adolescent and Young Adult (AYA) Patients with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML): A Single-Center Retrospective Analysis. *Blood*, **2021**, 138, 3687-3687	2.2	0
346	Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program. *Blood*, **2021**, 138, 4669-4669	2.2	0
345	Phase II Study of Venetoclax Added to Cladribine (CLAD) and Low Dose AraC (LDAC) Alternating with 5-Azacytidine (AZA) in Older and Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). *Blood*, **2021**, 138, 367-367	2.2	0
344	A Phase I/II Study of Sapacitabine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia. *Blood*, **2021**, 138, 3419-3419	2.2	0
343	Long-Term Follow-Up after Frontline Therapy with the Hyper-CVAD and Imatinib Mesylate Regimen in Adults with Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).. *Blood*, **2007**, 110, 9-9	2.2	0
342	Clinical Heterogeneity of AML Is Associated with Mutational Heterogeneity. *Blood*, **2018**, 132, 5240-5240	2.2	0
341	Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab (HCVAD-O) As Frontline Therapy for Adult Patients (pts) with CD20-Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL). *Blood*, **2019**, 134, 2577-2577	2.2	0
340	The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults. *Blood*, **2019**, 134, 4249-4249	2.2	0
339	Incidence of Central Nervous System (CNS) Relapse in De Novo Adult Acute Lymphoblastic Leukemia (ALL). *Blood*, **2014**, 124, 940-940	2.2	0
338	Homoharringtonine (HHT) with Imatinib in Chronic, Accelerated, and Blast Phase Chronic Myeloid Leukemia (CML). *Blood*, **2016**, 128, 5449-5449	2.2	0
337	A Phase II Study of Twice Daily Cytarabine and Fludarabine and Gentuzumab Ozogamycin (GO) In Patients (pts) with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS). *Blood*, **2010**, 116, 2188-2188	2.2	0
336	Final Report of a Phase II Trial of Vorinostat with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS). *Blood*, **2011**, 118, 763-763	2.2	0

335	Frontline Tyrosine Kinase Inhibitors (TKI) As Initial Therapy for Patients with Chronic Myeloid Leukemia in Accelerated Phase (CML-AP),. *Blood*, **2011**, 118, 3779-3779	2.2	0
334	Impact of Npm1, Flt3, and Ras Mutations on the Outcomes of Elderly Patients with Acute Myeloid Leukemia,. *Blood*, **2011**, 118, 3594-3594	2.2	0
333	Associations between complete remission and 2- to 3-year survival following 7 + 3 induction for acute myeloid leukemia. *Leukemia and Lymphoma*, **2021**, 62, 1967-1972	1.9	0
332	Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes. *Frontiers in Immunology*, **2021**, 12, 659625	8.4	0
331	Targeting health-related quality of life in patients with myelodysplastic syndromes - Current knowledge and lessons to be learned. *Blood Reviews*, **2021**, 50, 100851	11.1	0
330	Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. *Cancer*, **2021**, 127, 1894-1900	6.4	0
329	Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis. *Leukemia and Lymphoma*, **2021**, 1-6	1.9	0
328	Primary mediastinal germ cell tumor and clonally related and unique hematologic neoplasms with i(12p) and TP53 mutation: A report of two cases.. *Annals of Diagnostic Pathology*, **2022**, 59, 151951	2.2	0
327	ALL-216: Outcomes of Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Molecular Response at Three Months of Therapy. *Clinical Lymphoma, Myeloma and Leukemia*, **2020**, 20, S164-S165	2	
326	Targeted Therapy in Myelodysplastic Syndromes **2015**, 162-168		
325	Nontransplantation options for patients with myelodysplastic syndromes. *Biology of Blood and Marrow Transplantation*, **2011**, 17, S9-10	4.7	
324	In reply to Improving the prognostic evaluation of patients with lower-risk myelodysplastic syndromes by Kuendgen et al.. *Leukemia*, **2009**, 23, 185-185	10.7	
323	Therapy for older patients with acute myeloblastic leukemia: a problem in search of a solution. *Leukemia and Lymphoma*, **2012**, 53, 1013-4	1.9	
322	Epigenetics of leukemia239-256		
321	Role of epigenetic therapy in myelodysplastic syndrome. *Expert Review of Hematology*, **2008**, 1, 161-74	2.8	
320	Transcriptomic Signitures of Azacitidine (AZA) and Decitabine (DAC) Resistance in MDS and CMML. *Blood*, **2021**, 138, 4652-4652	2.2	
319	High-Throughput Characterization of Cytogenomic Heterogeneity of MDS Using High-Resolution Optical Genome Mapping. *Blood*, **2021**, 138, 105-105	2.2	
318	Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. *Blood*, **2021**, 138, 3363-3363	2.2	

317	Clinical Outcomes of Patients with Newly Diagnosed Myelodysplastic Syndrome with MLL Aberrations. *Blood*, **2021**, 138, 4673-4673	2.2
316	Phase II Study of Lower-Intensity Frontline Therapy for Newly Diagnosed Patients with AML Who Are Unfit or Otherwise Not Eligible for Frontline Clinical Trials. *Blood*, **2021**, 138, 4420-4420	2.2
315	Dr. Elihu H. Estey (1946-2021). *American Journal of Hematology*, **2021**, 97, 166	7.1
314	Single-Cell RNA Sequencing Analysis Reveals Mechanisms of Initiation and Progression in Chronic Myelomonocytic Leukemia. *Blood*, **2021**, 138, 2588-2588	2.2
313	Characteristics and Outcomes of Adult Patients with Malignancy-Associated Hemophagocytic Lymphohistiocytosis: A Single-Center, Prospective Analysis. *Blood*, **2021**, 138, 1213-1213	2.2
312	Inhibition of MDM2 Improves the Therapeutic Effect of Hypomethylating Agents in Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML). *Blood*, **2021**, 138, 3664-3664	2.2
311	NPM1 Mutations Do Not Retain a Favorable Prognostic Impact in Adults with Advanced Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML). *Blood*, **2021**, 138, 2287-2287	2.2
310	Outcomes for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Treated with Frontline HCVAD-Based Chemotherapy. *Blood*, **2021**, 138, 2319-2319	2.2
309	The Transcriptional and Epigenetic Reprogramming of Aged Hematopoietic Stem Cells Drives Myeloid Rewiring in Clonal Hematopoiesis-Associated Cytopenias. *Blood*, **2021**, 138, 3273-3273	2.2
308	Clinical and Pathological Characteristics of Hypocellular Myelodysplastic Syndrome : A Single-Center Retrospective Study. *Blood*, **2021**, 138, 1527-1527	2.2
307	Clinical Characteristics and Contemporary Outcomes of Acute Myeloid Leukemia Evolving from Chronic Myelomonocytic Leukemia. *Blood*, **2021**, 138, 1224-1224	2.2
306	Clinical Characteristics and Outcomes of Patients Diagnosed with Acute Myeloid Leukemia with Expression of CD71. *Blood*, **2021**, 138, 4449-4449	2.2
305	Efficacy of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subgroup from the Ascertain Phase 3 Study. *Blood*, **2021**, 138, 3682-3682	2.2
304	Phase II Trial of Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Outcomes in Genomic Subgroups. *Blood*, **2021**, 138, 694-694	2.2
303	2 Chlorodeoxyadenosine (2-CdA) and Cytarabine (ara-C) Combination Is Effective and Safe in Idiopathic Hypereosinophilic Syndrome (HES).. *Blood*, **2004**, 104, 4764-4764	2.2
302	Aberrant DNA Methylation of the Src Tyrosine Kinase Hck Is a Frequent Event in Human Leukemia and May Predict for Poor Prognosis in Adult Acute Lymphocytic Leukemia (ALL).. *Blood*, **2004**, 104, 1542-1542	2.2
301	ARTS, a Pro-Apoptotic Mitochondrial Septin-Like Protein That Binds to XIAP, Is Silenced in Acute Lymphoblastic and Primitive Acute Myeloblastic Leukemia Cells.. *Blood*, **2004**, 104, 3378-3378	2.2
300	Detection of Aberrant DNA Methylation in Acute Lymphocytic Leukemia (ALL) Using a Real-Time Polymerase Chain Reaction (PCR) Assay.. *Blood*, **2004**, 104, 998-998	2.2

299	Is the Proposed World Health Organization (WHO) Classification for Chronic Myeloid Leukemia (CML) of Clinical Value in the Imatinib Era?.. *Blood*, **2004**, 104, 1014-1014	2.2
298	Survival Advantage for Patients (pts) with Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) Treated with Imatinib.. *Blood*, **2004**, 104, 1006-1006	2.2
297	Intracranial Hemorrhage (ICH) in Patients (pts) with Newly Diagnosed Leukemia: Incidence and Effect on Outcome.. *Blood*, **2004**, 104, 4530-4530	2.2
296	Phase I Study of Clofarabine Plus Idarubicin and Clofarabine Plus Idarubicin Plus Cytarabine (ARA-C) in Patients (PTS) with Relapsed and Primary Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myeloid Blast Phase of Chronic Myeloid Leukemia (CML).. *Blood*, **2004**, 104, 1809-1809	2.2
295	Phase I Study of Triapine and Cytarabine (ara-C) in Patients with Relapsed or Refractory Acute Leukemias and High-Risk Myelodysplastic Syndrome (MDS).. *Blood*, **2005**, 106, 4925-4925	2.2
294	Study of Intra-Venous Homoharringtonine (HHT) in the Treatment of Myelodysplastic Syndrome (MDS).. *Blood*, **2005**, 106, 4903-4903	2.2
293	Clofarabine Combinations in Acute Myeloid Leukemia (AML) Salvage: A Dose-Finding Phase I Study of Clofarabine Plus Idarubicin and Clofarabine/Idarubicin Plus Cytarabine (ara-C).. *Blood*, **2005**, 106, 2803-2803	2.2
292	Aberrant DNA Methylation of a Cell Cycle Regulatory Pathway Composed of p73, p15 and P57kip2 Is Associated with Poor Prognosis in Adult Patients with Philadelphia Chromosome Negative Acute Lymphocytic Leukemia (ALL).. *Blood*, **2005**, 106, 481-481	2.2
291	Characteristics and Outcomes of 38 Patients with Acute Myeloid Leukemia Evolving from Previous Well Characterized Myeloproliferative Disorder.. *Blood*, **2006**, 108, 2705-2705	2.2
290	Outcome after Detection of Minimal Residual Disease during Treatment with the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).. *Blood*, **2006**, 108, 1861-1861	2.2
289	Farnesyl Transferase Inhibitor (Tipifarnib, Zarnestra; Z) in Combination with Standard Chemotherapy with Idarubicin (Ida) and Cytarabine (ara-C) for Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).. *Blood*, **2006**, 108, 1999-1999	2.2
288	Phase I Trial of Sphingosomal Vincristine (SV, Marqibo) and Dexamethasone in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL).. *Blood*, **2006**, 108, 4539-4539	2.2
287	Incidence of Venothromboembolism (VTE) in Patients (pts) with Acute Lymphocytic Leukemia (ALL), Burkitt Leukemia/Lymphoma (BL) or Lymphoblastic Leukemia (LL).. *Blood*, **2006**, 108, 4534-4534	2.2
286	Methylation Profiling of Three Homogenous Cancers: Chronic Myelogenous Leukemia (CML), Acute Promyelocytic Leukemia (APL) and Gastrointestinal Stromal Tumors (GIST).. *Blood*, **2006**, 108, 736-736	2.2
285	RIZ1 Is Downregulated during CML Progression and Displays Tumor Suppressor Properties in CML Cell Lines.. *Blood*, **2006**, 108, 2134-2134	2.2
284	PEG-Intron Therapy in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders (MPD): Final Result of a Phase II Study.. *Blood*, **2006**, 108, 3636-3636	2.2
283	Frequency of NUP214-ABL1 Oncogene in Patients with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Analysis of the Activity of Imatinib and Nilotinib in NUP214-ABL1-Expressing T-ALL Cell Lines.. *Blood*, **2006**, 108, 710-710	2.2
282	Phase I Study of XL-119, a Rebeccamycin Analog, in Patients with Refractory Hematological Malignancies.. *Blood*, **2006**, 108, 1969-1969	2.2

281	Changes in DNA Methylation of Repetitive Elements during the Progression of Chronic Myelogenous Leukemia.. *Blood*, **2006**, 108, 4302-4302	2.2
280	Clinical Features and Prognosis of Patients with Myelodysplastic/Myeloproliferative Syndrome-Unclassified (MDS/MPD-U): Refractory Anemia with Ringed Sideroblasts with Thrombocytosis (RARS-T) Is a Favorable Prognostic Subgroup.. *Blood*, **2006**, 108, 2612-2612	2.2
279	Treatment of Myelodysplastic Syndrome (MDS) with Cytokine Immunotherapy for Low-Risk MDS.. *Blood*, **2007**, 110, 1463-1463	2.2
278	Phase II Study of Lenalidomide and Prednisone for Patients with Myelofibrosis.. *Blood*, **2007**, 110, 3545-3545	2.2
277	Genome-Wide DNA Methylation Profile of CLL with 17p del Allowed Identification of Multiple Epigenetically Inactivated Molecular Pathways with Prognostic Value in Human Leukemia.. *Blood*, **2007**, 110, 492-492	2.2
276	Therapy Related Acute Myelogenous Leukemia and Myelodysplastic Syndrome in Patients with Acute Lymphoblastic Leukemia Treated with the Hyper-CVAD Regimen.. *Blood*, **2007**, 110, 2832-2832	2.2
275	Efficacy of Azacytidine (5-AC) Given as Maintenance or Salvage Therapy for Patients (pts) with Acute Leukemia Post Allogeneic Stem Cell Transplantation (HSCT).. *Blood*, **2007**, 110, 3013-3013	2.2
274	Clinical Characteristics and Outcome of Patients (pts) with F317L BCR-ABL Kinase Domain (KD) Mutation after Therapy with Tyrosine Kinase Inhibitors (TKIs).. *Blood*, **2007**, 110, 1949-1949	2.2
273	Salvage Therapy with Standard Dose Cytarabine Is Appropriate for Patients with Acute Myelogenous Leukemia Refractory to Front-Line Therapy with Hypomethylating Agents.. *Blood*, **2007**, 110, 4382-4382	2.2
272	Kinetics of Bone Marrow Blasts during Remission Induction Course in Acute Myeloid Leukemia: Effect on Complete Remission and Relapse-Free Survival.. *Blood*, **2007**, 110, 1852-1852	2.2
271	Long-Term Significance of Achieving a Major Cytogenetic Response (MCyR) without a Complete Hematologic Response (CHR) among Patients (pts) with Chronic Myeloid Leukemia (CML) in Advanced Phase Treated with Second Generation Tyrosine Kinase Inhibitors (TKI).. *Blood*, **2007**, 110, 1944-1944	2.2
270	Genome-Wide Identification of Aberrant Promoter Associated CpG Island Methylation in Acute Lymphoblastic Leukemia.. *Blood*, **2007**, 110, 2127-2127	2.2
269	Phase II Study of CPX-351 (Cytarabine: Daunorubicin) Liposome Injection in Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) at High Risk for Induction Mortality. *Blood*, **2017**, 130, 892-892	2.2
268	Imapct of Clonal Hematopoiesis of Indeterminate Potential (CHIP) Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome. *Blood*, **2018**, 132, 1814-1814	2.2
267	Telomere Damage Maintains Hematopoietic Stem Cells (HSCs) in an Activated Metabolic State, Which Compromises Their Self-Renewal Capability. *Blood*, **2018**, 132, 174-174	2.2
266	Post Allogeneic Stem Cell Transplant (SCT) Cyclophosphamide Improves Progression Free Survival (PFS) in Pts with AML/MDS Treated with CTLA-4 or PD-1 Blockade Prior to SCT. *Blood*, **2018**, 132, 483-483	2.2
265	Dynamic Personalized Assessment in Patients with Chronic Myeloid Leukemia in Chronic Phase. *Blood*, **2018**, 132, 3026-3026	2.2
264	Survivorship in AML - Outcomes of Acute Myelogenous Leukemia (AML) Patients (pts) after Maintaining Complete Remission (CR) for at Least 3 Years (yrs). *Blood*, **2018**, 132, 3976-3976	2.2

263	Diverse Landscape of TET2 Variants in MDS and AML. *Blood*, **2018**, 132, 1479-1479	2.2
262	Does Trial Participation Improve Outcomes for Higher-Risk Myelodysplastic Syndromes (MDS) Patients Treated at Specialty Centers?. *Blood*, **2018**, 132, 3096-3096	2.2
261	Mutational and Clonal Landscape of Acute Myeloid Leukemia with Myelodysplastic Related Changes. *Blood*, **2018**, 132, 1514-1514	2.2
260	Evaluating the Evidence for Long-Term Benefit from Specialty Centers Versus Real World for MDS Patients Treated with HMA. *Blood*, **2018**, 132, 3095-3095	2.2
259	The Impact of Clonal Hematopoiesis of Indeterminate Potential on Survival in Patients with Newly Diagnosed Acute Myeloid Leukemia. *Blood*, **2018**, 132, 4359-4359	2.2
258	Granulocyte Transfusions for Neutropenic Patients with Perirectal and Perineal Infections. *Blood*, **2018**, 132, 2544-2544	2.2
257	Single-Cell Atlas of Driver Mutations in Acute Myeloid Leukemia (AML). *Blood*, **2018**, 132, 88-88	2.2
256	Outcomes of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Surviving More Than 5 Years (yrs) after Initial Therapy with TKIs. *Blood*, **2018**, 132, 5442-5442	2.2
255	Distinct Gene Expression Patterns of Minimal Residual Disease (MRD) Cells in High-Risk AML Patients Identified By RNA-Sequencing. *Blood*, **2018**, 132, 2757-2757	2.2
254	Outcomes in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Longer-Term Follow-up Demonstrates Poor Outcomes in Patients with Skin-Only Presentation. *Blood*, **2018**, 132, 3980-3980	2.2
253	Smoking Confers Poor Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI). *Blood*, **2018**, 132, 2664-2664	2.2
252	Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS. *Blood*, **2018**, 132, 3103-3103	2.2
251	Efficacy of Ponatinib after Multiple Lines of Therapy for Chronic Myeloid Leukemia. *Blood*, **2018**, 132, 3013-3013	2.2
250	Potential Predictors of Induction Failure and Complete Remission Duration in FLT3-ITD Mutated Acute Myeloid Leukemia. *Blood*, **2018**, 132, 3996-3996	2.2
249	RNA Expression Profile Using Targeted NGS As a Potential Predictor of Early Molecular Response and Relapse in Core-Binding Factor Acute Myeloid Leukemia. *Blood*, **2018**, 132, 5113-5113	2.2
248	Landscape of TP53 Abnormalities and Their Clinical Relevance in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia. *Blood*, **2018**, 132, 2791-2791	2.2
247	Dynamic Personalized Assessment of Outcome in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. *Blood*, **2018**, 132, 2695-2695	2.2
246	Evolutionary Action Score of Missense TP53 Mutations Can Predict Outcome in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. *Blood*, **2018**, 132, 1820-1820	2.2

245	2nd cycle Remission Achievement with 7+3 Is Associated with Shorter Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials. *Blood*, **2018**, 132, 3978-3978	2.2
244	Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR). *Blood*, **2019**, 134, 287-287	2.2
243	Prognostic Significance of IKZF1, PAX5, and CDKN2A Deletions in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD/MA with Dasatinib or Ponatinib. *Blood*, **2019**, 134, 2753-2753	2.2
242	Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect MDS/AML Registry. *Blood*, **2019**, 134, 4747-4747	2.2
241	Effectiveness of Bosutinib in Chronic Myeloid Leukemia (CML) Who Have Received Multi Tyrosine Kinase Inhibitors (TKIs). *Blood*, **2019**, 134, 2941-2941	2.2
240	Increasing Lengths of First Complete Remission with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia over the Past Four Decades: Analysis of SWOG Trial Data. *Blood*, **2019**, 134, 291-291	2.2
239	ILF2 Antisense Oligonucleotide Therapy and a CRISPR/Cas9-Based Screening for DNA Repair Effectors Identify Synthetic Lethal Approaches Enhancing Myeloma Cells Sensitivity to DNA Damage. *Blood*, **2019**, 134, 685-685	2.2
238	The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI). *Blood*, **2019**, 134, 3815-3815	2.2
237	Machine Learning Prediction for Complete Response to Hypomethylating Agents with or without Additional Agents in Patients with Newly Diagnosed Myelodysplastic Syndrome. *Blood*, **2019**, 134, 1720-1720	2.2
236	Early Intervention with Hypomethylating Agents in Transfusion-Independent Patients with Myelodysplastic Syndrome. *Blood*, **2019**, 134, 4252-4252	2.2
235	High-Resolution Next-Generation Whole Genome Optical Mapping As a Novel Molecular Diagnostic Tool for Comprehensive Assessment of Structural Chromosomal Variations in Myelodysplastic Syndromes. *Blood*, **2019**, 134, 5438-5438	2.2
234	Evolutionary Action (EA) Score of TP53 Mutations Defines Prognostic Subsets within TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia. *Blood*, **2019**, 134, 1719-1719	2.2
233	Comprehensive DNA 5-Hydroxymethylation Landscapes in Myelodysplastic Syndromes (MDS). *Blood*, **2019**, 134, 2996-2996	2.2
232	Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes. *Blood*, **2019**, 134, 1711-1711	2.2
231	Characteristics and Outcomes of Therapy-Related Versus De Novo Acute Myeloid Leukemia with Normal Karyotype. *Blood*, **2019**, 134, 3834-3834	2.2
230	Determinants of Outcomes of FLT3mut Acute Myeloid Leukemia with First Salvage Therapy. *Blood*, **2019**, 134, 2641-2641	2.2
229	Outcomes of Patients with Acute Myeloid Leukemia with Myelodysplastic Are Dependent on Diagnostic Criteria and Therapy. *Blood*, **2019**, 134, 647-647	2.2
228	Somatic Mutations Improve Risk Classification By Cytogenetic Abnormalities in Patients with Myelodysplastic Syndrome after Hematopoietic Stem Cell Transplantation. *Blood*, **2019**, 134, 512-512	2.2

227	Clonal Dynamics and Clinical Implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML). *Blood*, **2019**, 134, 17-17	2.2
226	Outcomes of Patients with Suboptimal /Warning Response to Tyrosine Kinase Inhibitors: A Comparison of the 2009 and 2013 Guidelines of the European Leukemianet. *Blood*, **2019**, 134, 2930-2930	2.2
225	A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs). *Blood*, **2019**, 134, 4237-4237	2.2
224	Outcome of Patients (pts) with Therapy-Related De Novo Acute Myeloid Leukemia (t-de novo AML): Single Institution Experience. *Blood*, **2014**, 124, 2273-2273	2.2
223	Association Between Down-Regulation of EZH2 and Abnormal Karyotype, Response to Hypomethylation Treatment, and Patient Survival in Myelodysplastic Syndromes. *Blood*, **2014**, 124, 3241-3241	2.2
222	Comparison of Risk Models for Patients with Lower Risk Myelodysplastic Syndromes. *Blood*, **2014**, 124, 1919-1919	2.2
221	Multigene Mutational Clinical Profiling Using Next Generation Sequencing in a Cohort of 451 Patients with MDS: Impact on Clinical Outcomes. *Blood*, **2014**, 124, 4658-4658	2.2
220	Therapy-Related Myeloid Neoplasms in Breast Cancer Patients: A Single-Institution Report of 150 Cases. *Blood*, **2014**, 124, 962-962	2.2
219	A Final Report: Phase I/II Study of Sequential Azacitidine and Lenalidomide in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). *Blood*, **2014**, 124, 164-164	2.2
218	Knowledge That the Myelodysplastic Syndromes (MDS) Are a Type of Cancer Does Not Influence Patient Perception of Treatment Discontinuation. *Blood*, **2014**, 124, 6015-6015	2.2
217	Long-Term Outcome of Patients with Myelodysplastic Syndromes (MDS) Treated with Hypomethylating Agents (HMA): A Report on Behalf of the MDS Clinical Research Consortium. *Blood*, **2014**, 124, 4641-4641	2.2
216	Improvement in Clinical Outcome of FLT3 Mutated AML Patients over the Last One and a Half Decade. *Blood*, **2014**, 124, 949-949	2.2
215	Relationship of Bone Marrow Blast (BMBL) Response to Overall Survival (OS) in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Rigosertib after Failure of Hypomethylating Agents (HMAs). *Blood*, **2014**, 124, 3259-3259	2.2
214	Azacytidine and Vorinostat in Patients with Chronic Lymphocytic Leukemia (CLL) Diagnosed with Therapy-Related Myelodysplastic Syndromes/Acute Myeloid Leukemia (t-MDS/AML). *Blood*, **2014**, 124, 5627-5627	2.2
213	Discontinuation of HMA Therapy after Achieving Complete or Partial Response: Retrospective Analysis of Survival after Long-Term Follow up. *Blood*, **2014**, 124, 4664-4664	2.2
212	A Mouse Model of Telomere Dysfunction Recapitulates Hallmark Features of Human Myelodysplastic Syndrome. *Blood*, **2014**, 124, 523-523	2.2
211	The Efficacy of Current Prognostic Models in Predicting Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure. *Blood*, **2014**, 124, 3275-3275	2.2
210	Association Between RUNX3 Hypermethylation and Acute Myeloid Leukemia Inv(16) Subtype. *Blood*, **2014**, 124, 3548-3548	2.2

209	Minimal Residual Disease (MRD) Assessed By Multi-Parameter Flow Cytometry (MFC) Is Highly Predictive of Outcome in Adult Patients with Acute Lymphoblastic Leukemia (ALL). *Blood*, **2014**, 124, 1079-1079	2.2
208	Prognostic Factors for Outcome in Patients (pts) with Refractory and Relapsed Acute Lymphocytic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (IO), a CD22 Monoclonal Antibody. *Blood*, **2014**, 124, 2288-2288	2.2
207	Frequency and Impact of Molecular Responses with Nilotinib (Tasigna) in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP). *Blood*, **2014**, 124, 3156-3156	2.2
206	Mutational Profile and Karyotypic Abnormalities of a Cohort of Clinical Trial Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Following Failure of Hypomethylating Agents (HMAs): Impact on Response to Rigosertib Therapy. *Blood*, **2014**, 124, 3258-3258	2.2
205	Phase II Study of Targeted Subcutaneous (SC) Bortezomib for Patients with Low- or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) with Evidence of NF-B Activation. *Blood*, **2014**, 124, 1930-1930	2.2
204	Association Between Downregulation of POT1 Expression and Chromosome 7 Deletion, Response to Hypomethylation Agent Treatment, and Patient Survival in Myelodysplastic Syndromes. *Blood*, **2014**, 124, 4663-4663	2.2
203	MYC Expression Is Prognostic in Therapy Related Acute Myeloid Leukemia (AML) and AML with Myelodysplastic Syndrome (MDS)-Related Changes. *Blood*, **2014**, 124, 5334-5334	2.2
202	The Prognostic Utility of the Current Risk Models in Predicting Outcomes of Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agents (HMA). *Blood*, **2014**, 124, 1935-1935	2.2
201	Retrospective Analysis of Survival in Patients with Acute Erythroid Leukemia (AML-6) Treated with Conventional Chemotherapy Versus Hypomethylating Agents. *Blood*, **2014**, 124, 2278-2278	2.2
200	A Phase II Feasibility Study of Prophylactic White Cell Transfusions for the Prevention of Infection in AML Patients Undergoing Induction Therapy. *Blood*, **2014**, 124, 1564-1564	2.2
199	Temporal Acquisition of FLT3-ITD or RAS Mutation at Transformation to AML from MDS: Clinical Implications. *Blood*, **2014**, 124, 4631-4631	2.2
198	Phase I-II Study of Sequential Therapy with Decitabine Followed By Clofarabine, Idarubicin, and Cytarabine (DAC-CIA regimen) in Relapsed/Refractory Acute Myeloid Leukemia (AML). *Blood*, **2014**, 124, 5283-5283	2.2
197	Long-Term Outcome of Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Single-Institution Experience. *Blood*, **2014**, 124, 1924-1924	2.2
196	Predictive Factors for Response and Survival in Patients with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent (HMA) Failure: Primary Resistance (PriRes) Vs. Secondary Resistance (SecRes). *Blood*, **2014**, 124, 1922-1922	2.2
195	Retrospective Analysis to Correlate Impact of Symptom Burden and Quality of Life to Treatment Outcome with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Chronic Phase. *Blood*, **2014**, 124, 4548-4548	2.2
194	Impact of Hypomethylating Agent Therapy in Myelodysplastic Syndromes with Chromosome 3 Abnormalities. *Blood*, **2015**, 126, 1705-1705	2.2
193	Frontline Hyper-CVAD with Ponatinib for Patients (pts) with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: Results of a Phase II Study. *Blood*, **2015**, 126, 2496-2496	2.2
192	Age Distribution and Pattern of Myeloid Marrow Mutations in Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) after Failure of Hypomethylating Agents (HMAs). *Blood*, **2015**, 126, 5257-5257	2.2

191	Idarubicin and Cytarabine Combined with Clofarabine or Fludarabine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: Interim Result of a Phase II Clinical Trial. *Blood*, **2015**, 126, 2508-2508	2.2
190	Telomere Dysfunction-Induced DNA Damage Drives Hematopoietic Stem Cell Fate. *Blood*, **2015**, 126, 1156-1156	2.2
189	Prognostic Implications of Pre-Treatment Hypodiploidy and Complex Cytogenetics in Adult Patients with Acute Lymphocytic Leukemia (ALL) Treated with Hyper-CVAD. *Blood*, **2015**, 126, 4874-4874	2.2
188	Outcome of Patients with T-Cell ALL Post Frontline Therapy Failure. *Blood*, **2015**, 126, 4873-4873	2.2
187	The Prognostic Value of Minimal Residual Disease (MRD) after Salvage Therapy in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL). *Blood*, **2015**, 126, 3771-3771	2.2
186	Pharmacological Inhibition of Histone Demethylase JMJD3 Reduces Leukemia Cell Survival and Represses Production of the Cytokine CCL2 in MDS/AML. *Blood*, **2015**, 126, 5219-5219	2.2
185	PDE4 Differential Expression Is a Potential Prognostic Factor and a Therapeutic Target in Myelodysplastic Syndromes. *Blood*, **2015**, 126, 5227-5227	2.2
184	Does the Achievement of MR4.5 Improve the Outcome of Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Front Line Tyrosine Kinase Inhibitors (TKI)?. *Blood*, **2015**, 126, 5158-5158	2.2
183	IKZF3 p.L162R Is a Recurrent Hotspot Mutation in Chronic Lymphocytic Leukemia (CLL). *Blood*, **2015**, 126, 4136-4136	2.2
182	Results of Intensive Chemotherapy in 434 Adult Patients (pts) with Philadelphia-Negative Acute Lymphoblastic Leukemia (ALL): Predictive Prognostic Model for Survival. *Blood*, **2015**, 126, 3722-3722	2.2
181	Prognostic Significance of Somatic Mutations in Treatment of AML in Salvage Setting: A Retrospective Analysis. *Blood*, **2015**, 126, 1313-1313	2.2
180	Long Term Outcome of Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid, Arsenic Trioxide with or without Gemtuzumab Ozogamicin. *Blood*, **2015**, 126, 3776-3776	2.2
179	North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia. *Blood*, **2015**, 126, 1138-1138	2.2
178	Liposomal Vincristine (Marqibo) Combined with Hyper-Cmad As Frontline Therapy for Patients with Acute Lymphoblastic Leukemia: A Result of a Phase II Clinical Trial. *Blood*, **2015**, 126, 3720-3720	2.2
177	Fatigue, Quality of Life and Related Symptoms: Patient Reported Outcomes in Myelodysplastic Syndrome, Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. *Blood*, **2015**, 126, 4456-4456	2.2
176	A Novel Model to Predict Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure. *Blood*, **2015**, 126, 2888-2888	2.2
175	The Impact of 20q Deletion on Clinical Presentation, Treatment Response and Survival in Patients with Acute Myeloid Leukemia (AML): The University of Texas MD Anderson Cancer Center Experience. *Blood*, **2015**, 126, 1369-1369	2.2
174	Outcome of Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (ALL) and Isolated Central Nervous System (CNS) Relapse. *Blood*, **2015**, 126, 2503-2503	2.2

173	Persistence of Minimal Residual Disease Assessed By Multi-Parameter Flow Cytometry Is a Strong Predictor of Outcome in Younger Patients with Acute Myeloid Leukemia. *Blood*, **2015**, 126, 2579-2579	2.2
172	Ubiquitin Editing of a Spliceosome Auxiliary Factor By TRAF6 Links Chronic TLR Signaling with Hematopoietic Defects and Myelodysplasia. *Blood*, **2015**, 126, 143-143	2.2
171	ILF2-YB1 Protein Interaction Modulates RNA Splicing to Induce Resistance to Chemotherapy in High Risk Multiple Myeloma. *Blood*, **2016**, 128, 359-359	2.2
170	Anti-Leukemia Effect of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Acute Myeloid Leukemia. *Blood*, **2016**, 128, 2756-2756	2.2
169	KIR Gene Haplotype: An Independent Predictor of Clinical Outcome in MDS Patients. *Blood*, **2016**, 128, 4330-4330	2.2
168	Updated Phase II Study of Targeted Subcutaneous (SC) Bortezomib for Patients with Low- or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) with Evidence of NF-ß Activation. *Blood*, **2016**, 128, 3191-3191	2.2
167	Characteristics and Outcomes of Older Patients with Secondary AML According to Treatment Approach. *Blood*, **2016**, 128, 2788-2788	2.2
166	Updated Results of a Randomized Phase II Trial of Idarubicin and Cytarabine with Clofarabine or Fludarabine in Patients with Newly Diagnosed Acute Myeloid Leukemia. *Blood*, **2016**, 128, 1067-1067	2.2
165	Validation of the 2016 Revision to the World Health Organization (WHO) Classification of Myelodysplastic Syndromes with Diploid Karyotype. *Blood*, **2016**, 128, 4319-4319	2.2
164	An Open-Label, Phase I Study of Dasatinib in Combination with Decitabine in Patients (Pts) with Accelerated or Blastic Phase Chronic Myeloid Leukemia (CML). *Blood*, **2016**, 128, 5433-5433	2.2
163	Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL) with Hypercvad Based Regimens. *Blood*, **2016**, 128, 2779-2779	2.2
162	Activity of Hypomethylating Agents in the Treatment of Therapy-Related Myelodysplastic Syndrome. *Blood*, **2016**, 128, 3177-3177	2.2
161	Eltrombopag for the Management of Thrombocytopenia Associated with Tyrosine Kinase Therapy in Patients with Chronic Myeloid Leukemia and Myelofibrosis. *Blood*, **2016**, 128, 3062-3062	2.2
160	Impact of Driver Mutations in Patients with Lower-Risk Myelodysplastic Syndromes Classified By the MD Anderson Lower-Risk Prognostic Scoring System. *Blood*, **2016**, 128, 4317-4317	2.2
159	Impact of the Next-Generation Sequencing Panel on Treatment Choice in Patients with Myelodysplastic Syndrome. *Blood*, **2016**, 128, 4340-4340	2.2
158	Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes (MDS): Are They Two Faces of the Same Coin? a Study on Behalf of the MDS Clinical Research Consortium (MDS CRC). *Blood*, **2016**, 128, 4321-4321	2.2
157	Additional Chromosomal Abnormalities in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors: Differential Outcomes According to Type of Chromosomal Abnormality. *Blood*, **2016**, 128, 1737-1737	2.2
156	Computational Analysis of Genomic Abnormalities from a Phase 3 Trial of Rigosertib in Higher-Risk MDS: Simulation of a Predictive Signature for Clinical Response. *Blood*, **2016**, 128, 4324-4324	2.2

155	Effect of Lenalidomide (LEN) Exposure on Response and Outcomes in Patients (Pts) with Lower-Risk Non-Del(5q) Myelodysplastic Syndromes (MDS). *Blood*, **2016**, 128, 3190-3190	2.2
154	Methotrexate Clearance in Adult Patients with B-Precursor Acute Lymphoblastic Leukemia Treated with the Mini-Hyper-CVD Regimen. *Blood*, **2016**, 128, 5194-5194	2.2
153	Increased Number of Driver Mutations Is a Predictor of Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes. *Blood*, **2016**, 128, 51-51	2.2
152	Outcomes of Adult Patients with Relapsed/Refractory Burkitt or Burkitt-like Leukemia/Lymphoma. *Blood*, **2016**, 128, 5150-5150	2.2
151	Prognostic Value of Clonal Evolution at the Time of Diagnosis in Patients with Chronic Myeloid Leukemia Treated with Frontline Tyrosine Kinase Inhibitors. *Blood*, **2016**, 128, 3064-3064	2.2
150	Patterns of Relapse in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Who Achieve Complete Molecular Response with Chemotherapy Plus a Tyrosine Kinase Inhibitor. *Blood*, **2016**, 128, 3977-3977	2.2
149	Prediction for Sustained Deep Molecular Response of BCR-ABL Levels in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). *Blood*, **2016**, 128, 1224-1224	2.2
148	Cryptic Philadelphia Chromosome in Newly Diagnosed Chronic Phase CML (CML-CP): Clinical Characteristics and Treatment Outcome after Treatment with 5 TKI Modalities. *Blood*, **2016**, 128, 3082-3082	2.2
147	A Phase II Trial of Omacetaxine Mepesuccinate for Patients with High-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agents. *Blood*, **2016**, 128, 4328-4328	2.2
146	Clonal Hematopoiesis Increases Risk of Therapy-Related Myeloid Neoplasms. *Blood*, **2016**, 128, 38-38	2.2
145	Archetypes of AML Defined Using Whole Exome Sequencing and Clinical Characteristics in a Diverse Group of Patients. *Blood*, **2016**, 128, 597-597	2.2
144	Clinical Characteristics of Philadelphia Positive T-Cell Lymphoid Leukemias - (de novo and blast phase CML). *Blood*, **2016**, 128, 5436-5436	2.2
143	Factors Affecting Survival Outcomes in Patients with Blast Phase CML (CML-BP) in the Tyrosine Kinase Inhibitor (TKI) Era: A Cohort Study of 498 Patients. *Blood*, **2016**, 128, 1220-1220	2.2
142	Disease-Related Mortality in Patients with Lower-Risk Myelodysplastic Syndrome (MDS). *Blood*, **2008**, 112, 5073-5073	2.2
141	Epigenetic Inactivation of Notch Signaling Target Genes HES in B Cell Acute Lymphoblastic Leukemia.. *Blood*, **2008**, 112, 3372-3372	2.2
140	Outcome of First Salvage Therapy in Core Binding Factor Associated Acute Myelogenous Leukemia Is Less Than Optimal. *Blood*, **2008**, 112, 2952-2952	2.2
139	The Heterogeneous Prognosis of Patients with Myelodysplastic Syndrome (MDS) and Chromosome 5 Abnormalities: How Does It Relate to the Original Lenalidomide Experience in MDS?.. *Blood*, **2008**, 112, 1644-1644	2.2
138	The Combination of a Histone Deacetylase (HDAC) Inhibitor with the BCL-2 Inhibitor GX15-070 Has Synergistic Antileukemia Effect by Inducing Both Apoptotic and Autophagic Pathways.. *Blood*, **2008**, 112, 1633-1633	2.2

137	Experience with the Combination of a Hypomethylating Agent and Valproic Acid in Pediatric Acute Myelogenous Leukemia. *Blood*, **2008**, 112, 4036-4036	2.2
136	Increase in the Incidence of Secondary Acute Myeloid Leukemia (2-AML): A Single Institution Experience Over 20 Years.. *Blood*, **2008**, 112, 1498-1498	2.2
135	Phase II Study of Thymoglobulin, Cyclosporine and G-CSF for Initial Treatment of Aplastic Anemia and Low Risk Myelodysplastic Syndrome. *Blood*, **2008**, 112, 5080-5080	2.2
134	Integrating Newer Prognostic Factors in Evaluation of Previously Treated Patients with CLL Receiving Salvage Treatment.. *Blood*, **2008**, 112, 2078-2078	2.2
133	Antileukemia Activity of JNJ-26481585, a Potent Second-Generation Histone Deacetylase Inhibitor. *Blood*, **2008**, 112, 2631-2631	2.2
132	Outcome of Patients with Chronic Myeloid Leukemia (CML) with Multiple ABL1 Kinase Domain Mutations during Tyrosine Kinase Inhibitor Therapy.. *Blood*, **2008**, 112, 2111-2111	2.2
131	Integrating Newer with Traditional Prognostic Factors in Evaluating Patients with CLL Receiving Frontline Chemoimmunotherapy.. *Blood*, **2008**, 112, 2094-2094	2.2
130	Malignancies Occurring during Therapy with Tyrosine Kinase Inhibitors (TKI) for Chronic Myeloid Leukemia (CML) and Other Hematologic Malignancies.. *Blood*, **2008**, 112, 2125-2125	2.2
129	Clinical Parameters in 391 Iron-Overloaded Patients with Lower-Risk MDS Enrolled in a Prospective, Non-Interventional Multicenter Registry.. *Blood*, **2009**, 114, 4834-4834	2.2
128	Patients with Relapsed CLL and 17p Deletion by FISH Have Very Poor Survival Outcomes.. *Blood*, **2009**, 114, 1248-1248	2.2
127	A Comparative Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Azacitidine Following Subcutaneous (SC) and Oral Administration in Subjects with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML), Results From a Phase 1 Study.. *Blood*, **2009**, 114, 1772-1772	2.2
126	Characteristics and Outcome of Patients with Acute Myeloid Leukemia (AML) Refractory to One Cycle of High Dose Cytarabine-Based Induction Chemotherapy.. *Blood*, **2009**, 114, 1038-1038	2.2
125	The Combination of PEITC (Phenehyl Isothiocyanate) with a Histone Deacetylase Inhibitor (HDACi) Has Synergistic Antileukemia Activity by Overcoming a Redox-Mediated Resistance Pathway.. *Blood* , **2009**, 114, 1739-1739	2.2
124	A Phase 1 Dose-Escalation Study of the Novel KSP Inhibitor ARRY-520 in Advanced Leukemias.. *Blood*, **2009**, 114, 2047-2047	2.2
123	The Outcome of Patients (pts) with Acute Promyelocytic Leukemia (APL) Who Fail Both All□trans-retinoic Acid (ATRA) and Arsenic Trioxide (ATO).. *Blood*, **2009**, 114, 4143-4143	2.2
122	Clofarabine Plus Low-Dose Cytarabine Induction Followed by Consolidation with Clofarabine Plus Low-Dose Cytarabine Alternating with Decitabine as Frontline Therapy for Patients (pts) with Acute Myeloid Leukemia (AML) □60 Years (yrs).. *Blood*, **2009**, 114, 2058-2058	2.2
121	Favorable Outcome for Lymphoblastic Lymphoma (LL) After Frontline Therapy with the Hyper-CVAD Regimens: An Update.. *Blood*, **2009**, 114, 4099-4099	2.2
120	Clinical Characterization and Proteomic Consequences of Mutated Ras in Acute Myeloid Leukemia.. *Blood*, **2009**, 114, 330-330	2.2

119	A Phase 1 Study of Dose-Dense 5-Aza-2?-Deoxycitidine (decitabine) in Relapse Refractory Acute Lymphocytic Leukemia (ALL).. *Blood*, **2009**, 114, 2030-2030	2.2
118	Predictive Factors for Response and Outcome in Patients (pts) Treated with Second Generation Tyrosine Kinase Inhibitors (2-TKI) for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Post Imatinib Failure.. *Blood*, **2009**, 114, 509-509	2.2
117	Outcome of Therapy-Related Acute Promyelocytic Leukemia (t-APL) with or without Arsenic Trioxide (ATO) as a Component of Frontline Therapy.. *Blood*, **2009**, 114, 1050-1050	2.2
116	DNA Methylation and Gene Expression Analysis in a Phase II Randomized Study of Decitabine Vs. Decitabine Plus Valproic Acid in MDS and AML.. *Blood*, **2009**, 114, 3808-3808	2.2
115	Chemoimmunotherapy with a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome for Patients with De Novo Philadelphia Negative Precursor B-Cell Acute Lymphoblastic Leukemia (ALL).. *Blood*, **2009**, 114, 836-836	2.2
114	A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, in Elderly Patients with AML Previously Untreated or in First Relapse.. *Blood*, **2009**, 114, 1061-1061	2.2
113	BARD1: a New Target In Leukemia. *Blood*, **2010**, 116, 4642-4642	2.2
112	Point Mutations In Myelodysplastic Syndromes Are Associated with Clinical Features and Are Independent Predictors of Overall Survival. *Blood*, **2010**, 116, 300-300	2.2
111	Analysis of Regulatory miRNAs of Histone Demethylase JMJD3 In MDS CD34+ Hematoprogenitor Cells. *Blood*, **2010**, 116, 609-609	2.2
110	Decitabine Is Effective and Safe In Patients with Chronic Myelomonocytic Leukemia. *Blood*, **2010**, 116, 4032-4032	2.2
109	Prognostic Factors Associated with Progression of Myelodysplastic Syndromes (MDS) to Acute Myeloid Leukemia (AML) In Patients (pts) Treated with Decitabine. *Blood*, **2010**, 116, 4956-4956	2.2
108	Clinical Characterization, Prognostic Implications, and Response to Therapy In Patients with Myelodysplastic Syndrome (MDS) and Chromsome 17 Abnormality: A Single Institutional Experience. *Blood*, **2010**, 116, 2930-2930	2.2
107	Final Report of a Phase II Trial of Vorinostat, Idarubicin and Cytarabine In Previously Untreated Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS). *Blood*, **2010**, 116, 2189-2189	2.2
106	Seven-Year Follow-up Data on Sequential Prospective Trials of Imatinib 400mg Vs 800mg Daily Schedule for Front-Line Treatment of Chronic Myeloid Leukemia (CML).. *Blood*, **2010**, 116, 3438-3438	2.2
105	Decitabine Is Effective In Patients with Myelodysplastic Syndromes Who Failed Prior Intensive Regimen: No Negative Impact of Prior Therapy. *Blood*, **2010**, 116, 2936-2936	2.2
104	Third Party Umbilical Cord Blood Regulatory T Cells Prevents Graft Versus Host Disease In a Xenogenic Murine Model.. *Blood*, **2010**, 116, 3737-3737	2.2
103	Phase I Study Results of Gimatecan In the Treatment of Myelodysplastic Syndrome (MDS). *Blood*, **2010**, 116, 1883-1883	2.2
102	Death In Complete Remission Among Patients with Acute Myeloid Leukemia: A Preventable Problem?. *Blood*, **2010**, 116, 2710-2710	2.2

101	Proteomic Profiling In CD34+CD38- Stem Cells and CD34+ Cells From 185 Myelodysplasia Patients Using Reverse Phase Proteins Arrays (RPPA) Reveals Recurrent Proteins Expression Signatures with Prognostic Implications. *Blood*, **2010**, 116, 2126-2126	2.2
100	Long-Term Outcome for De Novo or Minimally Treated Burkitt-Type Lymphoma/Leukemia (BL/B-ALL) After Therapy with Hyper-CVAD and Rituximab. *Blood*, **2010**, 116, 1781-1781	2.2
99	MYBL2 Is a Candidate Tumor Suppressor Gene In MDS. *Blood*, **2010**, 116, 1865-1865	2.2
98	Incidence of Secondary Neoplasms In Patients with Acute Promyelocytic Leukemia Treated with All-Trans-Retinoic Acid (ATRA) with Chemotherapy or with Arsenic Trioxide (ATO).. *Blood*, **2010**, 116, 1085-1085	2.2
97	Cytogenetic Evolution (CE) In Patients (pts) with Low and Intermediate Risk Myelodysplastic Syndromes (MDS) Is Associated with Poor Prognosis. *Blood*, **2010**, 116, 2941-2941	2.2
96	Outcome After Failure to Second Generation Thyrosine Kinase Inhibitors(TKI) Treatment as Frontline Therapy for Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase(CP).. *Blood*, **2010**, 116, 3442-3442	2.2
95	Prognostic Significance of Mutations In Isocitrate Dehydrogenase (IDH) Enzyme Isoforms 1 and 2 and Single Nucleotide Polymorphisms (SNP) In IDH1, In Patients with Acute Myeloid Leukemia Treated with High Dose Cytarabine and Idarubicin Induction. *Blood*, **2010**, 116, 2706-2706	2.2
94	Levels of Mir-29b or Mir-101 Do Not Predict Response In Patients (pts) with Acute Myelogenous Leukemia (AML) Treated with the Combination of 5-Azacytidine, Valproic Acid and ATRA. *Blood*, **2010**, 116, 1701-1701	2.2
93	Different Definitions of Progression-Free Survival (PFS) and Event-Free Survival (EFS) May Result In Perceived but Not Real Differences In Long-Term Outcome When Comparing Trials In Chronic Myeloid Leukemia (CML). *Blood*, **2010**, 116, 672-672	2.2
92	Therapeutic Modalities and New Molecular Targets in MDS **2011**, 219-238	
91	Pretreatment Patient Characteristics Associated with Achieving Bone Marrow Minimal Residual Disease-Free Status with Frontline Fludarabine, Cyclosphosphamide, Rituximab (FCR) Chemoimmunotherapy for CLL,. *Blood*, **2011**, 118, 3902-3902	2.2
90	Phase 1 Dose-Ranging Study of Oral Ezatiostat Hydrochloride (Telintra , TLK199) in Combination with Lenalidomide (Revlimid) in Patients with Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS). *Blood*, **2011**, 118, 2778-2778	2.2
89	Clofarabine Does Not Impact Negatively the Outcomes of Patients with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Stem Cell Transplantation and Is Not Associated with Higher Liver Toxicity Rates Compared with Standard Chemotherapy. *Blood*, **2011**, 118, 1489-1489	2.2
88	Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients Younger Than 61 Years with Newly Diagnosed Acute Myeloid Leukemia (AML). *Blood*, **2011**, 118, 1550-1550	2.2
87	Impact of Epigenetic Therapy Versus Conventional Chemotherapy on Survival of Elderly Patients with Acute Myeloid Leukemia. *Blood*, **2011**, 118, 1494-1494	2.2
86	AR-67, a DNA Topo-Isomerase I Inhibitor, Demonstrates Acceptable Tolerability and Preliminary Activity in a Phase II Trial of Patients with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML),. *Blood*, **2011**, 118, 3820-3820	2.2
85	Very Long-Term Follow-up Results of Imatinib Mesylate Therapy in Chronic Phase Chronic Myeloid Leukemia After Failure of Interferon Alpha Therapy. *Blood*, **2011**, 118, 2749-2749	2.2
84	Activating Mutations of the FMS-Like Tyrosine Kinase-3 (FLT3) At Complete Response and Relapse in Patients with Acute Myeloid Leukemia,. *Blood*, **2011**, 118, 3557-3557	2.2

83	Twice Daily Fludarabine and Cytarabine Combination Is Effective in Patients with Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndromes, and Blast Phase Chronic Myeloid Leukemia,. *Blood*, **2011**, 118, 3629-3629	2.2
82	Phase II Study of the Histone Deacetylase Inhibitor Panabinostat (LBH589) in Patients with Low or Intermediate-1 Risk Myelodysplastic syndrome. *Blood*, **2011**, 118, 1731-1731	2.2
81	Incidence, Characteristics, and Outcome of FLT3-ITD Mutations in AML Arising from an Antecedent Hematologic Disorder. *Blood*, **2011**, 118, 2522-2522	2.2
80	Improved Survival in Chronic Myeloid Leukemia (CML) Since the Introductin of Imatinib Therapy - A Single Institution Historical Experience. *Blood*, **2011**, 118, 2750-2750	2.2
79	Randomized Open-Label Phase II Study of Decitabine in Patients with Low- or Intermediate-1 Risk Myelodysplastic Syndromes,. *Blood*, **2011**, 118, 3812-3812	2.2
78	EUTOS Score Is Not Predictive for Survival and Outcome in Patients (pts) with Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKIs) At MD Anderson Cancer Center (MDACC),. *Blood*, **2011**, 118, 3769-3769	2.2
77	Safety, Pharmacokinetics, and Efficacy of BP-100.1.01 (L-Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS),. *Blood*, **2011**, 118, 3639-3639	2.2
76	Patients' Comorbidities and Overall Survival in Primary Myelofibrosis (PMF). *Blood*, **2011**, 118, 5164-5164	2.2
75	Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis. *Blood*, **2011**, 118, 2598-2598	2.2
74	Final Report of a Randomized Study of Decitabine Versus Conventional Care (CC) for Maintenance Therapy in Patients with Intermediate and High Risk Acute Myeloid Leukemia (AML) in First or Subsequent Complete Remission (CR). *Blood*, **2011**, 118, 1530-1530	2.2
73	Impact of Combining Targeted Agents with High-Dose Cytarabine-Based Induction Chemotherapy on Acute Myeloid Leukemia Outcomes: The M.D. Anderson Cancer Center Experience. *Blood*, **2011**, 118, 1539-1539	2.2
72	Long Term Results of Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome: Analysis of Prognostic Factors. *Blood*, **2011**, 118, 4531-4531	2.2
71	Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia Over the Last 5 Decades At M.D. Anderson Cancer Center. *Blood*, **2011**, 118, 2606-2606	2.2
70	Clofarabine-Containing Chemotherapy Does Not Increase the Risk of Infectious Complications in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). *Blood*, **2011**, 118, 4256-4256	2.2
69	Early Clearance of Peripheral Blood Blasts but Not White Blood Cells Is a Powerful Prognostic marker for complete Response and Overall Survival in Patients with Acute Myeloid Leukemia (AML) receiving Induction Chemotherapy. *Blood*, **2011**, 118, 1553-1553	2.2
68	ROS Activation Independent From Iron Overload in MDS. *Blood*, **2011**, 118, 2798-2798	2.2
67	Clinical or Sub-Clinical Pancreatitis (PA) Associated with Nilotinib (Nb) As Frontline for Chronic Myelogenous Leukemia (CML). *Blood*, **2011**, 118, 4443-4443	2.2
66	Acquisition of Cytogenetic Abnormalities (CA) Is a Very Poor Prognostic Feature in Patients (pts) with Low and Intermediate-1 (int-1) Risk Myelodysplastic Syndromes (MDS),. *Blood*, **2011**, 118, 3802-3802	2.2

65	Allogeneic Hematopoeitic Stem Cell Transplantation (AHSCT) Versus Hypomethylating Agents (HMA) in Patients (pts) with Myelodysplastic Syndrome (MDS): A Case-Control Study. *Blood*, **2011**, 118, 1707-1707	2.2
64	Outcomes for Adult Lymphoblastic Leukemia (ALL) Are Mainly Influenced by Age and Status of Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) After Therapy with the Modified Hyper-CVAD (with or without Rituximab) Regimen. *Blood*, **2011**, 118, 1524-1524	2.2
63	Predictors of Outcome In Adult Patients with Acute Myeloid Leukemia In First Relapse,. *Blood*, **2011** , 118, 3569-3569	2.2
62	Safety and Efficacy of Frontline Nilotinib (Nb) for Chronic Phase (CP) Chronic Myeloid Leukemia (CML) in Diabetic Patients (pts). *Blood*, **2011**, 118, 2764-2764	2.2
61	Acute Leukemia and Myelodysplastic Syndrome: Outcomes in Patients with Chronic Lymphocytic Leukemia (CLL) At MD Anderson Cancer Center (MDACC). *Blood*, **2011**, 118, 981-981	2.2
60	EphrinB1 Activation As a Potential New Treatment Option in AML. *Blood*, **2011**, 118, 5235-5235	2.2
59	Outcome of Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) with Relapse After Tyrosine Kinase Inhibitor (TKI) Therapy. *Blood*, **2011**, 118, 1518-1518	2.2
58	Cytogenetic and Molecular Characterization of Sweet's Syndrome in Patients with Acute Myeloid Leukemia.. *Blood*, **2012**, 120, 2587-2587	2.2
57	Final Report of Combination of Sorafenib, Idarubicin, and Cytarabine for Initial Therapy in Younger Patients with Acute Myeloid Leukemia. *Blood*, **2012**, 120, 1516-1516	2.2
56	Updated Results of a Phase I/II, Randomized Study of Clofarabine Combined with Idarubicin and Cytarabine (CIA) or Fludarabine Combined with Idarubicin and Cytarabine (FIA) for the Treatment of Patients (pts) with Newly Diagnosed or Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML). *Blood*, **2012**, 120, 3610-3610	2.2
55	Infectious Complications in Patients with Relapsed Acute Myeloid Leukemia (AML) Receiving Clofarabine Versus Fludarabine-Containing Salvage Chemotherapy Regimens. *Blood*, **2012**, 120, 4322-4322	2.2
54	The Outcome of Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib Outside of a Clinical Trial or On a Clinical Trial At a Single Institution. *Blood*, **2012**, 120, 1693-1693	2.2
53	Refined MD Anderson Prognostic Scoring System (MDAPS-R) for Chronic Myelomonocytic Leukemia (CMML). *Blood*, **2012**, 120, 3797-3797	2.2
52	Comparative Analysis of the Value of Consolidation with Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT) Versus High-Dose Cytarabine (HDAC) Based Chemotherapy in Patients (pts) with Acute Myeloid Leukemia (AML) with Chromosome Seven Abnormalities. *Blood*, **2012**, 120, 2029-2029	2.2
51	Results of A Phase I Study of Ruxolitinib in Patients (pts) with Relapsed/Refractory Acute Leukemia. *Blood*, **2012**, 120, 3617-3617	2.2
50	A Prognostic Score System for Survival in Secondary AML: Review of 1073 Patients Observed At MDACC. *Blood*, **2012**, 120, 131-131	2.2
49	Disparity in Perceptions of Disease, Treatment Effectiveness and Treatment Adherence Between Physicians and Patients with Myelodysplastic Syndromes (MDS). *Blood*, **2012**, 120, 4949-4949	2.2
48	Low Frequency of Molecular Alterations of H3.3-Atrx-Daxx Chromatin Remodeling Component Genes in Myelodysplastic Syndromes (MDS). *Blood*, **2012**, 120, 3844-3844	2.2

47	Dynamics of Molecular Response in Patients (pts) with Acute Myeloid Leukemia (AML) Withy Core Binding Factor (CBF) Abnormalities Treated with High-Dose Cytarabine Regimen. *Blood*, **2012**, 120, 3609-3609	2.2
46	Upregulation of Focal Adhesion Kinase, a Potential Therapeutic Target, in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS).. *Blood*, **2012**, 120, 2827-2827	2.2
45	Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) On Peripheral Blood (PB) and Bone Marrow (BM) Samples for Monitoring Minimal Residual Disease (MRD) in Patients (pts) with Acute Promyelocytic Leukemia (APL) Treated with All-Trans-Retinoic Acid (ATRA) and Arsenic Trioxide (ATO).. *Blood*, **2012**, 120, 2623-2623	2.2
44	A Randomized Study of Low Dose Oral Clofarabine 10 Mg Versus 20 Mg (flat dose) Daily □5 for Patients with Higher-Risk Myelodysplastic Syndrome (MDS). *Blood*, **2012**, 120, 3851-3851	2.2
43	Biological and Clinical Features of Patients with Acute Myeloid Leukemia Bearing Trisomy 21. *Blood* , **2012**, 120, 1488-1488	2.2
42	Serum Amyloid Protein A 1 (hSAA1) Is Overexpressed in Myelodysplastic Syndromes and Potentially Mediates Toll-Like Receptor 2 Innate Immunity Signaling in CD34+ Hematopoietic Stem Cells. *Blood*, **2012**, 120, 1703-1703	2.2
41	Lack of Association of Mutations in IDH1, IDH2, DNMT3A with Outcome in Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents (□ Histone Deacetylase Inhibitors).. *Blood*, **2012**, 120, 2483-2483	2.2
40	Incidence and Prognostic Impact of Cytogenetic and Molecular Clonal Evolution in Relapsed and Refractory Acute Myeloid Leukemia (AML) Patients: Study of Sequential Cytogenetic and Molecular Mutational Analysis.. *Blood*, **2012**, 120, 2562-2562	2.2
39	Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients . *Blood*, **2012**, 120, 43-43	2.2
38	Very High Rate of Leukemic Transformation and Poor Survival in Patients with Lower Risk Myelodysplastic Syndrome (MDS) Who Dynamically Acquire FLT3 Molecular Alteration (FLT3m): Study of 290 MDS Patients with Sequential Mutation Analysis. *Blood*, **2012**, 120, 3802-3802	2.2
37	Analysis of Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm. *Blood*, **2012**, 120, 3554-3554	2.2
36	Cytogenetic and Molecular Characterization of Extramedullary Disease (EMD) in Patients (pts) with Acute Myeloid Leukemia (AML).. *Blood*, **2012**, 120, 2592-2592	2.2
35	Incidence and Outcomes of a Rare Translocation t(3,5) in Patients (pts) with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). *Blood*, **2012**, 120, 1456-1456	2.2
34	Toll-Like Receptor (TLR) Signaling Adaptor Protein MYD88 in Myelodysplastic Syndromes (MDS). *Blood*, **2012**, 120, 556-556	2.2
33	Dynamics and Prognostic Impact of Peripheral Blood Blast Clearance in Patients with Acute Myeloid Leukemia (AML) Receiving FLT3 Inhibitor Therapy in Combination with Induction Chemotherapy. *Blood*, **2012**, 120, 1417-1417	2.2
32	Expression Profiles of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinases (TIMPs) in Myelodysplastic Syndromes (MDS): Level of MMP-9 Is Associated with Improved Prognosis in MDS Patients. *Blood*, **2012**, 120, 3845-3845	2.2
31	Patient (Pt)-Driven Discontinuation of Tyrosine Kinase Inhibitor Theray in Chronic Phase Chronic Myeloid Leukemia (CML) - Single Institution Experience. *Blood*, **2012**, 120, 3783-3783	2.2
30	Deregulation of TLR2-JMJD3 Innate Immunity Signaling, Including a Rare TLR2 SNP As a Potential Somatic Mutation, in Myelodysplastic Syndromes (MDS). *Blood*, **2012**, 120, 1700-1700	2.2

29	Twice Daily Fludarabine and Cytarabine Combination (BID-FA) Is Effective in Pts with De Novo Acute Myeloid Leukemia (AML), Relapsed/Refractory (R/R) AML, High-Risk Myelodysplastic Syndromes (MDS), and Blast Phase Chronic Myeloid Leukemia (CML-BP). *Blood*, **2012**, 120, 4939-4939	2.2
28	Prognostic Models for Patients with Myelodysplastic Syndromes **2013**, 153-167	
27	Phase II Study Of Combination Of Hyper-CVAD With Ponatinib In Front Line Therapy Of Patients (pts) With Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). *Blood*, **2013**, 122, 2663-2663	2.2
26	MD Anderson Scoring System (MDACC) Predicts Outcomes After Hematopoietic Stem Cell Transplantation (HSCT) Better Than Other Prognostic Classifications In MDS. *Blood*, **2013**, 122, 3340-3340	2.2
25	Effect Of Comorbidities In Myelodysplastic Syndrome By Revised-IPSS and Age. *Blood*, **2013**, 122, 1530-1530	2.2
24	Impact Of The Achievement Of a Complete Cytogenetic Response (CCyR) On Outcome In Patients (pts) With Myelodysplastic Syndromes (MDS) Treated With Hypomethylating Agents (HMA). *Blood*, **2013**, 122, 2801-2801	2.2
23	Characteristics and Outcomes Of Patients (pts) With Multiple Myeloma (MM) Who Develop Therapy (t)-Related Myelodysplastic Syndrome (MDS), t-Chronic Myelomonocytic Leukemia (CMML), Or t-Acute Myeloid Leukemia (AML). *Blood*, **2013**, 122, 1424-1424	2.2
22	Incidence Of and Risk Factors For Acute Myeloid Leukemia Involvement Of The Central Nervous System. *Blood*, **2013**, 122, 3883-3883	2.2
21	Fludarabine and Cytarabine Based Induction Therapy Is Associated With High Response Rate and Durable Remission With Low Treatment Related Mortality In Elderly Patients With Core-Binding Factor AML (CBF-AML). *Blood*, **2013**, 122, 3945-3945	2.2
20	Overexpression Of Mir-125a In Bone Marrow CD34+ cells Of Patients With Myelodysplastic Syndrome Is Correlated To a Poor Prognosis and May Contribute To The Pathogenesis Of The Disease Through The Modulation Of NF-Kb Activation and Enhancement Of Differentiation Arrest. *Blood*, **2013**, 122, 5206-5206	2.2
19	Incidence, Clinical Characteristics, and Prognostic Relevance Of Clonal T-Cell Receptor Positive (TCR+) Populations In Patients With Myelodysplastic Syndrome (MDS). *Blood*, **2013**, 122, 5231-5231	2.2
18	Survivorship In AML - Outcomes Of Acute Myelogenous Leukemia (AML) Patients (pts) After Maintaining Complete Remission (CR) For At Least 3 Years. *Blood*, **2013**, 122, 3886-3886	2.2
17	Clofarabine Plus Low-Dose Cytarabine Induction Followed By Clofarabine Plus Low-Dose Cytarabine Alternating With Decitabine Consolidation In Acute Myeloid Leukemia Frontline Therapy For Older Patients. *Blood*, **2013**, 122, 3948-3948	2.2
16	Longer Follow-Up Of The Combination Of Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy For Patients Younger Than 61 Years With Newly Diagnosed Acute Myeloid Leukemia (AML). *Blood*, **2013**, 122, 1451-1451	2.2
15	A Phase II Study Of The Combination Of Azacitidine and Lenalidomide In Patients (pts) With Higher Risk Myelodysplastic Syndromes (MDS). *Blood*, **2013**, 122, 2751-2751	2.2
14	Myelodysplastic/Myeloproliferative Neoplasms, Unclassifiable (MDS/MPN, U): Natural History and Clinical Outcome By Therapeutic Approach. *Blood*, **2013**, 122, 2825-2825	2.2
13	FOXP3 Is a Direct Target Of miR15a/16 in Umbilical Cord Blood Regulatory T Cells. *Blood*, **2013**, 122, 3261-3261	2.2
12	Clinical Characteristics and Outcomes In Patients With Acute Promyelocytic Leukemia (APL) and Hyperleukocytosis. *Blood*, **2013**, 122, 1343-1343	2.2

11	Assessment Of EZH2 Expression In CD34+ Bone Marrow Progenitor Cells Of Patients Of Myelodysplastic Syndromes (MDS). *Blood*, **2013**, 122, 2805-2805	2.2
10	EphB1 Downregulation In Acute Myeloid Leukemia: Suppressing p53-Dependent DNA Damage Control System. *Blood*, **2013**, 122, 2484-2484	2.2
9	Recurrent Patterns Of Histone Methylation and Acetylation Regulating Protein Expression In Acute Myelogenous Leukemia (AML). *Blood*, **2013**, 122, 3733-3733	2.2
8	Down-Regulated Expression Of Protection Of Telomeres 1 (POT1) Gene In Bone Marrow Hematopoietic Progenitor Cell Compartment Has Prognostic Value In Myelodysplastic Syndromes (MDS). *Blood*, **2013**, 122, 1511-1511	2.2
7	Differential Prognostic Impact Of Peripheral Blood Blast Clearance In AML Based On Type Of Therapy and FLT3 Mutation Status. *Blood*, **2013**, 122, 2584-2584	2.2
6	Fidelity of peripheral blood for monitoring genomics and tumor immune-microenvironment in myelodysplastic syndromes. *EJHaem*, **2020**, 1, 552-557	0.9
5	Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes. *American Journal of Hematology*, **2021**, 96, E111-E114	7.1
4	Predicting severe toxicities with intensive induction chemotherapy for adult acute myeloid leukemia: analysis of SWOG Cancer Research Network trials S0106 and S1203. *Leukemia and Lymphoma*, **2021**, 62, 1774-1777	1.9
3	Use of Oral Hypomethylating Agents for the Treatment of Myelodysplastic Syndromes. *Clinical Lymphoma, Myeloma and Leukemia*, **2021**, 21, S73-S76	2
2	Update on treatments for patients with myelodysplastic syndrome. *Clinical Advances in Hematology and Oncology*, **2010**, 8, 407-9	0.6
1	Myeloid neoplasms with 8q24/ MYC rearrangement are frequently associated with myelodysplasia, complex karyotype, TP53 alterations, and inferior survival. *British Journal of Haematology*,	4.5